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1    Introduction    
 
1.1 Natural products as lead structures for therapeutical drug development  
 
Today high-throughput screening (HTS) of substance libraries has become an integral part of 
pharmaceutical research in order to identify hits for drug research.
1
 The majority of 
commercially available molecules and by extension also the majority of screening libraries, 
lack typical structural motifs and ring scaffolds which can be found in Natural Products 
(NPs).
2
 Therefore it is interesting to note that natural products nevertheless still play a major 
role in the successful research for novel drug candidates. From January 1981 through 
December 2010 over 50% of 1073 small-molecules, which were so called new chemical 
entities (NCEs) and introduced as drugs in Western medicine were natural product derived. 
That means over 50% were NPs, derivatives of NPs or synthetic compounds with NP derived 
pharmacophore and only 36% of the NCEs were truly devoid of natural inspiration.
3
 
       
28%
6%
< 0,5%
11%
5%
14%
36%
ND
N
NB
S*/NM
S*
S/NM
S
 
Figure 1.1: Source of small molecules approved drugs in the time frame 1981 - 2010 
N: Natural product; NB: Natural product botanical; ND: Derived from a natural product (e.g. semisynthetic 
modification); S*: Made by total synthesis, but the pharmacophore is/was from a natural product; S*/NM: 
Natural product mimic (direct inhibitor/antagonists of the natural substrate) made by total synthesis with natural 
product pharmacophore; S/NM: Natural product mimic (direct inhibitor/antagonists of the natural substrate) 
made by total synthesis; S: Synthetic compound completely devoid of natural inspiration 
 Introduction  
 
 
2 
 
An advantage of NPs is that they are more complementary to biological three-dimensional 
structure space, which comprises the protein binding sites for potential ligands. Natural 
products, as well as their biological targets, e. g. receptor/proteins are produced by interaction 
with biosynthetic enzymes. This constitutes the concept of ‘biosynthetic imprint’ or shared 
‘protein fold topology’ (PFT), which explains a closer relationship of NPs to biological space 
that facilitates interactions with biological therapeutic targets via common ‘natural product 
binding motifs’.4,5 The deep knowledge on PFT which implies identification of PFT and 
natural product binding motifs, can also be used as drug discovery tool to identify potential 
drug targets and possible ligands in drug research.
4
 But also classical HTS drug discovery is 
supposed to benefit from the enhanced inclusion of NP scaffolds which are typically 
neglected by common screening libraries.
2
 
In this regard it has to be taken into account, that nature does not manufacture drugs for 
humans. Hits derived from NP drug discovery, as well as hits from HTS screening of 
synthesized compounds, usually require extensive optimization to obtain therapeutically 
useable drugs. Natural products therefore rather provide lead structures as starting points for 
drug optimization than being directly therapeutically usable drugs. Once an active skeleton 
has been identified as lead, combinatorial chemistry with its superior development capability 
proves its strength and can reveal the complete potential of natural products.
3,6
 
The following two chapters will focus on natural products obtained from fungal sources. 
 
1.2    Fungal metabolites as drugs or lead structures for therapeutical drug development 
 
Classical sources for bioactive NPs are derived from plants, bacteria, fungi and animals.
7
 The 
fungal kingdom includes many species which have demonstrated to be a fruitful source of 
structurally highly diverse bioactive metabolites.
8
 It is assumed that production of fungal 
secondary metabolites depends on environmental conditions and interaction with competitors 
or hosts. Therefore production of such compounds are considered to allow occupation of 
special ecological niches or rather provide competitive advantages against competitors.
9
 In 
some cases these metabolites have been implicated with diseases like aspergillosis where they 
are considered as virulence factors. Especially filamentous fungi like different Aspergillus 
species are known to interact with human immune system. Fungal secondary metabolites like 
the immunosuppressive gliotoxin produced by several Ascomycota play an important role as 
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virulence factor.
10
 As the innate immune response is the primary line of defense against 
fungal respiratory infections, immunosuppressive acting agents may assist the fungi to evade 
immune clearance, and to increase their pathogenicity in order to colonize new niches.
10
 
    In contrast many of these secondary metabolites have been used in medicine, due to their 
prominent bioactivities, helpful for a range of indications.
7
 Immunosupressive compounds 
like the cyclopeptid cyclosporin A, first time isolated from the fungus Tolypocladium inflatum 
(originally misidentified as Trichoderma polysporum)
11,12
 and derivatives of mycophenolic 
acid, first time isolated from the fungus Penicillium glaucum
13
, have become very valuable 
therapeutics for organ transplant recipients to prevent  transplant rejection.
11
 
 
 
Figure 1-2: Immunosuppressive compounds isolated from fungi or derived from fungal metabolites. 
 
More recently fingolimod (FTY720) was introduced as the first orally active 
immunomodulatory drug for the treatment of multiple sclerosis, a neurodegenerative chronic 
autoimmune disorder.
14
 Fingolimod itself is derived of myriocin (ISP-1), first time isolated 
from the fungus Myriococcum albomyces.
15
 
It is interesting to note that most of these immunosuppressive fungal compounds also display 
antibiotic or antifungal activities which open up speculations about their real physiological 
role in fungal colonies. 
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Figure 1-3: Approved immunomodulatory compound fingolimod and its parent lead structure. 
 
The progress in organ transplantation, possible also due to the availability of advanced 
immunosuppressives, and the growing population of AIDS patients led to increased numbers 
of immunocompromised patients. These patients are threatened by infections with 
opportunistic fungi like Candida spp. or Aspergillus spp. Antimycotics, which are ironically 
derived from fungal secondary metabolites, are an important contribution to encounter these 
life threatening infections. 
The isolation of the cyclic lipopeptides echinocandin B from Aspergillus species
16
 and 
pneumocandin B0 from  Glarea lozoyensis
17
 led to the development of  β-1,3-D-glucan 
synthase inhibitors like anidulafungin (LY303366) and caspofungin (MK-0991) 
17,18
 These 
have become very important antifungal agents because they demonstrated excellent clinical 
efficacy and more favourable adverse event profiles than traditional antifungal agents.
18
 Other 
β-1,3-D-glucan synthase inhibitors derived from papulacandin B isolated from Papularia 
sphaerosperma are currently under development
19,20
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Figure 1-4: Approved antifungal compounds and their parent lead structures. 
 
Their mode of action as inhibitors of fungal cell wall synthesis has given this group of 
antimycotic agents the informal name ‘fungal penicillins’. This name is based on the famous 
bacterial cell wall inhibitors derived from the tripeptid penicillin, which had been isolated 
from a fungal strain as well, Penicillium chrysogenum (formaly known as Penicillium 
notatum).
21,22
 
 
 
Figure 1-5: Potential lead structure for new antifungal compounds and core structure for β-lactam antibiotics. 
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Beside antibiotics and immunomodulatory compounds, fungal metabolites have been 
developed for many other indications. In some cases commercially very successful, like the 
cholesterol lowering agent lovastatin (monacolin K, mevinolin) and its derivatives. Lovastatin 
has originally been isolated from Monascus ruber and Penicillium citrinum and led to the 
development of the drug class of statins, which are used to prevent atherosclerosis and related 
coronary heart diseases. 
23–25
 
 
 
 
 
Figure 1-6: Lead structure and first approved cholesterol lowering agents of the drug class of statins. 
 
1.3    Potential of natural products derived from microorganisms from extraordinary 
habitats 
 
Terrestrial sources for natural products have been investigated intensively. Although they still 
bear an enormous potential, (e.g. only 15% of higher plants have been phytochemically 
investigated so far) the increased endeavour to investigate more uncommon less investigated 
habitats appears to be promising when trying to discover novel bioactive chemotypes.
7
 The 
marine environment has gained a lot of attraction to natural product researchers. The 
enormous marine biodiversity equates to chemical diversity and lead to the isolation of an 
impressive number of complex bioactive compounds. Some of these have gained access to 
clinical trials or are even already used as drugs, like the antitumor agent trabectidin (ET743), 
isolated from the tunicate Ecteinascidia turbinata.
26–28
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Figure 1-7: The marine natural product trabectidin (Yondelis
®
) is an approved anti-cancer drug 
 
One reason for the plenty of highly bioactive compounds might be the circumstance that 
secondary metabolites play an important role as chemical defense for marine organisms, 
especially for vulnerable macroorganisms like soft corals, sponges or slugs.
29–31
 Further 
prominent features of marine ecosystems are the associations between micro- and 
macroorganisms. Thereby associated microbes are considered to contribute eventually to the 
chemical defence of their hosts.
32
 
Marine derived fungi are found in marine animals like sponges, and algae as epi- or 
endobionts.
26
 Most of these isolated fungi are not obligate marine and do not appear to 
contribute directly to the biosynthesis of natural products found in marine organisms. 
However many of these fungi seem to be adapted to the marine habitat and there are reports 
which describe genetically and biochemically differences between marine derived and 
terrestrial fungi from the same genus, which makes them interesting for natural product 
researchers.
26
 
Other interesting approaches target for extremophilic microbes found in ‘extreme habitats’. 
Those habitats are normally hostile for life e.g. because of pH value, temperature or salt/metal 
content. This include acidophile microbes from acidic sulphurous hot springs or rather 
alkalophiles from alkaline lakes. Hyperthermophile microbes from deep sea vents are also 
barophile, while cryophile microbes have been isolated from arctic and antartic waters. 
Halophile microbes occupy environments with a concentration of salt five times greater than 
the salt concentration of the ocean and there are microbes known, that live in metal rich and in 
some cases also very acidic polluted environments for example found in derelict mine sites. 
7,33
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2    Scope of the present study  
 
Natural products from fungal sources provide an astonishing diversity of bioactive molecules. 
These compounds have a high potential for drug discovery in a wide array of therapeutic 
indications and there are many successful stories of approved drugs so far. Thereby marine-
derived fungi are considered as a very promising source. 
The main goal of this study is the isolation, identification and biological evaluation of 
secondary metabolites from the marine-derived fungus Dichotomomyces cejpii. This fungus 
was chosen for intensive investigation on the basis of promising results from spectroscopic 
analysis and positive antibiotic agar diffusion tests of fungal crude extracts. Furthermore 
analysis of available literature had shown that this fungus had been scarcely chemically 
investigated so far.  
In order to achieve this goal a classical approach for natural product research is envisaged, 
which is in case of antbiotic activity, supported by bioactivity guided fractionation. 
An array of cultivation experiments on different culture media shall examine suitable 
conditions for large scale cultivation. On the basis of the chemical and biological results, the 
most promising cultivation conditions shall be selected for large scale cultivation. Therefore 
biological tests in form of agar diffusion assays for antibacterial and antifungal activity and 
1
H NMR spectroscopy and LC-MS analyses for chemical characterization are available.  
The obtained extracts of these large scale cultivations, shall be further processed by 
separation, using diverse chromatographic methods. It is intended to use the interpretation of 
experimental spectroscopic (NMR, UV, IR, OR) and mass spectrometric data for chemical 
investigation and structure elucidation of isolated pure compounds. 
In addition to in vitro antibiotic activity tests, the collaboration with several work groups 
allows further bioactivity tests of pure isolated compounds, with an emphasis on activities 
toward cannabinoid and type II nuclear receptors and for Aβ-42 lowering activity. 
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3    Materials and methods 
 
3.1    Origin and taxonomy of sponge samples 
 
Marine sponge samples had been collected by Dr. Ullrich Höller via snorkelling and SCUBA 
diving at the coral reef surrounding Bare Island, New South Wales Australia in depth between 
3-15 m. Taxonomical identification of the sponge sample was performed by Dr. R. 
Desqueroux-Faundez, Musée d’Histoire Naturelle Genève. 
The collected marine sample of Callyspongia spec. cf C. flammea, Desqueyroux-Faundez 
1984 (CT 293 K), which is relevant for the context of the present study, served as substrates 
for the isolation of associated microbes. 
 
 
 
Figure 3-1:  Sample collection at Bare Island, marked with a red arrow on the maps. (The map is taken from: 
https://www.google.de/maps/place/Bare+Island) 
 Materials and methods  
11 
 
3.2    Fungal material 
 
3.2.1    Origin, isolation and taxonomy of fungal sample 
 
The marine-derived fungus Dichotomomyces cejpeii was isolated from a sample of the sponge 
Callyspongia sp. cf. C. flammea. The isolation of the fungus was carried out using an indirect 
isolation method. Sponge samples were rinsed three times with sterile H2O. After surface 
sterilization with 70% EtOH for 15 s the sponge was rinsed in sterile artificial seawater 
(ASW). Subsequently, the sponge material was aseptically cut into small pieces and placed on 
agar plates containing isolation medium: agar 15 g/L, ASW 800 mL/L, glucose 1 g/L, peptone 
from soymeal 0.5 g/L, yeast extract 0.1 g/L, benzylpenicillin 250 mg/L, and streptomycin 
sulfate 250 mg/L. The fungus growing out of the spongeal tissue was separated on biomalt 
medium (biomalt 20 g/L, agar 10 g/L, ASW 800 mL/L) until the culture was pure. The 
isolated fungus was identified by P. Massart and C. Decock, BCCM/MUCL, Catholic 
University of Louvain, Belgium. A specimen is deposited at the Institute for Pharmaceutical 
Biology, University of Bonn, isolation number “293K09”, strain number 225. 
 
3.2.2    Cultivation and extraction of selected fungal strain for prescreening  
 
The fungal isolate (293K09) was cultivated in a small scale (5 x 100 mL Petri dishes) for 
screening purposes by Ekaterina Eguereva, Irene Loef and Henrik Harms (Institute for 
Pharmaceutical Biology, University of Bonn, Germany), utilizing four different solid media 
(BMS, MPY, REA, Tennelin ). All four media were autoclaved prior to use. After one month 
of cultivation at room temperature, the fungal biomasses, including the medium were 
homogenized using an Ultra-Turrax apparatus and the mixtures were extracted with EtOAc (3 
x 100 mL). The solvents were subsequently removed at reduced pressure at 37 °C until 
dryness of the residues. These residues will be referred to as “screening extracts” in this study 
and were used to evaluate the qualification of the individual culture medium for large 
cultivation. Therefore biological activity and spectroscopical properties of the screening 
extracts were analysed.  
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 BMS medium: 15 g/L agar, 20 g/L biomalt extract, ad 1 L ASW (artificial sea water: 
0.1 g/L KBr, 23.48 g/L NaCl, 10.61 g/L MgCl2 x 6 H2O, 1.47 g/L CaCl2 x 2 H2O, 0.66 
g/L KCl, 0.04 g/L SrCl2 x 6 H2O, 3.92 g/L Na2SO4, 0.19 g/L NaHCO3 ,and 0.1 g/L 
H3BO3). 
 MPY medium: 15 g/L agar, malt extract 20 g/L, peptone 2.5 g/L, yeast extract 2.5 
g/L) ad 1 L demineralized water. 
 REA medium (without polysorbate 80): 20 g/L agar 20g/L rice for rice extract, ad 1 L 
demineralized water.  
 Tennelin medium: agar 15g/L, mannitol 50 g/L, 5 g KNO3 , 1g KH2PO4, 0.5g MgSO4 
x 7 H2O, 0.1g NaCl, 0.2 g CaCl2, 20 mg FeSO4 x 7 H2O, 10 ml Liquid 2: [ZnSO4x 7 
H2O 880 mg/L, CuSO4 x 5 H2O, 40 mg/L MnSO4 x 4 H2O, 7.5 mg/L, Boracid, 6 
mg/L, 4 mg/L (NH4)6Mo7O4 x H2O ad 1 L Aqua dem.], ad 1 L demineralized water. 
3.2.3    Cultivation and extraction of selected fungal strain for detailed chemical   
investigations 
Upscaled cultivations (10 L solid medium) were generated for detailed chemical 
investigations of the fungal strain with the two most promising culture media. Therefore the 
nutrient rich MPY medium and the minimal medium Tennelin were selected. 
The fungal sample was cultivated in Fernbach flasks at room temperature for 30 or 40 days, 
respectively, using the same media as for screening purposes. The homogenized fungal 
biomass and cultivation medium was extracted with EtOAc exhaustively and the solvent was 
subsequently removed at reduced pressure and 37 °C. Specific cultivation conditions were as 
follows: 
 Cultivation medium 1: 10 L solid MPY medium in 40 Fernbach flasks for 30 days. 
(see Figure 3-2a) 
 Cultivation medium 2: 10 L solid Tennelin medium in 40 Fernbach flasks for 40 
days (see Figure 3-2b) 
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a) Dichotomomyces cejpii preculture and large scale cultivation on MPY medium                                  
                                     
b) Dichotomomyces cejpii preculture and large scale cultivation on Tennelin medium 
Figure 3-2:  Dichotomomyces cejpii growing on two different culture media a) and b) 
 
 
3.3    Chromatography 
 
3.3.1    Thin layer chromatoraphy (TLC) 
 
TLC was performed using either TLC aluminum sheets silica gel 60 F254 (Merck) or TLC 
aluminum sheets RP18 F254 (Merck) as stationary phase. Standard chromatograms of extracts 
and fractions were developed on silica gel using PE-acetone in different mixtures (standard: 
70-30), or on RP18 TLC plates with MeOH/H2O mixtures (standard: 70-30), both under 
saturated conditions at room temperature. Chromatograms were detected under UV light (254 
and 366 nm), vanillin-H2SO4 reagent (0.5 g vanillin dissolved in a mixture of 85 ml methanol, 
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10 mL acetic acid and 5 mL H2SO4, TLC plate heated at 100°C after spraying) and with van 
Urk reagent reagent (50 mg 4-(Dimethylamino)-benzaldehyd dissolved in 1 ml H2SO4 conc, 
ad 100ml EtOH 95%) if compounds with indole moiety were suspected. 
 
 3.3.2    Vacuum liquid chromatography (VLC) 
Sorbents for VLC were silica gel 60 (0.063–0.200 mm, Merck), silica gel 60 (0.040–0.063 
mm, Merck) or Polygoprep 60 C18 (0.05 mm, Macherey-Nagel). Columns were wet-packed 
under vacuum, using PE or dichloromethane for normal-phase, and MeOH for reversed-phase 
conditions. Glass wool layer above the sorbent material was used to protect the sorbent 
material against disturbance. Before applying the sample solution, the columns were 
equilibrated with the first designated eluent.  
 
3.3.3    High performance liquid chromatography (HPLC) 
Preparative HPLC was carried out using four different systems: A: Waters system, controlled 
by Waters Millenium software, consisting of a 600E pump, a 996 PDA, and a 717 plus 
autosampler; B: HPLC system controlled by Merck Hitachi Model D-7000 Chromatography 
Data Station Software HPLC System Manager Version 4.0 software, consisting of L6200 A 
intelligent pump; D 6000 interface and an L4500 PDA; C: controlled by HP ChemStation for 
LC Rev.A.06.03[909] software, consisting of a L-7100 Merck Hitachi pump and a HP-series 
1050 detector; D: HPLC composed of a Waters 515 pump together with a Knauer K-2300 
differential refractometer.  
 
3.4    Structure elucidation 
The chemical structures of the isolated compounds were elucidated using one and two 
dimensional NMR techniques in combination with MS methods. ACD/Labs-software NMR-
calculations were utilized to support the NMR-based structure elucidation (ACD/Labs-
software, 2006). If necessary, optical rotation was determined and further spectroscopic 
methods, such as UV and IR spectroscopy provided additional structural information. The 
determination of the absolute configuration of sugar moieties was performed using chiral 
 Materials and methods  
15 
 
stereoselective HPLC columns via retention times comparison. Identity of isolated 
compounds in comparison to previously published structures was judged due to the 
1
H and 
13
C NMR data, and specific optical rotation. Database and literature searches were carried out 
using the MarinLit database (MarinLit database
®
, AntiBase database
®
 and the SciFinder
®
 
database. Chemical structures were designated as new, if they could not be found in any of 
these databases. 
 
3.4.1    NMR spectroscopy 
All NMR spectra were recorded using either a Bruker Avance 300 DPX operating at 300 
MHz (
1
H) and 75 MHz (
13
C) or a Bruker Avance 500 DRX spectrometer operating at 500 
MHz for (
1
H) and 125 MHz for (
13
C) respectively. NMR Spectra were processed using 
Bruker 1D WIN-NMR, 2D WIN-NMR or XWIN-NMR Version 2.6, 3.1 and 3.5 software, or 
Bruker TopSpin software package Version 1.3. Spectra were recorded in CDCl3, acetone-d6 
or CD3OD and were referenced to residual solvent signals with resonances at δH/C 7.26/77.0 
(CDCl3), 1.93/117.7 (acetone-d6), 3.35/49.0 (CD3OD) and 2.04/29.8 (acetone-d6). Multiplicity 
of carbons was deduced by 
13
C and DEPT experiments. Structural assignments were based on 
spectra resulting from one or more of the following NMR experiments: 
1
H, 
13
C, DEPT135, 
1
H-
1
H COSY, 
1
H-
13
C direct correlation (HSQC), 
1
H-
13
C long range correlation (HMBC), 
1
H-
1
H NOESY. Two dimensional NMR measurements were guided by Dr. Stefan Kehraus 
(Institute for Pharmaceutical Biology, University of Bonn, Germany). 
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3.4.2    Mass spectrometry (MS) 
HPLC-ESIMS (referred to as LC-MS or HPLC-MS) measurements were performed by 
Ekaterina Eguereva (Institute for Pharmaceutical Biology, University of Bonn, Germany) 
employing an Agilent 1100 Series HPLC including DAD, with RP C 18 column (Macherey-
Nagel Nucleodur 100, 125 mm x 2 mm, 5 µm) and gradient elution (0.25 mL/min, NH4Ac 
buffer 2 mmol, from MeOH 10: H2O 90 in 20 min to 100% MeOH, then isocratic for 10 min), 
coupled with an API 2000, Triple Quadrupole LC/MS/MS, Applied Biosystems/MDS Sciex 
and ESI source. All samples for LC-MS (extracts, fractions, and pure compounds) were 
solved in MeOH (1 mg/mL) for injection into the HPLC-ESIMS system. 
LREIMS and HREIMS were recorded on a Finnigan MAT 95 spectrometer, and HRESIMS 
on a Bruker Daltonik micrOTOF-Q Time-of-Flight mass spectrometer with ESI source, all 
carried out by C. Sondag (Department of Chemistry, University of Bonn, Germany). HRESI 
FT/ICR MS was conducted by H. Hamacher (Bayer Industry Services, Leverkusen, Germany) 
via applying a Bruker Daltonics APEX–III FT-ICR-MS spectrometer. 
 
3.4.3    UV measurements 
UV spectra were recorded on a Perkin-Elmer Lambda 40 with UV WinLab Version 2.80.03 
software, using 1.0 cm quartz cells. The molar absorption coefficient ε was determined in 
accordance with the Lambert-Beer-Law: 
 
 
A
   A= c b 
L
molmol cm
c b cm
L
 
 
          
 
 
ε = molar absorption coefficient 
A = absorption at peak maximum 
c = concentration 
b = layer thickness of solution 
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3.4.4    IR spectroscopy 
IR spectra were recorded as film, using a Perkin-Elmer FT-IR Spectrum BX spectrometer. 
Analysis and reporting were performed with Spectrum v3.01 software. 
 
3.4.5    Optical rotation 
 
Optical rotation measurements were conducted on a Jasco model DIP-140 polarimeter (1 dm, 
1 cm
3
 cell) operating at the wavelength λ=589 nm corresponding to the sodium D line at room 
temperature. The specific optical rotation [α]D
T
 was calculated pursuant to: 
 
[]
D
T
=
100 x 
c x l
 
T = temperature [ºC] 
D = sodium D line at λ=589 nm 
c = concentration [g/100 mL] 
l = cell length [dm] 
 
The compounds were dissolved in an appropriate organic solvent (e.g., MeOH). The rotation 
angles α were determined as an average value based on at least 10 measurements. 
 
3.5    Chemical derivatizations 
 
3.5.1   Carbamat formation of compound 4 
 
The carbarmat formation of compounds 4 was conducted in accordance with the procedure 
utilized by Stock and Brückner et al, 2010.
34
 Emindole SB (4) (7.6 mg) was stirred with 3.5 
µL propylisocyanat (ρ 0.908 g/ml) and 0.58 mg MoO2Cl2 in 1 ml CH2Cl2 at room temperature 
for 96 h. Every 12 hours additional 3.5 µl propylisocyanat were added. The reaction was 
quenched with 15.7 µl diethylamin after 96 hours. The solvent was removed under vacuum to 
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give a brown residue, which was suspended in 2 ml CH2Cl2 and 3 ml H2O. Liquid-liquid 
extraction was utilized 5 times. The obtained CH2Cl2 phase was removed under vacuum again 
and further purified using RP18-HPLC system B (Nucleodur 100-S 250mm x 4.6 mm) with 
H2O-ACN (82:180), 1.5 mL/min as the eluent system gave 3.5 mg of the desired emindole 
SB-N-propylcarbamate, analysed via 
1
H and 
13
C NMR as well as HRMS. 
 
3.6    Evaluation of biological activity 
 
3.6.1    Agar Diffusion Assay in Working Group König 
 
Antimicrobial tests of extracts and isolated pure compounds were performed by Edith Neu 
(Institute for Pharmaceutical Biology, University of Bonn) following the method described by 
Schulz et al. (Schulz et al., 1995). The bacteria Bacillus megaterium de Bary (Gram positive) 
and Escherichia coli (Migula) Castellani & Chambers (gram negative), the fungi 
Microbotryum violaceum (Pers.) Roussel (Ustomycetes), Eurotium rubrum (formerly E. 
repens) König, Spieckermann & Bremer (Ascomycetes) (all from DSMZ; Braunschweig, 
Germany), and Mycotypha microspora Fenner (Zygomycetes kindly provided by B. Schulz, 
Institute of Microbiology, University of Braunschweig, Germany) were used as test 
organisms. Sample solutions contained 1 mg/mL per test sample. 50 µL (equivalent to 50 µg) 
of each solution were pipetted onto a sterile antibiotic filter disk (Schleicher & Schuell 2668), 
which was then placed onto the appropriate agar medium and sprayed with a suspension of 
the test organism. Growth media, preparation of spraying suspensions, and conditions of 
incubation were carried out according to Schulz et al. (Schulz et al., 1995). Growth inhibition 
was defined as follows: growth of the appropriate test organism was significantly inhibited 
compared to a negative control; total inhibition: no growth at all in the appropriate zone. 
Benzyl penicillin (1 mg/mL MeOH), streptomycin (1 mg/mL MeOH) and miconazole (1 
mg/2 mL DCM) were used as positive controls.  
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3.6.2    Agar Diffusion Assay in Working Group Sahl 
 
Antimicrobial tests of extracts and isolated pure compounds were performed by Michaele 
Josten (Institute for medical microbiology, University of Bonn). 
Culture plates (5% sheep blood Columbia agar, BD) were overlaid with 3 ml Tryptic soy soft 
agar, inoculated with TSB (Tryptic soy broth, Oxoid) growth suspension of the bacteria to be 
tested. Compounds were diluted to a concentration of 1mg/ml (Syringomycin 0,5mg/ml) with 
DMSO and 3 µl of this dilution were placed on the surface of the agar. Compounds diffuse 
into the agar and the size of the inhibition zone was measured after 24 hours incubation at 37 
°C. 
 
MIC determinations 
MIC determinations were carried out in microtiter plates. Strains were grown in half-
concentrated Mueller-Hinton
 
broth (Oxoid). MICs with serial twofold dilution steps
 
were 
performed (1:2). Bacteria
 
were added to give a final inoculum of 10
5
 CFU/ml in a volume
 
of 
0.2 ml. After incubation for 24 h at 37 °C the MIC was read as the lowest compound 
concentration
 
causing inhibition of visible growth. 
 
3.6.3    Radioligand Binding Studies at CB1 and CB2 Receptors 
 
Assays were performed by Viktor Rempel and Clara Schoeder (Institute for Pharmaceutical 
Chemistry, University of Bonn). Competition binding assays were performed versus the 
cannabinoid receptor agonist radioligand [
3
H](-)-cis-3-[2-hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-hydroxy-propyl)-cyclohexanol (CP55,940) as described 
before.
35
 Stock solutions of test compounds were prepared in DMSO. The final DMSO 
concentration in the assay was 2.5%. Data were obtained from three independent experiments, 
performed in duplicate.  
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3.6.4    cAMP Accumulation Assays 
 
Assays were performed by Viktor Rempel and Clara Schoeder (Institute for Pharmaceutical 
Chemistry, University of Bonn). The measurement of intracellular cAMP concentration was 
performed as described before.
36
 Inhibition of adenylate cyclase activity was determined in 
CHO cells stably expressing the CB1 or CB2 receptor subtype using a competition binding 
assay for cAMP quantification. Data were obtained from three independent experiments, 
performed in duplicate.  
 
3.6.5    β-Arrestin-Recruitment Assays 
 
Assays were performed by Viktor Rempel and Clara Schoeder (Institute for Pharmaceutical 
Chemistry, University of Bonn). Recruitment of β-arrestin to the respective GPCR was 
detected by using the β-galactosidase enzyme fragment complementation technology (β-
arrestin PathHunter assay, DiscoverX) as previously described.
35
 CHO cells stably expressing 
the respective receptor were seeded in a volume of 90 µL into a 96-well plate and were 
incubated at a density of 20.000 cells/well in assay medium (Opti-MEM, 2% FCS, 100 U-mL
-
1
 penicillin, 100 µg mL
-1
 streptomycin, 800 µg mL
-1
 geneticin and 300 µg mL
-1
 hygromycin) 
for 24 h at 37°C. Test compounds were diluted in PBS buffer containing 10% DMSO and 
0.1% BSA and 10 µL were added to 90 µL of the cell culture, followed by incubation for 90 
min at 37°C. For determination of β-arrestin recruitment to GPR18, the commercial detection 
reagent was used, according to the suppliers protocol (DiscoverX). The detection reagent for 
GPR55 was prepared by mixing the chemiluminescent substrate Galacton-Star (2 mM), with 
the luminescence enhancer Emerald-II and a lysis buffer (10 mM TRIS, 1 mM EDTA, 100 
mM NaCl, 5 mM MgCl2, 1% Triton-X; pH 8) in a ratio of 1:5:19. After the addition of 50 
µL/well of detection reagent to the cells, the plate was incubated for further 60 min at RT. 
Finally luminescence was determined in a luminometer (TopCount NXT, Packard / Perkin-
Elmer). Screening for antagonism of test compounds was performed in the presence of 10 µM 
∆9-THC (GPR18), or 1 µM of LPI (GPR55), respectively. IC50 values of compounds were 
determined in the presence of a constant concentration of 7.5 µM ∆9-THC (GPR18), or 1 µM 
LPI (GPR55), respectively. Data were obtained from three independent experiments, 
performed in duplicate.  
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3.6.6    Acid Hydrolysis and Chiral-phase HPLC 
 
To 0.5-2.0 mg of test substance 2 mL 2 M HCl was added and the resulting solution was 
heated at 80 °C for 5 h under reflux. The residual solvent was removed under reduced 
pressure and the residue was solved in 1 mL EtOH. This solution was used for chiral-phase 
HPLC analysis using the Merck HPLC system B with the ELSD detector under following 
conditions: Compounds 1: Merck HPLC system B with ELSD detector was employed 
applying the conditions: column 1, Diacel CHIRALPAK IA column Nr 1 (250 mm x 4.6 mm, 
5 µm); mobile phase, hexane-EtOH (70-30); flow, 0.5 mL min-1. Using these conditions the 
α-D-mannose had a retention time of 11.2 min, β-D-mannose of 17.0 min, α-L-mannose of 
13.1 min, and β-L-mannose of 22.4 min, respectively. 
Compounds 10 and 11: Merck HPLC system B with ELSD detector was employed applying 
the conditions: column 2, Diacel CHIRALPAK IA column Nr 2 (250 mm x 4.6 mm, 5 µm); 
mobile phase, hexane-EtOH (75-25); flow, 0.5 mL min-1. Using these conditions the α-D-
mannose had a retention time of 12.5 min and α-L-mannose of 13.1 min  
 
3.6.7    Cell viability/cytotoxicity tests 
 
3.6.7.1    In vitro Cytotoxicity with L-6 Cells 
 
Assay was performed by Dr. Marcel Kaiser (Swiss Tropical and Public Health Institute, 
Basel) Assays were performed in 96-well microtiter plates, each well containing 100 µL of 
RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine 
serum, and 4000 L-6 cells (a primary cell line derived from rat skeletal myoblasts).
37
 Serial 
drug dilutions of 11 threefold dilution steps covering a range from 100 to 0.002 μg mL-1 were 
prepared. After 70 hours of incubation the plates were inspected under an inverted microscope 
to assure growth of the controls and sterile conditions. 10 µL of Alamar Blue was then added 
to each well and the plates incubated for another 2 h. Then the plates were read with a 
Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation using an 
excitation wave length of 536 nm and an emission wave length of 588 nm. The IC50 values 
were calculated by linear regression from the sigmoidal dose inhibition curves using 
SoftmaxPro software (Molecular Devices Cooperation, Sunnyvale). Podophyllotoxin (Sigma 
P4405) was used as the control.
38
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3.6.7.2    MTS survival assay 
 
N2a cells stably transfected with human APP695 were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM/optiMEM), supplemented with 5% fetal bovine serum, 1% 
penicillin-streptomycin solution and G418 (Sigma, St. Louis, MO, USA) (0.1 mg/mL) in a 
humidified atmosphere at 37°C with 5% CO2. N2a-APP695 cells were plated at a density of 
approximately 10,000 cells per well on 96-well plates in Dulbecco’s modified Eagle’s 
medium (DMEM/optiMEM), supplemented with 0.5% fetal bovine serum. After 24 h 
incubation, the conditioned media were replaced by new media containing compounds at the 
final concentrations indicated. Viability of cells was measured by MTS-formazan reduction 
using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, 
USA) at 18 h post treatment. Incubation was pursued for 1h30 (37°C, 5% CO2 and 95% 
humidity). Optical density (OD) was measured at 490 Δ 630 nm using a microELISA reader. 
10 μM was used as final compound concentration. Blanks without cells and untreated cells 
were used as control. Cell viability was calculated as Cell viability (%) = (OD of treated cell – 
OD of blanks) / (OD of controls (vehicle treated cells) – OD of blanks) x 100. 
 
3.6.7.3    Viability and proliferation assessment by trypan blue exclusion test 
 
Assay performed by Barbora Orlikova (Department of Pharmacy, Seoul National University) 
to assess percentage of viable cells within sample and to determinate the proliferation trypan 
blue exclusion test was used. Trypan blue is a vital stain that belongs to the family of azo 
compounds. As selective dye trypan blue stains only dead cells, passing through their plasma 
membrane. Viable cells chamber. In order to assess the cell viability, the percentage of 
unstained cells (K562) to the total amount of cells within the sample was calculated and 
normalized to 100% of control cells viability. In order to assess cell proliferation the 
concentration of unstained cells was determined and normalized to 100% of control cells 
concentration.  
 
3.6.8    Amyloid β-42 production induction assay 
 
Assay performed by WG Meijer (ManRos Therapeutics, Roscoff). N2a cells stably 
transfected with human APP695 were maintained in Dulbecco’s modified Eagle’s media 
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(DMEM/optiMEM) as described above. After 18 h incubation, the conditioned media were 
replaced by new media containing compounds at the indicated final concentrations. After 18 h 
incubation, the cultured media were harvested for Amyloid β-42 determination by ELISA 
assay. Aβ-42 levels were measured in a double antibody sandwich ELISA using a 
combination of monoclonal antibody (mAb) 6E10 (SIG-39320, Covance, Eurogentec, 
Seraing, Belgium) and biotinylated polyclonal Aβ-4239 antibody (provided by Dr. P.D. Mehta, 
Institute for Basic Research in Developmental Disabilities, Staten Island, USA).
39
 Briefly, 
wells of microtiter plates (Maxisorp, Nunc, ThermoFisher Scientific, Illkirch, France) were 
coated 100 μL mAb 6E10 diluted in carbonate-bicarbonate buffer (buffer (0.015 M Na2CO3 + 
0.035 M NaHCO3) pH 9.6) at a 1.5 μg/mL final concentration, and plates were incubated 
overnight at 4°C. The plates were then washed with PBST (PBS containing 0.05% Tween-20) 
and blocked for 1 h with 1% BSA in PBST to avoid non-specific binding. Following a 
washing step, 100 μL of cell supernatant was added and incubated for 2 h at room temperature 
(RT) on a shaking device. Plates were then washed with PBST and 100 μL of biotinylated 
antibodies (diluted to 1 μL/mL in PBST containing 0.5% BSA) were added and incubation 
was carried out for 75 min at RT under constant shaking. After a washing step, streptavidin-
Poly-HRP (horseradish peroxidase) conjugate (Pierce, ThermoFisher Scientific, Illkirch, 
France), diluted in PBS + 1% BSA, was added and incubation was carried out for 45 min at 
RT under continuous shaking. After washing, 100 μL of OPD (o-Phenylenediamine 
Dihydrochloride, Pierce, ThermoFisher Scientific, Illkirch, France) in pH 5.0 citrate buffer 
(0.049M citric acid monohydrate + 0.1M Na2HPO4*2H2O + 1 mL H2O2 30%/L) were added 
as a substrate and after 15 min incubation at room temperature, the reaction was stopped by 
addition of 100 μL 1 N sulfuric acid. OD was measured at 490 nm using a plate reader 
(BioTek Instrument, El 800, Gen 5 software). 10 μM of the compounds were used as a final 
concentration. Blank without cells, vehicle treated cells and cells + 100 μM Aftin-5, the 
reference activator of extracellular Aβ-42 production40 were used as control. Aftin-5 was 
produced by ManRos Reagents and is available from Adipogen International, San Diego. Aβ-
42 were calculated as (x=x0-b.ln(a/(DO-y0)-1) with x = amount of Aβ-42, x0 = -5.06.10-10 , 
y0 = -11.4656, a = 14.8527and b = 4.15.10
-10
. Fold change in Aβ-42 levels was calculated as 
Fold change = Amount of Aβ-42 in sample treated cells / amount of Aβ-42 in control (vehicle 
treated cells) 
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3.6.9    Amyloid β Quantification 
 
Assay performed by WG Meijer (ManRos Therapeutics, Roscoff). Standard curves were 
prepared with synthetic Aβ-42 HFIP treated (JPT Peptide Technologies) and Aβ-42 specific 
polyclonal antibody. Curve fitting was performed using a 4 parameters sigmoid equation 
(SigmaPlot, Systat). Results are expressed as fold change ± s.d. The fold change was 
calculated by dividing the amount of Aβ peptides produced by treated cells by the of Aβ 
peptides produced by untreated cells. All experiments were performed in triplicate.  
 
3.6.10    Effects on inhibition of Amyloid β-42 production induced by Aftin-5 
 
Assay performed by WG Meijer (ManRos Therapeutics, Roscoff). N2a cells stably 
transfected with human APP695 were maintained in Dulbecco’s modified Eagle’s media 
(DMEM/optiMEM), as described above. After 18 h incubation, the conditioned media were 
replaced by new media containing respective sample at the indicated final concentrations. 
After 1 h incubation, Aftin-5 is added (100 μM 1% DMSO final). After 18 h incubation, the 
cultured media were harvested for Amyloid β-42 determination by ELISA assay. Compounds 
were tested in concentrations 0.1, 0.33, 1.0, 3.3, 10 μM. Blanks without cells, vehicle treated 
cells, cells + 100 μM Aftin-5 and cells + 10 μM DAPT (N-[(3,5-difluorophenyl)acetyl]-
Lalanyl-2-phenyl]glycine-1,1-dimethylethyl ester) were used as controls.  
 
3.6.11    Protein kinase assays  
 
Assay performed by WG Meijer (ManRos Therapeutics, Roscoff). Protein kinase assay buffer 
Buffer A : 10 mM MgCl2, 1 mM EGTA (MW 380.4), 1 mM DTT (MW 154.2), 25 mM 
Tris/HCl (MW 121.1) and 50 μg/ml Heparin.  
Buffer C: 20 mM ß-glycerophosphate, 10 mM p-nitrophenylphosphate, 25 mM MOPS, 5 mM 
EGTA, 15 mM MgCl2, 1 mM DTT and 0.1 mM sodium vanadate.  
Preparation and assay of protein: 
41
 
Kinase activities were assayed in buffer A or C, with their corresponding substrates, in the 
presence of 15 μM [γ-33P] ATP (3,000 Ci/mmol; 10 mCi/mL, PerkinElmer, Courtaboeuf, 
France) in a final volume of 30 μL. After 30 min incubation at 30°C, the reaction was stopped 
by harvesting on a FilterMate harvester (Packard) onto P81 phosphocellulose papers (GE 
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Healthcare). Filters were washed in 1% phosphoric acid. 20 μL of scintillation fluid were 
added and the incorporated radioactivity was measured in a Packard counter. Blank values 
were subtracted and activities calculated as pmoles of phosphate incorporated during the 30 
min incubation. The activities were expressed in % of the maximal activity, i.e. in the absence 
of inhibitors. Controls were performed with appropriate dilutions of DMSO.  
CDK1/cyclin B (M phase starfish oocytes, native) was prepared as previously described .
42
 
Kinase activity was assayed in buffer A, with 1 mg histone H1/mL.  
CDK2/cyclin A (human, recombinant, expressed in insect cells) was assayed as described for 
CDK1/cyclin B. CDK5/p25 (mammalian, recombinant, expressed in E. coli) was assayed as 
described for CDK1/cyclin B. CDK9/cyclin T (human, recombinant, expressed in insect 
cells) was assayed as for CDK1/cyclin B using the Tide 7/9 substrate 
(YSPTSPSYSPTSPSYSPTSPSKKKK, Proteogenix, Oberhausbergen, France) (500 μM). 
CK1δ/ε (porcine brain, native, affinity purified on axin-2 beads [6]) was assayed as described 
for CDK1 but in buffer C and using the CK1-specific peptide substrate (CKs: 
RRKHAAIGSpAYSITA, Proteogenix, Oberhausbergen, France) (1 mM). CLK1 (Human, 
recombinant, expressed in E. coli as GST fusion protein) was assayed in buffer A (+ 0.15 mg 
BSA/ml) with RS peptide (GRSRSRSRSRSR, Proteogenix, Oberhausbergen, France) (1 
μg/assay). DYRK1A (human, recombinant expressed in Escherichia coli as a glutathione S-
transferase fusion protein) were purified by affinity chromatography on glutathione-agarose 
and assay as described for CDK1/cyclin B using Woodtide (KKISGRLSPIMTEQ, 
Proteogenix, Oberhausbergen, France) (1.5 μg/assay) as a substrate, a residue of transcription 
factor FKHR. GSK-3α/β (porcine brain, native, affinity purified on axin-1 beads [7]) was 
assayed as described for CDK1 using a GSK-3–specific substrate (GS-1: 
YRRAAVPPSPSLSRHSSPHQSpEDEEE; Sp stands for phosphorylated serine, Proteogenix, 
Oberhausbergen, France) (250 μM). 
 
3.6.12    Luciferase-based reporter system to detect agonism toward NR 
Tests were performed by Dr. Paulsen Steinar (The Norwegian Structural Biology Centre and 
Department of Chemistry, University of Tromsø) following the method described by Ciocoiu 
et al.,2010 and Tzameli et al., 2004
43,44
: Cos-1 cells (ATCC no. CRL-1650) were maintained 
in DMEM (Invitrogen, Carlsbad, CA) containing gentamicin (10 μg/ml) and fetus bovine 
serum (10%), at 37°C in a humidified atmosphere of 5% CO2. Cell confluence never reached 
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above 80% before sub-culturing or transfection. The pSG5-Gal4-hPPAR-LBD (α, γ and β/δ 
isotypes) and the pSG5-Gal4-hLXR-LBD (α and β/δ isotypes) expression constructs were 
generous gifts from Dr. Hilde Nebb, University of Oslo, Norway. The pGL3-5XUAS-SV40 
luciferase reporter construct was purchased from Promega Corporation, Madison, WI.  Cos-1 
cells were transiently transfected with 1.7 µg of the expression plasmids and 8.5 µg of the 
reporter construct per 1 x 10
7
 cells. Transient transfection was achieved using the Neon 
electroporation system (Invitrogen). Cells were seeded (2 x 10
4
/well) in 96-plates (white F96 
microwell, Nalge Nunc Int., Rochester, NY) and allowed to attach (5 hrs) before test 
compounds was added. Test compound dissolved in DMSO was tested in dilution series made 
prepared in cell medium. Following incubation for 19 hrs cell media was a sucked of by a 
multi-canal vacuum pipette and cells washed in PBS, at room temperature.Results were 
developed by adding D-luciferin K-salt (0.12 mg/ml) dissolved in 30 mM HEPES 
supplemented with 1 mM MgSO4 and 0.5 mM in a volume of 50 µl per well. Following 10 
min of incubation at room temperature the light signal was read on an Envision instrument, 
PerkinElmer, Turku, Finland. 
  
Assay Positive 
control 
AC 
uM 
DMSO 
% 
WS 
mM 
AS in DMEM/FCS 
  
PPARγ Rosiglitazone 5 0.05 10 5 µl of 10 mM in 5 ml = 10 uM 
PPARβ/δ GW501516 1 0.01 10 2 µl of 10 mM in 10 ml = 2 uM 
PPARα Bezafibrate 100 0.072 138 7.2 µl of 138 mM in 5 ml = 200 μM 
LXRα T0901317 1 0.02 5 2 µl of  WS in 5 ml = 2 μM 
LXRβ T0901317 1 0.02 5 2 µl of  WS in 5 ml = 2 μM 
AC: Assay concentration; WS: working stock; AS: assay stock DMEM/FCS: cell growth 
medium. All dissolved in DMSO (100 %) to make up the working stocks. As negative 
controls, cell medium supplemented with DMSO equivalent to  the positive control was used. 
 
 
3.6.13    Enzyme inhibitory activity 
 
Tests were performed by Working group Guetschow (Pharmaceutical Institute University of 
Bonn) Inhibitory activity was tested toward Cathepsin L, Cathepsin B, Cathepsin K following 
the method described by Frizler et al., 2011 
45
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Inhibitory activity was tested toward human leukocyte elastase following the modified 
method  described by Gütschow et al. 
46
 (Enzo, 250 ng/mL, [MeOSuc-Ala-Ala-Pro-Val-pNA] 
= 100 μM, 1.5% DMSO, 25 °C;Inhibitory activity was tested toward bovine chymotrypsin, 
bovine trypsin and porcine cholesterol esterase following the method described by Pietsch 
und Gütschow, 2005 
47
 
 
3.6.14    Label-Free Dynamic Mass Redistribution (DMR) Assay for FFA receptor      
expressing cells  
 
Cell based dynamic mass redistribution assays were performed by Manuel Grundmann 
(Institute for Pharmaceutical Biology, University of Bonn)  as described previously in 
detail
48,49
, using the Enspire® benchtop optical label-free system in conjunction with the Mini 
Janus liquid handing station (Perkin Elmer, Hamburg, Germany). Briefly refractive 
waveguide grating optical biosensors, integrated in 384-well microplates, allow extremely 
sensitive measurements of changes in local optical density in a detecting zone up to 150 nm 
above the surface of the sensor. Cellular mass movements induced upon GPCR activation can 
be detected by illuminating the underside of the biosensor with polychromatic light and 
measurement of changes in wavelength of the reflected monochromatic light that is a 
sensitive function of the index of refraction. The magnitude of this wavelength shift (in 
picometers) is directly proportional to the amount of DMR. Cells were seeded at a density of 
18,000 cells/well (FFA1-HEK, FFA2-HEK, FFA3-HEK, Flp-In T-Rex293) on fibronectin-
coated biosensor plates and were cultivated for 20-24 h (37 
°
C, 5 % CO2) to obtain confluent 
monolayers. Cells were treated with 1µg/mL Doxycycline for 5 h to induce the expression of 
the respective receptor protein. Before the assay, cells were washed twice with Hank’s 
buffered salt solution (HBSS) containing 20 mM HEPES and incubated for 1 h in the 
Enspire
®
 reader at 37 °C. The sensor plate was then scanned and a baseline optical signature 
was recorded. Hereafter, compound solutions were transferred into the biosensor plate and 
DMR was monitored for at least 4,000 s. Quantification of DMR signals for concentration 
effect curves was performed by calculation of the area under the curve (AUC) in DMR 
between 0 and 4,000 s. All optical DMR recordings were buffer and solvent corrected. For 
data normalization, indicated as relative response (%), DMR induced by 100µM ATP were 
set 100 % and bottom levels 0 %. Data calculation and EC50 value determination by nonlinear 
regression was performed using GraphPad Prism 5.04 (GraphPad Software). 
 Materials and methods  
28 
 
3.6.15   Cerebrosid-Sulfotransferase Assay 
 
Assay was performed by Isabell Zech  (Institute for Biochemie and Molekularbiologie, 
University Bonn)  following the modified procedure of Jungalwala et al. 
50
  
Modified volumina and concentrations:  
1 µg Galactosylceramid (Avanti Polar Lipids, 860544P, solved in CHCl3/MeOH 1:1)  
0.5 µl 10 % Triton X-100-solution (CHCl3/MeOH 2:1) 
3 µl of tested compounds (1 mM in 10 % DMSO) or 3 µl 10%-DMSO-solution.  
30 µl Reaction buffer  
1 µl CST-sample to start reaction 
Tris-HCl pH 7,1 (concentration: 100 mM, final concentration: 100 mM) 
MgCl2 (concentration: 20 mM, final concentration: 16 mM) 
PAP[35S] (Perkin Elmer, 250 µCi, Lot 0813) (concentration 0.33 nmol/µl, final 
concentration: 1.1µM) 
 
3.6.16   HIV Assay 
 
Assay was performed by Dr. Markus Helfer  (Institute of Virology, Helmholtz Zentrum 
München)  following the procedure of Kremb et al. 
51
 
 
3.6.17    Antiparasitic Assay 
 
Anti-parasitic activities were assessed by Dr. Marcel Kaiser (Swiss Tropical and Public 
Health Institute,Basel)  
 
3.6.17.1    In Vitro Antimalarial Activity Assay 
 
Plasmodium strain was cultured according to Trager and Jensen et al., 1976 
52
  and is 
described at mr4.org (sensitive strains: NF54). IC50 values were determined in vitro by 
measuring incorporation of the nucleic acid precursor [
3
H]hypoxanthine 
53
. In vitro time-, 
stage-, and concentration-dependent effects were assessed using pyrimethamine as a stage-
specific and slow acting control, as described elsewhere.
54
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3.6.17.2    Activity Against Other Parasitic Protozoa  
 
In vitro activity against T. brucei rhodesiense, T. cruzi, Leishmania donovani and was 
determined as described by Regalado et al., 2010
55
 
 
3.6.17.3    L. donovani Macrophage Assay:  
 
Mouse peritoneal macrophages (4 x 104 in 100 µL RPMI 1640 medium with 10% heat–
inactivated FBS) were seeded into wells of Lab–tek 16–chamber slides. After 24 h 1.2 x 105 
amastigote L. donovani in 100 µL were added. The amastigotes were taken from an axenic 
amastigote culture grown at pH 5.4. 4 h later the medium containing free amastigote forms 
was removed and replaced by fresh medium. Next day the medium was replaced by medium 
containing different compound dilutions. Parasite growth in the presence of the drug was 
compared to control wells. After 96 hours of incubation the medium was removed and the 
slides fixed with MeOH for 10 min followed by a staining with a 10% Giemsa solution. 
Infected and non–infected macrophages were counted for the control cultures and the ones 
exposed to the serial drug dilutions. The infection rates were determined. The results were 
expressed as % reduction in parasite burden compared to control wells, and the IC50 
calculated by linear regression analysis. 
56
 
 
 Results  
30 
 
4    Results 
 
4.1    Preparations and screening of fungal extracts and fractions to     
examine ideal culture conditions 
 
4.1.1    Screening of fungal extracts to examine ideal culture conditions for further 
investigations 
 
For screening purposes four different solid media (BMS, MPY, REA and Tennelin) were 
chosen for the cultivation of a marine-derived strain of Dichotomomyces cejpii. This strategy 
follows the idea of the so-called OSMAC approach (One Strain Many Compounds), which 
was developed by Zeeck and co-workers to achieve different secondary metabolite profiles 
from one organism.
57
 In contrast to the complex, nutrient rich media BMS (biomalt agar 
medium containing artificial seawater [ASW]) and MPY (malt, peptone, yeast agar medium), 
the REA (rice extract agar medium) and Tennelin media are minimal media, providing only a 
reduced amount and composition of nutrients. The Tennelin medium contains furthermore 
only exclusively selected ingredients, such as inorganic nitrate as sole nitrogen source. The 
fungal strain of Dichotomomyces cejpii was cultivated on each media as described before 
(3.2.2) and the four obtained crude extracts were further investigated. These “screening 
extracts” were screened for their antibiotic activities against different bacteria and fungi 
species. NMR spectroscopic and mass spectroscopic analysis was used to evaluate the crude 
extracts to judge the qualification of each media for a scaled up cultivation. As shown in 
Table 4-1, all extracts showed antibiotic activities. The media of the two extracts with the 
most prominent antibiotic activities were identified (MPY and Tennelin) and due to their 
likewise interesting spectroscopic data and sufficient biomass production selected for large 
scale cultivation  
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Table 4-1:  Antimicrobial activity of “screening extracts” obtained from Dichotomomyces cejpii cultivated on 
four different culture media 
Escherichia Bacillus Microbotryum Eurotium Mycotypha Chlorella
medium coli megaterium violaceum rubrum microspora fusca
BMS 0 3.0  (T) 0 0 2.5  (GI) 0
MPY 0 4.0 (T) 2.5 (GI) 0 2.5 (GI) 0
REA 3.0 (GI) 0 / / / /
Tennelin 2 .0 (GI) 3.0 (T) / / / /
growth inhibition (GI) and total inhibition (T) zones against test organisms [mm] 
sample concentration: 1 mg/mL (at 50 μg/disk level)
1
 
1
 50 μL (equivalent to 50 μg) of each sample solution (1 mg/mL) were pipetted onto a sterile filter disk. 
 4.1.2    Screening of fungal extracts and fractions for antibiotic activity 
 
The obtained material of large scale cultivation medium 1 (MPY) was tested for antibiotic 
activity and then fractionated by normal-phase (NP) vacuum liquid chromatography (VLC) 
using a stepwise gradient solvent system of increasing polarity starting with 100% CH2CL2 to 
100% EtOAc and to 100% MeOH which yielded 10 fractions. 
The obtained material of large scale cultivation medium 2 (Tennelin) was tested for 
antibiotic activities and then further fractionated as well, by NP VLC using a stepwise 
gradient solvent system of increasing polarity starting with 100% CH2CL2 to 100% EtOAc, to 
100% MeOH and H2O-MeOH (50-50) which yielded 11 fractions. Crude extracts and VLC 
fractions were tested for antibacterial activities in WG König. Crude extracts were 
additionally tested for anbiotic activities in WG Sahl. Agar diffusion tests of the fractions 
obtained from Tennelin medium revealed an increased antibiotic activitiy for some of the 
hydrophilic VLC fractions in comparison to the fractions of MPY medium. 
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Table 4-2:  Antimicrobial activity of fungal extracts and fractions obtained from two different media (3.6.1). 
Escherichia Bacillus Microbotryum Eurotium Mycotypha
medium coli megaterium violaceum rubrum microspora
large scale MPY 3.0 (T) 9.0 (T) 5.0 (GI) 3.5 (GI) 10.0 (T)
cultivation Tennelin 2.5 (T) 7.0 (T) 8.0 (T) 5.0 (T) 8.0 (T)
Fraction  1 MPY 2.5 (T) 9.0  (T) 6.0 (GI) 2.5 (GI) 10.0 (T)
Fraction  2 MPY 2.0 (T) 10.0 (T) 15.0 (T) 2.5 (T) 10.0 (T)
Fraction  3 MPY 0 10.0 (T) 10.0 (T) 0 10.0 (T)
Fraction  4 MPY 0 10.0 (T) 0 0 10.0 (T)
Fraction  5 MPY 0 10.0 (T) 0 0 2.0 (T)
Fraction  6 MPY 0 3.5 (GI) 0 0 0
Fraction  7 MPY 0 3.0 (GI) 0 0 0
Fraction  8 MPY 0 0 0 0 0
Fraction  9 MPY 0 0 0 0 0
Fraction 10 MPY 0 0 0 0 0
Fraction  1 Tennelin 0 0 0 0 0
Fraction  2 Tennelin 0 6.0 (T) 14.0 (T) 3.0 GI) 4.0 (T)
Fraction  3 Tennelin 5.0 (T) 11.0 (T) 6.0 (T) 5.0 (T) 8.0 (T)
Fraction  4 Tennelin 0 0 3.5 (T) 0 0
Fraction  5 Tennelin 0 2.0 (T) 3.0 (T) 3.5 (GI) 2.5 (T)
Fraction  6 Tennelin 0 3.0 (T) 0 0 0
Fraction  7 Tennelin 0 3.5 (T) 0 0 0
Fraction  8 Tennelin 0 3.0 (T) 3.5 (GI) 3.0 (GI) 0
Fraction  9 Tennelin 0 5.0 (T) 5.0 T) 4.0 (GI) 2.5 (GI)
Fraction 10 Tennelin 0 5.5 (T) 5.0 (T) 3 .0 (T) 2.0 (GI)
Fraction 11 Tennelin 0 5.5 (T) 5.0 (T) 2.5 (GI) 0
HF 10  MYA 0 0 0 0 0 /
HF 11 BMS 0 0 0 0 0 0
HF 11 CZ 0 0 0 0 0 0
HF 11 MYA 0 0 0 0 0 0
HF 12 BMS 0 0 0 0 0 0
HF 12 CZ 0 0 0 0 0 0
HF 12 MYA 0 0 0 0 0 0
HF 13 BMS 0 0 0 0 0 0
HF 13 CZ 0 0 0 0 0 0
HF 13 MYA 0 0 0 0 0 0
HF 14 BMS 0 0 0 0 0 0
HF 14 CZ 0 0 0 0 0 0
HF 14 MYA 0 0 0 0 0 0
HF 15 BMS 0 0 0 0 0 0
HF 15 CZ 0 0 0 0 0 0
HF 15 MYA 0 0 0 0 0 0
HF 16  BMS 0 0 0 0 0 0
HF 16  CZ 0 0 0 0 0 0
HF 16  MYA 0 0 0 0 0 0
HF 17 BMS 0 0 0 0 0 0
HF 17 CZ 0 0 0 0 0 0
HF 17 MYA 0 0 0 0 0 0
HF 18 BMS 0 0 0 0 0 0
HF 18 CZ 0 0 0 0 0 0
HF 18 MYA 0 0 0 0 0 0
HF 19 BMS 0 3 (GI) 0 0 0 0
HF 19 CZ 0 3 (GI) 0 0 0 0
HF 19 MYA 0 4 (GI) 0 0 0 0
HF 20 BMS 0 0 0 3 (GI) 0 0
HF 20 CZ 0 0 0 0 0 0
HF 20 MYA 0 3 (T) 0 3 (GI) 0 0
HF 21 BMS 0 3 (GI) 0 0 0 0
HF 21 CZ 0 3 (GI) 0 0 0 0
HF 21 MYA 0 2 (GI) 0 0 0 0
HF 22 BMS 0 0 0 0 0 0
sample concentration: 1 mg/mL (at 50 μg/disk level)
1
growth inhibition (GI) and total inhibition (T) zones against test organisms [mm] 
 
1
 50 μL (equivalent to 50 μg) of each sample solution (1 mg/mL) were pipetted onto a sterile filter disk. 
 
 
Table 4-3:  Antimicrobial activity of crude extracts obtained from three different media, monitored by agar 
diffusion assays in AG Sahl (3.6.2). 
MPY
1
Tennelin
1
REA
2
large scale large scale screening
6 (T) 6 (T) /
9 (T) 8 (T) 0
8 (T) 6 (T) /
12 (T) 6 (T) 0
0 0 0
13 (T) 10 (T) 0
12 (T) 4 (T) 0
7 (T) 4 (T) 0
Corynebacterium xerosis 16 (T) 20 (T) 0
Mycobacterium smegmatis 12 (T) 5 (T) 0
Echerichia coli 11 (T) 5 (T) 3  (GI)
Citrobacter freundii 7 (T) 4 (T) 0
Klebsiella pneumoniae subsp. Ozeanae 0 0 /
Arthrobacter crystallopoietes 16 (T) 8 (T) 4 (GI)
Candida albicans 9 (T) 0 /
/ 5 (T) /
CZ 0 0 0 0
MYA 0 3 (T) 0 3 (GI)
BMS 0 3 (GI) 0 0
CZ 0 3 (GI) 0 0
MYA 0 2 (GI) 0 0
BMS 0 0 0 0
sample concentration: 1 mg/mL (at 3 μg
1
 or 5 µg
2
 / spot
growth inhibition (GI) and total inhibition (T) zones against test organisms [mm] 
Staphylococcus aureus (MSSA)
Staphylococcus aureus (MRSA)
Staphylococcus simulans 
Staphylococcus epidermidis (MRSE)
Enterococcus faecium 
Bacillus subtilis 
Bacillus megaterium
test organism
Listeria welchimeri 
Candida glabrata  
3-5 μL (equivalent to 3-5 μg) of each sample solution (1 mg/mL) were pipetted onto the agar (3.6.1). 
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4.2    Isolation and evaluation of compounds with antagonistic activity at 
GPR18 and cannabinoid receptors  
 
4.2.1   Introduction to the examined cannabinoid and related receptors 
 
Cannabinoid (CB) receptors belong to the G protein-coupled receptor (GPCR) superfamily
58
 
and are divided into two distinct subtypes, designated CB1 and CB2. Both receptors are 
coupled to Gi/0 proteins mediating adenylate cyclase inhibition, which results in reduced 
intracellular cAMP levels.
59,60
 The CB1 receptor is highly expressed in the central nervous 
system, but is also present in peripheral tissues, including heart, liver, lungs and kidneys.
61,62
 
CB1 activation mediates a variety of physiological responses including analgesia, stimulation 
of appetite, and psychoactive effects, e.g. euphoria. The CB2 receptor is mainly present in 
organs and cells of the immune system including, spleen, tonsils, thymus, T-lymphocytes, 
macrophages and B-cells, and its activation results in analgesic and immunomodulatory 
effects.
61–63
  
Non-selective CB1/CB2 agonists like dronabinol (Marinol®) and nabilone (Cesamet®) are 
therapeutically used for the suppression of chemotherapy-induced nausea and vomiting,
64
 for 
the treatment of neuropathic pain, and for the therapy of anorexia in patients suffering from 
AIDS.
61
 Furthermore, beneficial effects for patients with fibromyalgia and multiple sclerosis 
have been reported.
61
 CB1-selective antagonists have gained much attraction, due to their 
suppressing effects on appetite and food intake.
65
 In addition, blockade of CB1 receptors was 
shown to ameliorate several metabolic parameters including triglyceride levels.
65,66
 Thus CB1-
selective antagonists are regarded as promising drugs for the treatment of obesity and 
metabolic disorders, such as diabetes and dyslipidemia.
67
 However, the first approved CB1-
antagonist, rimonabant, has meanwhile been withdrawn from the market due to its side-
effects, which included anxiety, depression and suicidality.
68
 These are attributed to an 
interaction with central CB1 receptors.
69,70
 Therefore current strategies focus on the 
development of CB1 antagonists that do not penetrate into the brain.
68–72
 This may be 
achieved by increasing the compounds’ polarity.72 Besides their potential use in patients with 
obesity and metabolic disorders, peripherally acting CB1 antagonists are regarded as 
promising drugs for the treatment of coronary artery disease, inflammatory bowel disorders 
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and arthritis.
67 
CB2-selective antagonists/inverse agonists are of interest as potential drugs for 
the therapy of osteoporosis, and for the treatment of dermatitis provoked by allergic skin 
inflammation.
64,73–75  
Meanwhile, several reports have indicated the existence of further CB receptors, and the 
orphan receptors GPR18 and GPR55 have been proposed as potential candidates.
76–78  
Several 
cannabinoids including the nonselective agonist ∆9-tetrahydrocannabinol (∆9-THC), as well as 
the selective CB1 inverse agonist rimonabant were shown to interact with GPR18 and 
GPR55.
35,79–82
 GPR18 is coupled to Gi proteins and is highly expressed in spleen, thymus, 
leukocytes, testis and endometrium.
79,83,84
 As an endogenous agonist for GPR18 N-
arachidonoylglycine (NAGly) was proposed by several groups.
84–87
 However, this could not 
be confirmed by other laboratories, including ours, in various assay systems.
88,89
 The 
physiological role of GPR18 is poorly understood. Studies indicate an involvement of the 
receptor in endometriosis, regulation of intraocular pressure, and microglial 
activation.
79,87,90,91
 Potent and selective GPR18 agonists and antagonists are urgently needed 
as pharmacological tools to further explore the physiological effects of this putative novel CB 
receptor subtype, which has potential as a novel drug target.  
The primarily G12,13-coupled GPR55 is mainly expressed in the brain, as well as in 
osteoclasts and osteoblasts.
77,92–94
 In addition, the receptor was shown to be highly expressed 
in several cancer cell lines, such as glioblastoma, astrocytoma, breast cancer, prostate and 
ovarian carcinomas.
95,96
 GPR55 antagonists are considered as potential drugs for the treatment 
of cancer and neuropathic pain.
80,95,96
 Besides its interaction with cannabinoids, the receptor is 
activated by 1-lysophosphatidylinositol (LSI), an endogenous lipid that does not interact with 
the established CB receptors.
35,97,98
  
Here we report on novel indole derivatives derived from a marine fungal source. Our study 
shows that compounds of fungal origin have the potential to serve as lead structures for the 
development of novel ligands for GPCRs – for CB receptors and the related orphan receptor 
GPR18. 
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4.2.2    Isolation of compounds 1–6 from Dichotomomyces cejpii 
 
Bioassay- and chemical (LC-MS and 
1
H NMR)-guided fractionation of the crude extracts, 
obtained from the marine derived fungus Dichotomomyces cejpii on two different media, 
yielded 6 indoloditerpenes in total (1–6, compound 7 is a semisynthetic derivative of 5; 
Figure 4-13). The investigated fungal strain was cultivated on cultivation medium 1 as 
described before (3.2.2–3.2.3). 
Fungal biomass and media were homogenized using an Ultra-Turrax apparatus and 
extracted with 5 L EtOAc to yield 4.1 g of extract. This material was fractionated by NP 
vacuum liquid chromatography (VLC) using a stepwise gradient solvent system of increasing 
polarity starting with 100% CH2Cl2 to 100% EtOAc and to 100% MeOH which yielded 10 
fractions. Compound 1 (emindole SB beta-mannoside) was isolated from VLC fraction 7, 
while compounds 2, 3 and 4 were found in VLC fraction 2. Fraction 7 was separated via 
reversed phase C18 (RP18)-VLC using stepwise elution with MeOH-H2O (70-30) to 100% 
MeOH which yielded 7 fractions. Subfraction 7.6 was further purified by RP C18-HPLC 
system D (Nucleodur 100-S 250 mm x 8 mm) using MeOH-H2O (95-5), 2.0 mL min
-1
. 
Compound 1 was isolated as a white powder in subfraction 7.6, tR: 10 min (6.5 mg). 
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Figure 4-1:  Isolation scheme for compound 1. For reasons of clarity only the most important fractions are listed. 
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VLC fraction 2 was separated with a NP VLC, eluted stepwise with CH2Cl2-petroleum 
ether (50-50), up to 100% CH2Cl2, and 100% MeOH which yielded 15 fractions. Subfraction 
2.1 and VLC fraction 1 were separated three times with a solvent/solvent extraction with 
hexane (100%) and MeOH-H2O (60-40) using a separation funnel. The combined hexane 
phases were further separated with a NP VLC column and eluted stepwise with CH2Cl2-
petroleum ether (20-80), up to 100% CH2Cl2, 100% acetone, and 100% MeOH which yielded 
16 fractions. Subfraction 2.1.7 was further separated with a RP18-solid phase extraction (SPE) 
cartridge, eluted stepwise with MeOH-H2O (50-50), MeOH, acetone, and CH2Cl2 which 
yielded eight fractions. Subfraction 2.1.7.4 contained compound 2, while compounds 4 and 5 
were found in subfraction 2.1.7.5. Compound 2 (27-O-methylasporyzin C) was isolated via 
RP18-HPLC (Nucleodur 100-S 250 mm x 4.6 mm) with MeOH-H2O (82-18), 1.2 mL-min
-1
 as 
a white powder, tR: 12 min (2.0 mg) . Subfraction 2.1.7.5 was further purified via RP18-HPLC 
system C (Nucleodur 100-S 250 mm x 4.6 mm) with MeOH-H2O (87.5-12.5), 1.3 mL-min
-1
. 
Compound 4 (JBIR-03) was isolated as a yellowish white powder [tR: 23 min] (30.0 mg) and 
compound 5 (emindole SB) as a white powder [tR: 21 min] (7.2 mg). 
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Figure 4-2:  Isolation scheme for compounds 2, 4, 5 and 13. For reasons of clarity only the most important 
fractions are listed. 
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VLC fraction 1 contained compounds 3 and was distributed between hexane (100%) and 
MeOH-H2O (60-40) using a solvent/solvent extraction three times. The methanolic phase was 
further separated using a RP18 VLC column and eluted stepwise with H2O-MeOH (80-20) to 
100% MeOH, 100% CH2CL2 which yielded 8 fractions. Subfraction 1.4 was further separated 
with a second NP VLC column, eluted stepwise with petrolether-CH2CL2 (80-20), to 100% 
CH2CL2, 100% acetone, and to 100% MeOH which yielded 6 fractions. Compound 3 
(emindole SB-formate) was isolated from subfraction 1.4.1 via RP18-HPLC system C 
(Nucleodur 100-S 250 mm x 4.6 mm) with MeOH-H2O (90-20), 1.7 mL-min
-1
 as a white 
powder, tR: 46 min  (1.0 mg). 
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Figure 4-3:  Isolation scheme for compounds 3. For reasons of clarity only the most important fractions are listed. 
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The investigated fungal strain was cultivated on cultivation medium 2 as described before 
(3.2.2–3.2.3) 
Fungal biomass and media were homogenized using an Ultra-Turrax apparatus and 
extracted with 5 L EtOAc to yield 1.2 g of crude extract. This material was fractionated by 
normal-phase (NP) vacuum liquid chromatography (VLC) using a stepwise gradient solvent 
system of increasing polarity starting with 100% CH2CL2 to 100% EtOAc, to 100% MeOH 
and H2O-MeOH (50-50) which yielded 11 fractions. Compound 6 was isolated from VLC 
fraction 8 and 9. The combined fractions were separated via reversed-phase C18 (RP18)-VLC, 
eluted stepwise with H2O-MeOH (70-30), to 100% MeOH, and 100% CH2CL2, which yielded 
8 fractions. Subfraction 8.6 contained both compounds. Subfraction 8.6.3 was further purified 
using RP18 Xterra
TM
 250 x 4.6 mm) with H2O-MeOH (60-40), 1.2 mL/min to obtain 
compound 6 (asporyzin C) as a white powder, tR: 10.0 min (1.0 mg). 
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Figure 4-4:  Isolation scheme for compound 6, 9 and 10. For reasons of clarity only the most important fractions are 
listed. 
 
 
 
 
. 
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4.2.3    Structure elucidation of isolated indoloditerpenes  
 
The structure of the fungal metabolite 1 was deduced via analysis of spectroscopic data. The 
UV maximum at 281 nm indicated the presence of an aromatic moiety.
99
 An IR absorption at 
3347 cm
-1
 and 1651 cm
-1
 pointed toward several hydroxyl groups and a heterocyclic bound 
nitrogen, respectively. The molecular formula of compound 1 was deduced from the results of 
an accurate mass measurement (HRESIMS, m/z = 590.3440 (M+Na)
+
 to be C34H49NO6, and 
was supported by 
1
H and 
13
C NMR data (Table 4-1). The 
13
C NMR and DEPT135 spectra 
denote the presence of 34 resonances for five methyl groups, eight sp
3
 methylene groups, five 
sp
2 
methine, eight sp
3
 methine, and eight quaternary carbons in the molecule. 
The four aromatic methine carbons CH-16 to CH-19 form one 
1
H-
1
H spin system and are 
all connected as evidenced by mutual cross peak correlations in both, the COSY and HMBC 
spectra. They are also bound to the quaternary aromatic carbons C-15 and C-20, as confirmed 
by HMBC correlations, e.g. from H-16 and H-18 to C-20, and from H-17 and H-19 to C-15. 
The 
13
C NMR resonance frequencies of the quaternary carbon atoms C-2 and C-14 are 
characteristic for an indole ring system,
100–102
 which is additionally evident from HMBC 
correlations between H-16 and C-14 and the UV maximum of 1. A second spin system was 
deciphered from COSY correlations from H2-24 through to H3-28 and H3-29 and revealed a 4-
methylpent-3-ene, i.e. part of a terpene moiety. Two further substructures were also deduced 
from COSY correlations, i.e. mutual 
1
H couplings from H-7 to H2-6 and H2-5 on one side, and 
from H-9 to H2-10, H2-11, H-12 and H2-13 on the other side. HMBC correlations arising from 
the resonances of the three methyl groups CH3-21, CH3-22 and CH3-23 allowed to connect 
and extend these substructures, revealing the three central rings of 1, apart of the indole. The 
latter was mainly accomplished by taking into account HMBC correlations between the 
resonances for the methyl group CH3-21 and C-2, C-3, C-4 and C-12, and between the methyl 
group resonance CH3-22 and C-3, C-4, C-5, and C-9 as well as between the methyl group 
CH3-23 and C-7, C-8, C-9 and C-24. Additionally, further diagnostic heteronuclear couplings, 
e.g. between H2-10 and C-8 and between H2-13 and C-14 clearly allowed to deduce the 
complete structure of the aglycone part of the molecule. The relative configuration of the 
aglycone was assigned on the basis of a NOESY experiment (Table 4-1). NOESY correlations 
between H-12, H3-22 and H3-23 indicated that these protons are located on the same side of 
the molecule, whereas NOESY correlations between H-7, H-9 and H3-21 proved the opposite 
orientation of these substituents. Further proof for the trans-anellated ring system came from 
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NOESY correlations between H-12/H-13a and between H-21/H-13b. Comparison with 
literature 
1
H and 
13
C NMR data of related compounds like emindole SB
100
 and JBIR-03
101
 
confirmed the structure of the aglycone of 1. The absolute configuration of the 
indoloditerpene scaffold was assumed to be identical to that of the co-occurring compound 
emindole SB for which the absolute configuration had been determined.
101,103
 Additional 
1
H 
and 
13
C NMR resonance frequencies pointed toward a sugar moiety in the molecule. Thus, the 
methine groups CH-7, CH-1’, CH-2’, CH-3’, CH-4’, CH-5 and the methylene group CH2-6’ 
resonate in the range of δH 3.2 to 4.6 and δC 63 to 104, respectively. The COSY spectrum 
showed correlations for a spin system from H-1’ through to H2-6’ and established a pyranose 
moiety. Analysis of the coupling constants and NOEs revealed a mannopyranose.
104
 The 
anomeric configuration of the mannose was considered as β because of the magnitude of the 
heteronuclear coupling constant between the anomeric carbon and the respective proton (
1
JCH 
= 155 Hz).
105
 Hydrolysis and HPLC-ELSD analysis using a chiral-phase column revealed the 
sugar to have the D-configuration (Figure 4-6–4.9). The mannose is attached via the CH-7 
methine group to the indoloditerpene nucleus, due to a heteronulear long range coupling from 
H-1’ to C-7. The absolute configuration of the indoloditerpene scaffold of 1 is considered to 
be to the same as that of the co-occurring compound emindole SB for which the absolute 
configuration had been determined recently.
11,13
 The fungal metabolite 1 is thus an 
indoloditerpene, substituted with a dimethylallyl containing side chain and a mannose moiety, 
for which we suggest the trivial name emindole SB beta-mannoside . 
 
 
 
 
                                                                               
 
 
 
 
 
Figure 4-5:  NMR key correlations of compound 1 
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Carbohydrate analysis of compound 1 
Measurement conducted as described in 3.6.6 
 
 
Figure 4-6: HPLC chromatogram of D-Mannose 
 
 
Figure 4-7: HPLC chromatogram of L-Mannose 
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Figure 4-8: HPLC chromatogram of hydrolysis mixture 
 
 
Figure 4-9: HPLC chromatogram of hydrolysis mixture + L-Mannose 
 
The structure of the fungal metabolite 2 was found to be closely related to that of 1. The 
molecular formula of 2 was deduced as C29H41NO2Na from the results of an accurate mass 
measurement (HRESIMS, m/z = 458.3043 [(M+Na)]
+
).  
The structure of compound 2 differs from that of compound 1 solely by the missing sugar 
moiety at C-7 and some structural changes in the terpene side chain. The 
13
C NMR resonance 
frequency at δC 72.9 for the methine group CH-7 was shifted upfield by 11 ppm as compared 
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to 1 and thus, verified the presence of an unsubstituted hydroxyl group at that position.
100
 The 
structure of the terpenoid chain was elucidated by COSY correlations from H2-24 through to 
H-26 and HMBC correlations between the methyl groups CH3-28 and CH3-29 and CH-26. 
The configuration of the double bound between CH-25 and CH-26 was determined as E, 
based on a coupling constant of JH-25/H-26 = 15.7 Hz. Since C-27 was quaternary in 2 and 
resonated at δC 75.2, the methoxy group in the molecule, which was evident from 
1
H and 
13
C 
NMR resonance frequencies at δH 3.12 and δC 50.3, was clearly located at C-27. Furthermore, 
the NMR chemical shifts of the terpenoid moiety  were identical with those of the 4 methoxy-
4-methylpent-2-enyl unit in momordicosides K.
106
 The configuration of 2 was assigned in the 
same manner as described for 1. For the fungal metabolite 2 we suggest the name 27-O-
methylasporyzin C.  
 
 
 
 
 
 
 
 
Figure 4-10:  NMR key correlations of compound 2 
 
 
The structure of the fungal metabolite 3 was found to be closely related to that of 1. The 
molecular formula of 3 was deduced as C29H39NO2 from the results of an accurate mass 
measurement (HRESIMS, m/z = 433.29840). The structure of compound 3 differs from that of 
compound 1 solely by the missing sugar moiety at C-7 which was replaced by a carbonyl 
substituent. The 
13
C NMR resonance frequency at δC 76.8 for the methine group CH-7 was 
shifted upfield by 7 ppm as compared to 1 and verfied a different substitution pattern. The 
13
C 
NMR resonance frequency at δC 162.8 and the typical 
1H NMR resonance frequency at δH 
8.15, indicated the presence of an aldehyde moiety which could be linkend to C-7, due to 
HMBC correlations between the resonances for the methin group CH-7 and carbon atom C-
30. Furthermore, the NMR chemical shifts of the aldehyde moiety and methin CH-7 were 
almost identical with those of the corresponding aldehyde unit in the fungal compound 
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colletotrichin B.
107
 The configuration of 3 was assigned in the same manner as described for 
1. For the fungal metabolite 3 we suggest the name emindole SB-formate.  
 
 
 
 
 
 
 
 
 
Figure 4-11:  NMR key correlations of compound 3 
 
 
Comparison of data from NMR and mass spectroscopy with literature data, lead to the 
identification of compounds 4–6. The fungal metabolites 3–6 were identified as the 
indoloditerpene JBIR-03, emindole SB and asporyzin C, respectively.
100,101,103,108
 
It is remarkable that the optic rotation values of JBIR-03 could not be reliably measured in 
methanol, due to the low solubility of JBIR-03 in the solvent. Repeated measurement of 
JBIR-03 in CH3CN, showed negative optic rotation values, similar to other indoloditerpenes.  
        Figure 4-12: Structures of isolated indoloditerpenes. 
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Table 4-4: NMR spectroscopic data (300 MHz, acetone-d6) for emindole SB beta-mannoside (1)  
 
position δC , mult. δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC  
1
H-
1
H NOESY 
1 NH 9.80, brs - - - 
2 152.0, C - - - - 
3  53.8, C - - - - 
4  39.7, C - - - - 
5  33.3, CH2 1.81, m 6a,6b 9,22 - 
6  26.8, CH2 6a: 2.10, m 
6b: 1.86, m 
5,6b,7 
5,6a,7 
7,8 
7,8 
- 
- 
7  83.9, CH 3.62, m 6a,6b 1’ 9 
8  42.0, C - - - - 
9  40.7, CH 1.81, m 10a,10b 4,7,8 7,21 
10  23.3, CH2 10a: 1.63, m 
10b: 1.45, m 
9,10b,11a,11b 
9,10a,11a,11b 
- 
- 
- 
- 
11 25.9, CH2 11a: 1.75, m 
11b: 1.65, m 
10a,10b,11b,12  
10a,10b,11a,12 
- 
- 
- 
- 
12  49.7, CH 2.75, m  11a,11b,13a,13b - 13a,22 
13  28.0, CH2 13a: 2.62, dd (6.2, 13.2) 
13b: 2.29, dd (10.6, 13.2) 
12,13b 
12,13a 
2,3,12,14 
2,12,14 
12,13b 
13a,21 
14 117.7, C - - - - 
15 126.0, C - - - - 
16 118.6, CH 7.31, dd (1.8, 7.6) 17 14,18,20 17 
17 119.6, CH 6.92, td (7.6, 1.8) 16,18 15,16,19 16 
18 120.5, CH 6.96, td (7.6,  1.8) 17,19 16,19,20 19 
19 112.5, CH 7.28, dd (1.8, 7.6 ) 18 15,17,20 18 
20 141.5, C - - - - 
21 15.0, CH3 1.03, s - 2, 3, 4, 12 9,13b 
22 19.4, CH3 1.11, s -  3,4,5,9 12,23 
23 17.9, CH3 0.83, s - 7,8,9,24 22 
24 38.2, CH2 24a: 1.50, m 
24b: 1.27, m 
24b,25a,25b 
24a,25a,25b 
- 
- 
- 
- 
25 22.2, CH2 25a: 2.03, m  
25b: 1.93, m 
24a,24b,25b,26 
24a,24b,25a,26 
26,27 
26,27 
- 
- 
26 125.8, CH 5.13, t (7.0 ) 25a,25b,28,29 28,29 28 
27 131.1,  C - - - - 
28  25.9, CH3 1.66, s 26 29 26,27,29 26 
29  17.8, CH3 1.64, s 26,28 26,27,28  - 
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1´ 103.5, CH 4.63, s 2’ 7,2´,5’ 2´,3´,4’,5’ 
2´  72.2, CH 3.89, brd (3.3) 1´,3´ 3’,4’ 1’,3’ 
3´  75.5, CH 3.42, brdd, (3.3, 9.2) 2´,4´ 4’ 1’,2’ 
4´  69.2, CH 3.64, m 3´,5´ 3’,5’ 1’ 
5´  77.6, CH 3.25, ddd (3.3, 5.9, 9.2) 4´,6´ 3’ 1´,3´ 
6´  63.2, CH2 6´a: 3.82, dd (3.3, 12.1) 
6´b: 3.69, dd (5.9, 12.1) 
5´,6´b 
5´,6´a 
- 
5’ 
6’b 
6’a 
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Table 4-5: NMR spectroscopic data (300 MHz, acetone-d6) for 27-O-methylasporyzin C (2) 
 
Position δC , mult. δH ( J in Hz) 
1
H-
1
H COSY  
1
H-
13
C HMBC  
1
H-
1
H NOESY 
1 NH 9.77, brs - - - 
2 151.9, C - - - - 
3  53.7, C - - - - 
4  39.9, C - - - - 
5  33.3, CH2 1.80, m 6a,6b 9  - 
6  28.3, CH2 6a: 1.80, m 
6b: 1.68, m 
5,6b,7 
5,6a,7 
7,8 
7,8  
- 
7  72.9, CH 3.52, m  6a, 6b - 9 
8  43.1, C - - -   - 
9  41.1, CH 1.69, m  10a,10b 4 7,25 
10  23.2, CH2 10a: 1.75, m 
10b: 1.46, m 
9,10b,11b 
9,10a,11b 
- 
- 
- 
- 
11  25.9, CH2 11a: 1.74, m 
11b: 1.59, m  
11b,12 
10a,10b,11a,12 
- 
- 
- 
- 
12  49.7, CH 2.75, m 11a,11b,13a,13b,  - 13a,22 
13  27.9, CH2 13a: 2.61, dd (6.2, 13.2) 
13b: 2.28, dd (10.6, 13.2) 
12,13b 
12,13a 
2,3,12,14, 
2,12,14  
13b,12 
13a 
14 117.7, C - - - - 
15 125.9, C - - - - 
16 118.6, CH 7.30, dd, (1.8, 7.7) 17 14,18,20 17 
17 119.5, CH 6.90, td, (1.8, 7.7) 16,18 15,16,19 16 
18 120.5, CH 6.95, td, (1.8, 7.7) 17,19 16,19,20 19 
19 112.5, CH 7.28, dd (1.8, 7.7) 18 15,17,20 18 
20 141.5, C - - - - 
21  14.8, CH3 0.98, s - 2,3,4,12 5,9,13b 
22  19.1, CH3 1.10, s - 3,4,5,9 5,12,23 
23  16.8, CH3 0.84, s - 7,8,9,25 22,24a   
24  40.6, CH2 24a: 2.45, dd (6.2, 13.9)  
24b: 1.95, dd (8.8, 13.9) 
24b,25 
24a,25 
8,25,26 
8,25,26 
24b,23 
24a 
25 126.6, CH 5.66, ddd (6.2, 8.8, 15.7) 
 
24a,24b,26 24,26,27 28,29,30  
26 139.2, CH 5.50, d (15.7) 25 24,25,27,28 28,29,30 
27  75.2,  C - - - - 
28  26.9, CH3 1.22, s - 26,27,29 25,26,30 
29  26.3, CH3 1.22, s - 26,27,28 25,26,30 
30  50.3, CH3 3.12, s - 27 25,28,29 
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Table 4-6: NMR spectroscopic data (300 MHz, acetone-d6) for emindole SB-formate (3) 
 
position δC , mult. δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC  
1
H-
1
H NOESY 
1 NH 9.82, brs - - - 
2 151.9, C - - - - 
3  54.3, C - - - - 
4  40.3, C - - - - 
5  33.1, CH2 1.90, br m 6 9 - 
6  22.4, CH2 1.92, br m 5, 7 - - 
7  76.8, CH 4.99, br m 6 - 9 
8  41.4, C - - - - 
9  41.3, CH 1.86, m 10a,10b 10 7,21 
10  23.6, CH2 10a: 1.60, m 
10b: 1.50, m 
9,10b,11a,11b 
9,10a,11a,11b 
- 
- 
- 
- 
11 25.2, CH2 11a: 1.86, m 
11b: 1.67, m 
10a,10b,11b  
10a,10b,11a,12 
- 
- 
- 
- 
12  50.2, CH 2.76, m  11b,13a,13b - 11a,22 
13  28.3, CH2 13a: 2.62, dd (6.2, 13.2) 
13b: 2.29, dd (7.7, 13.2) 
12,13b 
12,13a 
2,3,12,14,16,  
2,12,14,  
12,13b 
13a,22 
14 118.0, C - - - - 
15 126.2, C - - - - 
16 118.7, CH 7.28, dd (6.6) 17 17, 18 17,18 
17 119.7, CH 6.91, td (6.6) 16,18 16,19 16,19 
18 120.8, CH 6.94, td (6.6) 17,19 16,19 16,19 
19 112.6, CH 7.26, dd (6.6 ) 18 15,17,20 17,18 
20 142.1, C - - - - 
21 14.9, CH3 1.03, s - 2, 3, 4, 12 9,13b 
22 19.4, CH3 1.14, s - 3,5,8,9,23 12,23 
23 18.2, CH3 0.93, s - 7,8,9,22,24 22 
24 38.6, CH2 1.22, m 25 - - 
25 22.2, CH2 1.93, m 24,26 - - 
26 125.5, CH 5.05, m  25,28,29 - - 
27 132.2,  C - - - - 
28  26.0, CH3 1.67, s 26, 29 26,27,29 26 
29  17.7, CH3 1.60, s 26, 28 26,27,28  - 
30 162.8, C 8.15, s - 7 - 
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Table 4-7: NMR spectroscopic data (300 MHz) for compounds 4–6  
 JBIR-03  (4) 
(methanol-d4) 
emindole SB (5) 
(acetone-d6) 
asporyzin C (6) 
(acetone-d6) 
Pos. δC , mult. δH ( J in Hz) δC, mult. δH ( J in Hz) δC, mult.  δH ( J in Hz) 
1 - 9.78 brs - 9.76, brs NH - 
2 152.0, C - 152.0, C - 150.7, C - 
3  54.1, C -  53.9, C -  52.6, C - 
4  41.5, C -  40.0, C -  39.4, C - 
5  34.5, CH2 1.95, m  33.4, CH2 1.81, m  33.9, CH2 1.80, m 
6  23.6, CH2 10a: 1.90, m 
10b: 1.70, m 
 28.4, CH2 1.81, m 
1.71, m 
 28.4, CH2 6a: 1.85, m 
6b: 1.78, m 
7  87.5, CH 3.31, m  72.9, CH 3.53, m  72.3, CH 3.55, m  
8  46.2, C -  42.0, C -  42.0, C - 
9  47.8, CH 1.79, m  40.6, CH 1.79, m  40.0, CH 1.65, m  
10  26.5, CH2 1.58, m  23.5, CH2 10a: 1.66, m 
10b: 1.46, m 
 22.2, CH2 10a: 1.76, m 
10b: 1.49, m 
11  26.4, CH2 11a: 1.70, m 
11b: 1.57, m 
 26.0, CH2 11a: 1.74, m 
11b: 1.66, m 
 24.8, CH2 11a: 1.75, m 
11b: 1.50, m  
12  50.3, CH 2.80, m  49.8, CH 2.76, m  48.8, CH 2.80, m 
13  28.4, CH2 13a: 2.66, dd (6.6, 13.2) 
13b: 2.33, dd (10.6, 13.2) 
 28.0, CH2 13a: 2.62, dd (6.6, 13.2) 
13b: 2.30, dd (10.6, 13.2) 
 27.6, CH2 13a: 2.65, dd (6.3, 13.2) 
13b: 2.31, m 
14 117.9, C - 117.7, C - 116.7, C - 
15 126.3, C - 125.4, C - 126.3, C - 
16 118.7, CH 7.33, m 118.6, CH 7.31, dd (1.8, 7.6) 117.2, CH 7.32, m 
17 119.7, CH 6.97, brtd (7.6, 1.8) 119.5, CH 6.92, td (7.6, 1.8) 119.1, CH 6.95, m 
18 120.7, CH 6.99, brtd (7.6, 1.8) 120.5, CH 6.95, td (7.6, 1.8) 121.9, CH 6.98, m 
19 112.6, CH 7.33, m 112.5, CH 7.28, dd (1.8, 7.6) 111.1, CH 7.30, m 
20 142.1, C - 141.6, C - 141.0, C - 
21  15.0, CH3 1.07, s  15.0, CH3 1.03, s  13.5, CH3 0.94, s 
22  21.0, CH3 1.14, s  19.4, CH3 1.11, s  17.8, CH3 1.16, s 
23  15.4, CH3 0.94, s  17.3, CH3 0.83,s  15.3, CH3 0.88, s 
24  49.5, CH2 24a: 2.01, m 
24a: 1.29, m 
 38.2, CH2 24a: 1.68, m 
24b: 1.21, m 
 38.9, CH2 24a: 2.36, m  
24b: 2.00, m 
25 75.3, CH 4.89, m  22.1, CH2 25a: 2.00, m 
25b: 1.91, m 
121.8, CH 5.75, m 
 
26 127.9, CH 5.38, brd (8.8) 126.1, CH 5.11, brt (6.7) 138.5, CH 5.40, m 
27 135.6, C - 131.0, C -  73.0,  C - 
28  26.0, CH3 1.78, s  25.9, CH3 1.66, s  28.5, CH3 1.31, s 
29  18.0, CH3 1.74, s  17.7, CH3 1.61, s  28.8, CH3 1.36, s 
*extracted from HMBC meassurement 
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4.2.4    Semisynthetic preparation of compound 7 
 
Compound 7 was prepared as described in 3.5.1 to yield 3.5 mg. 
Proposed structure of the semisynthetical product was confirmed by NMR and MS 
measurements (Table 4-8). The structure of the fungal metabolite 7 was found to be closely 
related to that of 1. The molecular formula of 7 was deduced as C32H46N2O2 from the results 
of an accurate mass measurement (HRESI-MS m/z 513.3442 [(M+Na)]
+
). We suggest the 
trivial name emindole SB-N-propylcarbamate for compound 7. 
 
 
Figure 4-13: Carbamoylation of emindole SB with propylisocyanate 
 
a)  b)   c)                                                        
 
Figure 4-14: a) Experimental setup; RP18 TLC, MeOH-H2O (90-10) of b) synthesis product and educt, detected 
with vanillin-H2SO4-reagent after 24h; c) synthesis product, detected with vanillin-H2SO4-reagent after 96h.
educt educt and 
synthesis 
product 
educt and 
synthesis 
product 
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Table 4-8: NMR spectroscopic data (300 MHz, acetone-d6) for emindole SB-N-propylcarbamate (7)  
Position δC , mult. δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC  
1 NH 6.2 - - 
2 151.9, C - - - 
3 53.9, C - - - 
4  39.7, C -  - 
5  33.1, CH2 1.85 6a,6b,7 6,7,9 
6  25.9, CH2 6a 1.86 
6b 1.70 
5,6b,7 
5,6a,7 
- 
4,5,7,8 
7  75.6, CH 4.69, dd   (4.4, 9.9) 5,6a,6b - 
8  41.0, C - - - 
9  41.3, CH 1.81, br m 10a,10b,11a,11b 6,8 
10 23.3, CH2 10a 1.65, m 
10b 1.47, m 
9, 11a,11b 
9, 10a,11a,11b  
- 
11 25.2, CH2 11a 1.75,  m 
11b 1.64,  m 
9,10a,10b,11b 
9,10a,10b,11a, 12 
3 
12 49.8, CH 2.76,  m 11b,13a,13b - 
13 27.9, CH2 13a 2.63, dd (6.6, 13.2) 
13b 2.31 (10.6, 13.2) 
13b,12 
13a,12 
2, 3, 12, 14  
2, 12, 14  
14 117.8, C - - - 
15 125.9, C - - - 
16 118.7, CH 7.31, dd (1.1, 3.7, 7.3) 17,18 15, 17, 18  
17 120.6, CH 6.93, dd (1.8, 7.3, 12.8) 16,19 15, 19, 20 
18 119.6, CH 6.96, dd (1.8, 7.3, 12.8) 17,19 15, 19, 20 
19 112.5, CH 7.28, dd (1.1, 3.7) 17,18 15, 17, 18 
20 141.7, C - - - 
21 15.0, CH3 1.06 (s) - 2,3, 4,12 
22 19.4, CH3 1.13 (s) - 3 ,4, 5 
23 18.0, CH3 0.85 (s) - 7,4, 8, 9,24 
24 38.5, CH2 1.25, dd (8.4, 16.1)   25a,25b - 
25 22.1, CH2 25a 2.06,  m  
25b 1.84  m 
24,26 - 
26 125.6, CH 5.06, t (7.3 ) 25a,25b,28,29 - 
27 131.4 , C - - - 
28 25.9, CH3 1.64, s 26 26,27,29 
29 17.6,  CH3 1,58, s 26 26,27,28 
30 157.0, C - - - 
31 NH 6.2, s - - 
32 43.2, CH2 3.08, m (6.6, 13.2, 19.4)  31,33 30 
33 23.9, CH2 1.50, dd (7.3,14.6) 32,34 32,34 
34 11.5, CH3 0.89 32,33 32,33 
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Emindole SB beta-mannoside (1): white amorphous compound (6.5 mg; 0.65 mg L
-1
). 
[α]D
25 + 33.1 (c 0.36, MeOH); UV (MeOH ) λmax (log ε) 229 (4.27), 281 (3.67) nm; IR (ATR) 
νmax 3347, 2924, 1651, 1454, 1375, 1303, 1254, 1072, 1025, 740 cm
-1
; 
1
H and 
13
C NMR data 
(Table 4-4); ESI-MS m/z  568 [M+H]
+
, 586 [M+NH4]
+
; HRESI-MS m/z  590.3440 [M+Na]
+
 
(calcd for C34H49NO6Na, m/z 590.3452).  
 
27-O-methylasporyzin C (2): white amorphous compound (2.0 mg; 0.2 mg L
-1); [α]D
25 
- 
27.6 (c 0.17, MeOH); UV (MeOH ) λmax (log ε) 229 (5.31), 280 (4.76) nm; IR (ATR) νmax 
3361, 2924, 1642, 1585, 1376, 1202, 1072, 1376, 1202, 668, 631 cm
-1
; 
1
H and 
13
C NMR data 
(Table 4-5); ESI-MS m/z 436 [M+H]
+
; HRESI-MS m/z 458.3043 [M+Na]
+
 (calcd for 
C29H41NO2Na,  m/z 458.3030). 
 
Emindole SB beta-formate (3): white amorphous compound (1.0 mg; 0.1 mg L
-1). [α]D
25 
- 
5.7 (c 0.23, MeOH); UV (MeOH ) λmax (log ε) 228 (3.56), 280 (3.06) nm; IR (ATR) νmax 
3385, 2924, 2850, 1720, 1512, 1248,  1180, 1032, 668, 630cm
-1
; 
1
H and 
13
C NMR data (see 
Table 4-6); ESI-MS m/z  434 [M+H]
+
, 432 [M-H]
-
, HRESI-MS m/z  433.2984 [M+Na]
+
 
(calcd for C29H39N2O2, m/z 433.2981).  
 
JBIR-03 (4): white amorphous compound (30.0 mg, 3.0 mg L
-1); [α]D
25 
- 18.1 (c 1.10, 
CH3CN) [lit: [α]D
24.5 
+46.2 (c 0.05, MeOH)
101
]; 
1
H and 
13
C NMR data (Table 4-7); ESI-MS 
m/z 404 [M+H]
+
.  
 
Emindole SB (5): white amorphous compound (7.2 mg, 0.72 mg L
-1); [α]D
25 
 - 24.2 (c 
0.12, acetone), [lit: [α] D
25
 -19 (c 0.2, CHCl3)
103
]; 
1
H and 
13
C NMR data (Table 4-7); ESI-MS 
m/z 406 [M+H]
+
. 
 
Asporyzin C (6): white amorphous compound (1.0 mg; 0.1 mg L
-1
); 
1
H and 
13
C NMR data 
(Table 4-7); ESI-MS m/z 422 [M+H]
+
; 480 [M+HAc-H]
-
. 
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Emindole SB-N-propylcarbamate (7): white amorphous compound (3.5 mg); [α]D
25 
+ 6.1 
(c 0.14, CH3CN); UV (MeOH ) λmax (log ε) 228 (3.95), 280 (3.32) nm; IR (ATR) νmax 3385, 
2924, 2850, 1720, 1512, 1248,  1180, 1032, 668, 630cm
-1
; 
1
H and 
13
C NMR data (Table 4-8); 
ESI-MS m/z 491 [M+H]
+
; 489 [M-H]; HRESI-MS m/z 513.3442 [M+Na]
+
 (calcd for 
C32H46N2O2Na,  m/z 513.3451). 
4.2.5    Biological activity of indoloditerpenes 
 
Synthetic CB receptor ligands based on an indole scaffold have been described, e.g. the 
CB1/CB2 agonist (R)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-naphthalenylmethanone (WIN55,212-2), and the CB2 antagonist/inverse 
agonist6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxy-phenyl) 
methanone (AM630).
73,109,110 
Recently, we identified amauromine (8, Figure 4-16), an indole 
derivative derived from the marine fungus Auxarthron reticulatum, as a novel lead structure 
for CB1-selective antagonists.
111
 Due to structural similarities between the here reported 
indoloditerpenes (1–7) and amauromine we investigated 1–2, 4–5 and 7 in radioligand 
binding and functional assays (inhibition of forskolin-stimulated cAMP accumulation) at 
human CB1 and CB2 receptors. In addition we studied indole derivatives for their interaction 
with the CB receptor-like orphan GPCRs GPR18 and GPR55 using β-arrestin translocation 
assays.
35,112
 (see 3.6.3–3.6.5) 
All isolated examined indole derivatives interacted with one or more of the four 
investigated receptors (Table 4-9). Examples for concentration-inhibition curves are shown in 
Figure 4-15 and  Figure 4-16. None of the compounds showed any significant effect on 
GPR55 at the highest test concentration of 10 µM. All of the active compounds were 
characterized as receptor antagonists in functional assays at CB1 and/or CB2 receptors and/or 
GPR18 (see Table 4-10). 
The new fungal metabolite emindole SB beta-mannoside (1), a pentacyclic indole 
derivative, displayed preferenced binding to the CB2 receptor with a Ki value of 10.6 µM. 
cAMP accumulation assays showed that it was a CB2 antagonist since it did not lead to 
receptor activation (see Table 4-10). It is surprising that the CB2 receptor accepted the polar 
sugar moiety attached to the lipophilic core structure in compound 1. One explanation may be 
that the sugar moiety points towards the extracellular aqueous space of the receptor. In 
contrast to the majority of known CB receptor ligands indole derivative 1 shows high water-
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solubility due to the attached mannose. Thus, compound 1 may be a starting point for the 
development of water-soluble CB2 receptor antagonists with increased affinity.  
Its aglycon-derivative emindole SB (compound 5) was about 5-fold more potent at the CB2 
receptor (Ki 2.24 µM) than mannoside 1, and displayed additional affinity for the CB1 
receptor (Ki 7.05 µM).  
The new pentacyclic indole derivative 27-O-methylasporyzin C (2), which is lacking the 
sugar moiety of 1 and features a different side-chain , was found to be an antagonist at the 
CB-like receptor GPR18 with an IC50 value of 13.4 µM measured in a functional assay versus 
7.5 µM THC (corresponding to its EC80) (Table 4-9 and 4-10, Figure 4-15). Compound 2 
showed some selectivity versus all of the other investigated receptors, CB1, CB2 and GPR55. 
So far, selective GPR18 antagonists are unknown. Therefore 2 may be used as a tool to study 
GPR18, and as a lead structure for further optimization. 
Compound 4, a hexacyclic indole derivative, was almost equipotent at CB1 (Ki 4.40 µM) 
and CB2 (Ki 4.76 µM) receptors, and similarly active at GPR18 (IC50 9.91 µM). At GPR18, 
the inhibition curves for compounds 2 and 4 went down below basal values (Figures 4-15 C 
and D) indicating an inverse agonistic mode of action for these two compounds. 
We additionally investigated the recently published selective CB1 antagonist amauromine 
(8)
111
 for an interaction with the CB-like receptors GPR18 and GPR55. Like 2 and 4, 
amauromine showed no significant interaction with GPR55, but it exhibited a remarkable 
inhibition of GPR18 (IC50 3.74 µM, Figure 4-12). Our results show that the binding pocket of 
GPR18 appears to be closely related to those of the CB receptors, while GPR55 has clearly 
different structural requirements. 
Due to our results we endeavoured the synthesis of an emindole SB derivative with a 
substitution at the hydroxylgroup at C-7 similar to compound 1, following the hypothesis that 
a substitution at this position might shift compound properties toward more selective CB2 
receptor activities. Unfortunetly the N-propylcarbamate (7) failed to interact with one of these 
receptors indicating that other substitution patterns with maybe more hydrophilic moieties 
should be tested. 
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Figure 4-15: Concentration-inhibition curves. (A) Inhibition of specific [
3
H]CP55,940 binding by 
compound 1 at CB2 receptors (Ki CB2 10.6 µM); (B) inhibition of specific [
3
H]CP55,940 binding by 
compound 5 at CB1 (▼, Ki 7.05 µM) and CB2 receptors (■, Ki 2.24 µM); (C, D) inhibition of ∆
9
-THC (7.5 
µM)-induced β-arrestin recruitment by 2 (C, IC50 13.4 µM), and 4 (D, IC50 9.91 µM), respectively. Data 
points represent means ± SEM of three independent experiments, performed in duplicates. 
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Figure 4-16: Structure of auromine (8) and inhibition of ∆9-THC (7.5 µM)-induced β-arrestin recruitment by 8 at 
GPR18 (IC50 3.74 µM). Data points represent means ± SEM of three independent experiments, performed in 
duplicates. 
 
[5] [1] 
[2] 
[4] 
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Table 4-9: Biological evaluation of compounds 1–2, 4–5 and 7–8 at human CB receptors and orphan 
receptors GPR18 and GPR55. 
Compound Radioligand binding vs. 
[
3
H]CP55,940 
Ki ± SEM (µM) 
β-Arrestin assays IC50 (µM) 
CB1 
 
CB2 
 
GPR18  GPR55  
Emindole SB beta-mannoside 
(1) 
>10  
(30%)
d 
10.6  
± 1.8 
 >10  
(15%)
b
 
>10  
(13%)
c                                                                                                                                                                                                                                                                                                                                                                           
 
27-O-methylasporyzin C (2) >10  
(39%)
d
 
>10  
(33%)
d
 
13.4  
± 1.3 
>10  
(31%)
c
 
JBIR-03 (4) 4.40  
± 1.07 
4.76  
± 1.39 
9.91  
± 2.59
 
>10 
 (0%)
c
 
Emindole SB (5) 7.05 
 ± 1.04 
2.24  
± 0.30 
>10  
(37%)
b 
>10  
(12%)
c 
Emindole SB-N-
propylcarbamate (7) 
>10  
(31%)
d
 
>10  
(26%)
d
 
>10  
(15%)
b 
>10  
(19%)
c 
Amauromine (8) 0.178
111
 >10
111
 3.74  
± 0.52
 
>10  
(17%)
c 
a Efficacy related to the maximum effect of the full agonist CP55,940 (1 µM = 100%). 
b %Inhibition of THC (10 µM)-mediated β-arrestin recruitment. 
c %Inhibition of LPI (1 µM)-mediated β-arrestin recruitment. 
d %Inhibition of [3H]CP55,940 binding. 
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Table 4-10: Intrinsic activities of compounds 1-2, 4-5 and 7–8 at CB receptors and GPR18 and GPR55 
Compound. cAMP Assays 
% inhibition of forskolin(10 µM)-
induced cAMP production 
β-Arrestin assays 
EC50 (µM) 
CB1 CB2 GPR18  GPR55  
Emindole SB beta-mannoside (1) n.d. (0%)  >10 (0%)
a
 >10 (0%)
b
 
27-O-methylasporyzin C (2) n.d. n.d. >10 (0%)
a
 >10 (0%)
b
 
JBIR-03 (4) (0%) (0%) >10 (0%)
a 
>10 (0%)
b
 
Emindole SB (5) (12%)
 
(0%)  >10 (0%)
a 
>10 (0%)
b 
Emindole SB-N-propylcarbamate 
(7) 
n.d n.d >10 (0%)
a 
>10 (0%)
b 
Amauromine (8) (6%) 
KB 66.6 nM 
n.d. >10 (0%)a  >10 (36%)b 
a% activation of β-arrestin recruitment related to the effect of THC (10 µM, set at 100%).b% activation of β-
arrestin recruitment related to the effect of LPI (1 µM, set at 100%), n.d: not detectable. 
 
 4.2.6    Discussion of indoloditerpenes and their biological activities 
 
Biological activity 
Due to increasing knowledge on the pathophysiological roles of the endocannabinoid 
signaling system, ligands for CB receptors and related GPCRs, such as GPR18 and GPR55, 
are currently in the focus of interest in drug research.  
Natural products are known to be an excellent source for the identification of novel lead 
compounds.
4,7  
It is interesting to note that CB receptor ligands from natural sources like 
plants and fungi have been isolated before. Non-selective CB receptor ligands have been 
obtained most prominently from Cannabis sativa,
113,114 
but also from Magnolia officinalis,
112
 
a medicinal plant used in Chinese traditional medicine, and from the fungus Eurotium 
repens.
115
 M. officinalis contains magnolol, which is an agonist at both CB receptor subtypes, 
however with a preference for CB2 (Ki CB1 3.15 μM; Ki CB2 1.44 μM). The same plant also 
contains honokiol which behaves as a CB1 agonist and a CB2 antagonist (Ki CB1 6.46 μM; Ki 
CB2 5.61 μM).
112
 Selective CB1 antagonists have also been isolated from plants and fungi. 
From the plant Voacanga africana the CB1-selective iboga-type bis-indole voacamine, and 
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two iboga-type monomeric alkaloids have been described,
116
 while the CB1-selective 
diketopiperazine amauromine was found in the fungus Auxarthron reticulatum.
111
 
Recently a group of structurally related indoloditerpenes, e.g. lolitrem B, have been 
reported to decrease immune responses associated with cytokine production in spleen and 
macrophages. These effects have up to now only been correlated with the observed inhibition 
of potassium channel function.
117,118
 However, reduction of cytokine production has also been 
noted for CB receptor antagonists.
119
 Due to our results an additional role of the CB receptor 
system for the observed immunosuppressive effects should be considered and further 
investigated. 
The herein described emindole SB beta-mannoside (1) is the first CB receptor antagonist 
from a fungal source with a preference for the CB2 receptor subtype. Compound 1 was 
examined for cytotoxic activity toward an L6 rat skeletal muscle cell line. In comparison to 
the cytotoxic reference compound podophyllotoxin with an IC50 of 0.007 μg/mL, compound 1 
was shown to hardly display any cytotoxic activity (IC50 32.8 μg/mL).
37,38,120
 
In addition we identified 2, 4 and 8 as the first ligands of fungal origin for the orphan 
receptor GPR18. Selective GPR18 antagonists are urgently needed as pharmacological tools 
to further elucidate the physiological role of this poorly characterized receptor. So far, no 
selective antagonists for the GPR18 have been described. GPR18 antagonists are regarded as 
potential drugs for the treatment of cancer and endometriosis.
79,121
 The structurally novel 
antagonists 1 and 2 may serve as important leads for the development of more potent and 
selective ligands for this therapeutically interesting CB receptor-related drug target. 
 
 
4.3    Isolation and evaluation of uncommon sterols and xanthocillin 
derivatives with Aβ-42 lowering activity 
 
4.3.1   Introduction to the role of Aβ-42 lowering agents in Alzheimer disease 
 
Alzheimer disease (AD) causes dementia in many elderly people and is an increasing 
problem, especially in aging western societies.
122
 The neurodegenerative AD is defined by 
two pathological features, amyloid plaques and aggregates of mis-folded tau proteins. 
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Accumulation of neurotoxic amyloid β peptides (AβP) like Aβ-42 within the brain plays an 
important role in the pathology of  Alzheimer disease.
122,123
 Aβ  precursor proteins (APPs) are 
cleaved by β- and γ-secretases and release several species of Aβ-peptides with different 
properties, depending on the cleavage site.
122,123
 Compounds influencing this cascade, i.e. 
inhibitors of β-secretases (BACE), γ-secretase (GSIs) and γ-secretase modulators (GSMs), are 
needed as research tools and investigated as potential therapeutical agents.
123–126,125,126
 Aftin-5 
an activator of extracellular Aβ-42 production, can be used to simulate essential aspects of 
AD in cell cultures and facilitates the identification of Aβ-lowering agents.40,123 
The therapeutic use of secretase inhibitors is regarded as critical, since they cause severe 
side effects. One well known reason for the latter is inhibition of the cleavage of substrates 
other than APP, like neuregulin-1 or Notch.
124,125
 To avoid this problem, the identification of 
secretase inhibitors which display increased substrate selectivity is desired. In order to 
achieve this, optimization of assays and biomarkers, allowing a more comprehensive 
assessment of secretase inhibitors is necessary.
124,125
 Another approach is the development of 
γ-secretase modulators. GSMs partially shift the preferred cleavage site of γ-secretase to 
various extents. Consequently the production ratio of AβP subspecies is influenced, without 
inhibiting the γ-secretase cleavage, completely.  
Here we report on novel, untypical sterol derivatives from a marine fungal source (9–11), 
as well as on two aromatic isonitrile containing xanthocillin X derivatives (12 and 13). 16-O-
desmethylasporyergosterol-ß-D-mannoside (9) and xanthocillin X dimethylether (12) reduced 
Aβ-42 production, in Aftin-5 treated cells. 
 
4.3.2    Isolation of compounds 9–13 from Dichotomomyces cejpii 
Bioassay- and chemical (LC-MS and 
1
H NMR)-guided fractionation of the crude extracts, 
obtained from the marine derived fungus Dichotomomyces cejpii on two different media was 
conducted. Cultivation medium 2 yielded two sterols (9–10) while cultivation medium 1 
yielded one sterol (11) and two xanthocillin derivatives (12 and 13). The investigated fungal 
strain was cultivated on cultivation medium 2 as described before (3.2.2–3.2.3) 
Fungal biomass and media of cultivation medium 2 (Tennelin) were homogenized using an 
Ultra-Turrax apparatus and extracted with 5 L EtOAc to yield 1.2 g of crude extract. This 
material was fractionated by normal-phase (NP) vacuum liquid chromatography (VLC) using 
a stepwise gradient solvent system of increasing polarity starting with 100% CH2CL2 to 100% 
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EtOAc, to 100% MeOH and H2O-MeOH (50-50) which yielded 10 fractions. Compound 9 
and 10 were isolated from VLC fraction 8 and 9. The combined fractions were separated via 
reversed-phase C18 (RP18)-VLC, eluted stepwise with H2O-MeOH (70-30), to 100% MeOH, 
and 100% CH2CL2, which yielded 8 fractions. Subfraction 8.6 contained both compounds. 
Using RP18-HPLC system C (Nucleodur 100-S 250mm x 4.6 mm) with H2O-MeOH (80-20), 
2.0 mL/min compound 9 (16-O-desmethylasporyergosterol-ß-D-mannoside) was isolated 
directly in subfraction 8.6.5 as a white powder, tR: 8 min (5.0 mg). 
Subfraction 8.6.3 was further purified using RP18-HPLC system B (Xterra
TM
 250 x 4.6 
mm) with H2O-MeOH (60-40), 1.2 mL/min to obtain compound 10 (16-O-
desmethylasporyergosterol-3-one-mannoside) as a yellowish white powder, tR: 6.5 min  (1.0 
mg). (see Figure 4-4 for isolation schema) 
For the isolation of compound 10–13 investigated fungal strain was cultivated on 
cultivation medium 1 (MPY) as described before (3.2.2–3.2.3). Fungal biomass and media 
were homogenized using an Ultra-Turrax apparatus and extracted with 5 L EtOAc to yield 4.1 
g of crude extract. This material was fractionated by NP vacuum liquid chromatography 
(VLC) using a stepwise gradient solvent system of increasing polarity starting with 100% 
CH2CL2 to 100% EtOAc and to 100% MeOH which yielded 10 fractions. Fraction 2 was 
separated via NP VLC, using stepwise elution with CH2CL2-petroleum ether (50-50) to 100% 
CH2CL2, and 100% MeOH which yielded 15 fractions. VLC fraction 1 and subfraction 2.1 
contained compound 12 xanthocillin X dimethylether, while subfraction 2.7 contained 
compound 11 (16-O-desmethylasporyergosterol).  
Subfraction 2.7 was further separated using a second NP VLC column and eluted stepwise 
with petroleum ether-CH2CL2 (50-50) to 100% CH2CL2, 100% acetone, 100% EtOAc and 
finally to EtOAc-MeOH (25-75) which yielded 15 fractions. Subfraction 2.7.4 and 2.7.5 were 
combined and further separated with a RP18-solid phase extraction (SPE) cartridge, eluted 
stepwise with H2O-MeOH (65-35), to 100% MeOH, and 100% CH2CL2 which yielded 6 
fractions. Subfraction 2.7.4.4 contained compound 11. Compound 11 (16-O-
desmethylasporyergosterol) was isolated via Diol-HPLC system D (Eurosphere Diol 100-S 
250 mm x 4.6 mm) with petroleum ether-acetone (75-25), 1.5 mL/min as a yellowish powder, 
tR: 17 min  (2.0 mg). 
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Figure 4-17:  Isolation scheme for compound 11. For reasons of clarity only the most important fractions are 
listed. 
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VLC fraction 1 and subfraction 2.1 contained xanthocillin X dimethylether (12) and 
xanthocillin X monomethylether (13). These fractions were separated three times with a 
solvent/solvent extraction with hexane (100%) and MeOH-H2O (60-40) using a separation 
funnel. The combined hexane phases were further separated with a NP VLC column and 
eluted stepwise with petroleum ether-CH2Cl2 (80-20), up to 100% CH2Cl2, 100% acetone, and 
100% MeOH which yielded 16 fractions. Subfraction 2.1.5 contained compound 12 and was 
further separated with a NP-HPLC system D (Eurospher II Si 250  x 8 mm ) with petroleum 
ether-CH2CL2 (50-50), 1.2 mL/min. Subfraction 2.1.5.2 was further purified using NP-HPLC 
system D (Eurospher II Si 250 x 4 mm) with petroleum ether-CH2CL2 (80-20) to obtain 
compound 12 (xanthocillin X dimethylether) as yellow needles, tR: 5 min  (20.0 mg). 
Subfraction 2.1.7 contained compound 13 and was further separated with a RP18-SPE 
cartridge, eluted stepwise with MeOH-H2O (50-50), MeOH, acetone, and CH2Cl2 which 
yielded eight fractions. Subfraction 2.1.7.4 contained compound 13 and was further purified. 
Xanthocillin X monomethylether (13) was isolated via RP18-HPLC (Nucleodur 100-S 250 
mm x 4.6 mm) with MeOH-H2O (82-18), 1.2 mL-min
-1
 as yellow needles, [tR: 12 min] (1.0 
mg). (see Figure 4-2 for isolation schema) 
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Figure 4-18:  Isolation scheme for compound 12. For reasons of clarity only the most important fractions are 
listed. 
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4.3.3    Structure elucidation of isolated sterols and xanthocillin X derivatives 
 
Compound 9 was obtained from the marine sponge-derived fungus Dichotomomyces cejpii 
and its structure was elucidated via analysis of spectroscopic data and chemical degradation. 
A UV maximum at 252 nm indicated the presence of a conjugated π π* system, whereas a 
broad IR absorption at 3389 cm
-1
 pointed toward hydroxy groups. The molecular formula of 
compound 9 was deduced from the results of an accurate mass measurement (HRESIMS, m/z 
=595.3603 (M+Na)
+
 as C34H52O7, indicating nine degrees of unsaturation. The 
13
C NMR and 
DEPT135 spectra denoted the presence of 34 resonances for six methyl groups, seven sp
3
 
methylene groups, four sp
2 
methine, eleven sp
3
 methine, and six quaternary carbons in the 
molecule (Table 4-11) 
The first substructure, an unsaturated decalin system, was deciphered from 
1
H-
1
H COSY 
correlations from H2-1 through to H-7, and HMBC cross peaks between the resonances for 
the methyl group CH3-19 and C-1, C-5, C-9 and C-10, as well as of H-7 to C-8 and C-9. 
Another partial structure was deduced from 
1
H-
1
H COSY correlations from H-9 to H2-11 and 
H2-12, extending the decalin ring by two methylene groups attached to C-9. A third 
1
H-
1
H 
spin system comprised solely H2-15 to H-16. HMBC correlations arising from the resonance 
of CH2-15 to C-14, as well as of the methyl group CH3-18 to CH2-12, C-13, C-14 and C-17, 
and of the methine group CH-16 to C-17 defined the C-13 to C-18 part of the molecule as a 
methyl substituted cyclopentane ring. Further heteronuclear couplings between CH-7 and C-
14, in addition to the above mentioned H-7/C-8 coupling allowed to connect the 
substructures, revealing the four characteristic rings of a sterol scaffold. The protons and 
carbon atoms of the methine groups CH-3 and CH-16 resonated at δH 3.56 and 5.08, and at δC 
71.6 and 79.4, respectively, proving a substitution with oxygen at these sites. The structure of 
the side chain was revealed from 
1
H-
1
H COSY correlations from H-22 through to H3-26/27 
and H3-28. This moiety could be extended and finally attached to the sterol scaffold due to 
HMBC correlations between the resonances for the methyl group CH3-21 and C-17, C-20 and 
C-22. Altogether, the molecule had four carbon-carbon double bounds, i.e. ∆6,7, ∆8,14,∆17,20 
∆22,23, which could be located due to the 13C NMR chemical shifts of the respective carbon 
atoms in a range of 125 to 147 ppm. At this point of the structure elucidation, eight of the nine 
degrees of unsaturation as suggested by the molecular formula were accounted for. 
Additional 
1
H and 
13
C NMR resonances pointed toward a sugar moiety in the molecule. 
The methine groups CH-1’, CH-2’, CH-3’, CH-4’, CH-5’ and the methylene group CH2-6’ 
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resonated in the range of δH 3.1 to 4.6 and δC 62 to 99, respectively. The 
1
H-
1
H COSY spectra 
showed correlations for a spin system from H-1’ through to CH2-6’ and allowed to established 
a pyranose ring. Analysis of the coupling constants and NOEs revealed mannopyranose.
104
 
Hydrolysis and HPLC-LSD analysis using a chiral column revealed the sugar to possess the 
D-configuration. The anomeric configuration of the mannose was considered as β, because of 
the magnitude of the heteronuclear coupling constant between the anomeric carbon and 
respective proton (
1
JCH = 154 Hz).
105
 The mannose is attached via the CH-16 methine group 
to the sterole nucleus, due to a heteronuclear long range coupling from H-1’ to C-16.  
The relative configuration of the sterol scaffold was assigned on the basis of a NOESY 
experiment and the magnitude of significant 
1
H-
1
H coupling constants. NOESY correlations 
between H-3, H-5 and H-9 indicated that these protons are located on the same side, i.e. α, of 
the molecule, whereas NOESY correlations between H-16 and H3-18 proved the opposite 
orientation, i.e. β. The configuration of ∆6,7 (JH-6/H-7 = 9.9 Hz) and ∆
8,14
 had to be Z and E, 
respectively to allow the ring closures of the steroid nucleus.  ∆22,23 was determined as E 
based on a coupling constant of JH-22/H-23 = 15.7 Hz. The double bound ∆
17,20
 was also 
assigned as E configured due to NOESY correlations between H-16 and H3-21.  The relative 
configurations (C-3, C-5, C-9, C-10, C-13, C-16) were thus assigned to be the same as those 
of the closely related asporyergosterol.
108,127
 The configuration at C-24 could not be 
determined. 
The fungal metabolite 9 is thus an ergostane steroid with an untypical number and location 
of double bounds and a mannose moiety, for which we suggest the trivial name 16-O-
desmethylasporyergosterol-ß-D-mannoside. 
 
 
Figure 4-19:  NMR key correlations of compound 9 
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Carbohydrate analysis of compound 9 
Measurement conducted as described in 3.6.6. 
Figure 4-20: HPLC chromatogram of D-mannose 
Figure 4-21: HPLC chromatogram of L-mannose 
Figure 4-22: HPLC chromatogram of the  hydrolysis mixture of 16-O-desmethylasporyergosterol-ß-D-
mannoside  
 
α- 
α-   
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 Figure 4-23: HPLC chromatogram of hydrolysis mixture of 16-O-desmethylasporyergosterol-ß-D-mannoside + 
L-mannose 
 
The structure of the fungal metabolite 10 was found to be closely related to that of 9. The 
molecular formula of 10 was deduced as C34H48O7 from the results of an accurate mass 
measurement (HRESIMS, m/z = 591.3293 [(M+Na)]
+
). The UV spectrum showed an 
additional UV maximum at 344 nm and thus indicated a more extended conjugated system. 
The 
13C NMR resonance at δC 71.6 for the CH-3 methine group in 9 was missing in the case 
of 10, instead a resonance at 202.2 ppm, as expected for a ketone moiety, appeared in the 
respective spectra for 10. Additionally, the presence of a double bound between CH-4 and C-
5 was indicated by the downfield shifted resonance frequencies for these two carbon atoms 
(δC 123.4 and δC 167.5), respectively. Altogether, this resulted in the assumed extended 
conjugated system, ranging from the carbonyl group at C-3 via ∆4,5, ∆6,7 and ∆8,14. 1H- and 13C 
NMR chemical shift values of ring A and B of the steroid scaffold were similar to the related 
compound ergosta-4,6,8(14),22-tetraen-3-one and confirmed the proposed structure.
128
  The 
relative configuration of 10 was assigned on the basis of a NOESY experiment and significant 
1
H-
1
H coupling constants (Table 4-12).  NOESY correlations between H-16 and H3-18 
indicated that these protons are located on the same side of the molecule, whereas H-9, whose 
1H NMR signal at δH 2.26, m, showed similar 
1
H NMR couplings at the respective resonance 
of 9, did not display any NOEs and was therefore orientated opposite to these substituents, as 
in compound 9. The double bound ∆17,20 was assigned as E configured due to NOESY 
correlations between H-16 and H3-21. The configuration of the ß-D-mannose was 
determinated in the same manner as described for 9 (4-23 and 4-24). The structure of 
compound 10 thus differs from that of compound 9 in that the hydroxyl group at C-3 of 9 is 
replaced by a carbonyl function, and by an additional double bound between C-4 and C-5. For 
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the fungal metabolite 10 (Figure 4-23), we suggest the name 16-O-
desmethylasporyergosteron-β-D-mannoside.  
 
 
 
Figure 4-24:  NMR key correlations of compound 9 
 
Carbohydrate analysis of compound 10 
Measurement conducted as described in 3.6.6. 
Figure 4-26: HPLC chromatogram of hydrolysis mixture of 16-O-desmethylasporyergosteron-ß-D-mannoside (10) 
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Figure 4-27: HPLC chromatogram of hydrolysis mixture of 16-O-desmethylasporyergosterol-ß-D-mannoside + L 
mannose 
 
 
 
Figure 4-25: Structure of isolated sterols. 
 
The molecular formula of 11 was deduced as C28H49O2 (HRESIMS, m/z =433.3077 (M+Na)
+
. 
The structure of compound 11 differs from that of compound 9 solely by the missing sugar 
moiety at C-16.  The 
13
C NMR resonance frequency at δC 72.6 for the methine group CH-16 
was shifted upfield by 8 ppm as compared to 9 and thus, verified the presence of an 
unsubstituted hydroxy group at this position. The configuration of 9 was assigned in the same 
manner as described for 9 (Figure 1). The fungal metabolite 9 is thus an ergostane steroid, for 
which we suggest the trivial name 16-O-desmethylasporyergosterole (4-23). 
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Table 4-11: NMR spectroscopic data (300 MHz, methanol-d4) of 16-O-desmethylasporyergosterol-ß-D-mannoside (9) 
 
Position δC , mult δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC 
1
H -
1
H NOESY 
1 34.7, CH2 1a: 1.91, m 
1b: 1.23, m 
1b,2a,2b 
1a,2a,2b 
- 
- 
- 
- 
2 31.5, CH2 2a: 1.74, m 
2b: 1.32, m 
1a,1b,2b, 3,4 
1a,1b,2a,3,4 
- 
- 
- 
- 
3 71.6, CH 3.56, m 2a,2b,4a,4b - 5 
4 39.9, CH2 4a: 1.92, m 
4b: 1.25, m 
2a,2b,3,4b,5 
2a,2b,3,4a,5 
- 
- 
6,19 
- 
5 45.7, CH 1.88, m 4a,4b,6,7 - 9 
6 131.3, CH 5.63, dd (5.1, 9.9) 5,7 5, 10 5,7 
7 125.5, CH 6.30, d (9.9) 5,6 5, 8, 9, 14 6, 15a 
8 127.7, C - - - - 
9 36.0, CH 2.58, m 11a,11b,12a - 5 
10 35.3, C - - - - 
11 20.5, CH2 11a: 1.69, m 
11b: 1.63, m 
9,12a,12b 
9,12a,12b 
- 
- 
- 
- 
12 36.3, CH2 12a: 2.49, m 
12b: 1.70,  m 
9,11a,11b,12b 
9,11a,11b,12a 
- 
- 
- 
- 
13 45.3, C - - - - 
14 144.9, C - - - - 
15 33.3, CH2 15a: 3.03, d  (15.7) 
15b: 2.40, m 
15b,16,1’ 
15a,16 
13, 14, 16, 17 
- 
7,15b,1’ 
15a,16 
16 79.4, CH 5.08, d (5.5) 15a,15b,21 13,14,17,20,1’ 15b,18(w), 21,1‘ 
17 146.4, C - - - - 
18 27.1, CH3 1.33, s - 12,13,14,17, 16(w),22 
19 23.1, CH3 0.80, s - 1,5,9,10 - 
20 133.8, C - - - - 
21 16.8, CH3 2.01, s - 17,20,22 16,23 
22 130.0, CH 6.69, d (15.7) 23,24 17,20,21,24 18,24 
23 136.2, CH 5.72, dd (8.4, 15.7) 22,24 20,24,28 21,24,25,28 
24 45.2, CH 2.10, m 22,23,25,28 - 22,23,26,28 
25 34.6, CH 1.62, m 24,26,27 - 26,27,28 
26 20.5, CH3 0.94, d (7.0) 25 24,25,27 25,28 
27 20.1, CH3 0.91, d (7.0) 25 24,25,26 25 
28 18.1, CH3 1.07, d (7.0) 24 23,24,25 23,24,26 
1´ 99.4, CH 4.57, s 2’ 16,2’ 15,16, 2’,3’,5’ 
2´ 73.3, CH 3.66, m 1’,3’,4’,5’ 3’,5’ 1’,3’ 
3´ 75.5, CH 3.46, dd (3.3, 9.5) 2’,4’ 2’,4’ 1’,5’ 
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4´ 68.2, CH 3.65, t (9.5) 2’,3’,5’ 3’ - 
5´ 78.3, CH 3.17, ddd (2.2, 4.8, 9.5) 4’, 6’a, 6’b - 1’, 3’, 6’a,6’b 
6´ 62.7, CH2 6’a: 3.93, dd (2.2, 11.7) 
6’b: 3.77, dd (4.8, 11.7) 
5’,6’b 
5’,6’a 
2’ 
- 
6’b 
6’a 
w: weak 
 
 
 
Table 4-12: NMR spectroscopic data (300 MHz) of 16-O-desmethylasporyergosteron-ß-D-mannoside (10) 
 
Position δC , mult δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC 
1
H -
1
H NOESY 
1 35.1, CH2 1a: 2.14, m 
1b: 1.88, m 
1b,2a,2b 
1a,2a,2b 
- 
- 
- 
- 
2 35.0, CH2 2a: 2.51, m 
2b: 2.42, m 
1a,1b,2b 
1a,1b,2a 
- 
- 
- 
- 
3 202.2, C - - - - 
4 123.4, CH 5.78, s 2b,6  6,10 6 
5 167.5, C - - - - 
6 126.3, CH 6.21, d (9.9) 4,7 5,8,10 4 
7 136.1, CH 6.97, d (9.9) 6 5 - 
8 126.9, C - - - - 
9 45.2, CH 2.26, m 11a,11b,12a - - 
10 38.1, C - - - - 
11 20.3, CH2 11a: 1.87, m 
11b: 1.80, m 
9,12a,12b 
9,12a,12b 
- 
- 
- 
- 
12 34.8, CH2 12a: 2.54, m 
12b: 1.63, m 
11a,11b,12b 
11a,11b,12a 
- 
- 
- 
- 
13 45.6, C - - - - 
14 154.7, C - - - - 
15 33.8, CH2 15a: 3.19, d  (15.7) 
15b: 2.59, m 
15b 
15a,16 
13 
- 
6 
- 
16 79.0, CH 5.15, d (5.5) 15b 13,14,17,1’ 18 (w),21 
17 145.1, C - - - - 
18 26.9, CH3 1.40, s - 12,13,14,17 16 (w) 
19 17.0, CH3 1.10, s - 1,5,9,10 - 
20 134.4, C - - - - 
21 16.8, CH3 2.03, s - 17,20,22 16 
22 129.8, CH 6.69, d (15.7) 23 17,20,24 - 
23 136.7, CH 5.76, dd (8.4, 15.7) 22,24 20,24,28 - 
24 45.3, CH 2.10, m 23,28 - - 
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25 34.6, CH 1.58, m (6.6, 13.2) 26,27 - - 
26 20.5, CH3 0.94, d (7.0) 25 24,25,27 25,27 
27 20.2, CH3 0.92, d (7.0) 25 24,25,26 25,26 
28 18.0, CH3 1.07, d (7.0) 24 23,24,25 - 
1´ 98.4, CH 4.61, s 2’ 16, 2’ - 
2´ 73.3, CH 3.66, m 1’,3’,4’,5’ - - 
3´ 75.5, CH 3.48, dd (3.3, 9.5) 2’,4’ - - 
4´ 68.4, CH 3.62, t (9.5) 2’,3’,5’ 5’ - 
5´ 78.4, CH 3.22, m 4’,6’a,6’b - - 
6´ 62.8, CH2 6’a: 3.91, dd (2.2, 11.7) 
6’b: 3.77, dd (4.8, 11.7) 
5’,6’b 
5’,6’a 
2’ 
- 
6b 
6a 
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Table 4-13: NMR spectroscopic data (300 MHz, acetone-d6) of 16-O-desmethylasporyergosterol (11)  
 
Position δC, mult δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC 
1
H -
1
H  NOESY 
1 34.4, CH2 1a: 1.82, m 
1b: 1.16, m 
1b,2a,2b 
1a,2a,2b 
- 
- 
- 
- 
2 31.7, CH2 2a: 1.66, m 
2b: 1.26, m 
1a,1b,2b,3 
1a,1b,2a,3 
- 
- 
- 
- 
3 70.8, CH 3.51, m 2a,2b,4a,4b - 5 
4 40.2, CH2 4a: 1.88, m 
4b: 1.23, m 
3,4b,5 
3,4a,5 
- 
- 
- 
- 
5 45.2, CH 1.83, m 3,4a,4b,6,7 - 3 
6 130.5, CH 5.54, dd (5.1, 9.9) 5,7 5,8,10 5,7 
7 125.3,CH 6.20, d (9.9) 5,6 5,8,9,14 6,15a 
8 127.4, C - - - - 
9 35.4, CH 2.55, m 11a,11b,12a - 5 
10 34.8, C - - - - 
11 20.1, CH2 11a: 1.62, m 
11b: 1.58, m 
9,12a,12b 
9,12a,12b 
- 
- 
- 
- 
12 36.2, CH2 12a: 2.43, m 
12b: 1.70,  m 
9,11a,11b,12b 
9,11a,11b,12a 
- 
- 
12b 
12a 
13 44.4, C - - - - 
14 145.1, C - - - - 
15 37.5, CH2 15a: 2.65, d  (15.7) 
15b: 2.40, m 
15b,16 
15a,16 
8,14,16,17 
8,14,16 
7,15b,16 
15a,16 
16 72.6, CH 4.70, d (5.1) 15a,15b 13,14,17,20 15b,18,21 
17 150.1, C - - - - 
18 26.8, CH3 1.26, s - 12,13,14,17 16,22 
19 23.0, CH3 0.74, s - 1,5,9,10 - 
20 130.2, C - - - - 
21 16.5, CH3 1.92, s - 17,20,22 16,23 
22 129.8, CH 6.65, d (15.7) 23 17,20,21,24 18,24 
23 134.6, CH 5.62, dd (8.4, 15.7) 22,24 22, 24, 28 21,28 
24 44.6, CH 2,07, m 22,23,28  22,23, 25 22,23,26,28 
25 34.1, CH 1.57, m 24,26,27 24,26,27,28 26,27,28 
26 20.3, CH3 0.88, d (7.0) 25 24,25,27 25,28 
27 20.0, CH3 0.86, d (7.0) 25 24,25,26 25 
28 18.0, CH3 1.01, d (7.0) 24 23,24,25 23,24,26 
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Aside from the sterols, two isocyanide containing xanthocillin derivatives, xanthocillin X 
dimethylether (12)  and xanthocillin X monomethylether (13) formerly obtained from strains 
of Aspergillus sp.
129
 and Dichotomomyces cejpii (formely known as Dichotomomyces 
albus)
130
, respectively,  could be re-islolated by us. The structure of both compounds were 
elucidated on the basis of detailed 
1
H and 
13
C NMR data comparison with literature 
values.
131–133
 
 
 
Figure 4-28: Structure of isolated xanthocillin X derivatives. 
 
Table 4-14: NMR spectroscopic data (300 MHz) for compound 12 and 13. 
 Xanthocillin X dimethylether  (12) 
(chloroform-d) 
Xanthocillin X monomethylether  (13) 
(acetone-d6) 
position δC , mult. δH ( J in Hz) δC , mult. δH ( J in Hz) 
1 173.1, C - 175.2, C - 
1’ 173.1, C - 175.0, C - 
2 127.4, CH - 116.1, C - 
2’ 127.4, CH - 116.1, C - 
3 124.7, C 7.01, s 128.1, CH 7.11, s 
3’ 124.7, C 7.01, s 128.7, CH 7.10, s 
4 125.8, C - 125.8, C - 
4’ 125.8, C - 125.8, C - 
5 131.7, CH 7.78, d (8.8) 132.9, CH 7.82, d (8.8) 
5’ 131.7, CH 7.78, d (8.8) 132.6, CH 7.89, d (8.8) 
6 114.4, CH 6.98, d (8.8) 114.4, CH 7.00, d (8.8) 
6’ 114.4, CH 6.98, d (8.8) 114.4, CH 7.09, d (8.8) 
7 161.0, C 6.98, d (8.8) 116.8, C 7.00, d (8.8) 
7’ 161.0, C 6.98, d (8.8) 115.3, C 7.09, d (8.8) 
8 114.4, CH 7.78, d (8.8) 116.8, CH 7.00, d (8.8) 
8’ 114.4, CH 7.78, d (8.8) 115.3, CH 7.09, d (8.8) 
9 
9’ 
131.7, CH 
131.7, CH 
7.78, d (8.8) 
7.78, d (8.8) 
132.9, CH 
132.6, CH 
7.82, d (8.8) 
7.89, d (8.8) 
10 55.4, CH3 3.87, s - - 
10’ 55.4, CH3 3.87, s 55.8, CH3 3.89, s 
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16-O-desmethylasporyergosterol-ß-D-mannoside (9): white amorphous compound (5.0 
mg; 0.5 mg/L); [α]D
25 
+ 40.8 (c 0.34, MeOH); UV (MeOH ) λmax (log ε) 252 (3.65) nm; IR 
(ATR) νmax 3389, 2938, 1681, 1366, 1305, 1136, 1053, 1021, 844, 668 cm
-1
; 
1
H and 
13
C NMR 
data (see Table 4-11); ESI-MS m/z 590 [M+NH4]
+
, 631 [M+HAc-H]
-
; HRESI-MS m/z 
595.3603 [M+Na]
+
 (calcd. for C34H52O7Na,  m/z 595.3611). 
 
  16-O-desmethylasporyergosteron-ß-D-mannoside (10): yellowish white amorphous 
compound (2.0 mg; 0.2 mg/L); [α]D
25
 + 26.5 (c 0.17, MeOH); UV (MeOH ) λmax (log ε) 246 
(3.77), 344 (3.73) nm; IR (ATR) νmax 3361, 2959, 1642, 1584, 1376, 1202, 1072, 668, 631 
cm-1; 
1
H and 
13
C NMR data (see Table 4-12); ESI-MS m/z 569 [M+H]
+
, 627 [M+HAc-H]-; 
HRESI-MS m/z 591.3293 [M+Na]+ (calcd. for C34H48NO7Na,  m/z 591.7305). 
 
16-O-desmethylasporyergosterol (11): yellowish amorphous compound (3.0 mg; 0.3 
mg/L). [α]D
25 + 145.4 (c 0.25, MeOH); UV (MeOH ) λmax (log ε) 252 (3.90) nm; IR (ATR) 
νmax  3426, 2923,  1735, 1655, 1418, 1386, 1237, 1180, 1051, 979, 878 cm
-1
; 
1
H and 
13
C NMR 
data (see Table 4-13); ESI-MS m/z  411 [M+H]
+
, 469 [M+HAc-H]
-
; HRESI-MS m/z  
433.3070 [M+Na]
+
 (calcd. for  C28H42O2Na,  433.3083).  
 
Xanthocillin X dimethylether (12): yellow needles (20.0 mg 2 mg/L). UV (MeOH ) λmax 
(log ε) 242 (3.27) 366 (3.80) nm; IR (ATR) νmax  2931,  2117, 1599, 1508, 1462, 1355, 1177, 
1025, 876, 825, 779 cm-1; 
13
CNMR data (see Table 4-14); ESI- MS m/z 317 [M+H]
+
, 334 
[M+NH4]
+
, 349 [M+CH3OH]
+
. 
 
Xanthocillin X monomethylether (13): yellow needles (1 mg 0.1 mg/L). 
11
H and 
13
C 
NMR data (see Table 4-14); ESI- MS m/z 303 [M+H]
+
, 301 [M-H]
-
. 
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4.3.4    Biological activities of isolated sterols and xanthocillin X derivatives 
 
We evaluated the steroid glycosid 16-O-desmethylasporyergosterol-ß-D-mannoside (9) and 
the isonitrile xanthocillin X dimethylether (12) in an Alzheimer’s disease cellular assay. 
Neither compound 9 nor 12 displayed relevant cytotoxic effects at a concentration of 10 μM 
(Figure 4-29) in N2a cells, which were transfected with human APP695. Then, the 
compounds were tested for their ability to induce amyloid β-42 production in N2a-APP695 
cells in comparison to the known amyloid β-42 production inducer Aftin-5. Neither 
compound 9 nor 12 induced amyloid β-42 production (±0.75 and ±0.8 fold change, 
respectively) in comparison to cells treated solely with Aftin-5 (±6.3 fold change) (Figure 4-
30). In a further experiment 100 µM Aftin-5 was used to induce amyloid β-42 production in 
N2a-APP695, and whether a pretreatment with compound 9 or 12 could inhibit this amyloid 
β-42 production. 
Both, 16-O-desmethylasporyergosterol-ß-D-mannoside (1) and xanthocillin X 
dimethylether (12) reduced Aβ-42 production in Aftin-5 treated cells (Figure 4-31). This 
activity was further confirmed in dose-response (0.1, 0.33, 1, 3.3 and 10 μM) experiments. 
(Figure 4-28) This effect was compared to that of N-[N-(3,5-difluorophenylacetyl)-l-alanyl-]-
(S)-phe-nylglycine-t-butylester (DAPT), a known inhibitor of Aβ-42 production. Cells solely 
treated with 100 µM Aftin-5 displayed a fold change (i.e. amount of Aβ peptides produced by 
treated cells compared to the Aβ peptides produced by untreated cells) about ±9.4 while a 
pretreatment with 10 µM of compound 9 , 12 and DAPT reduced fold change to ±3.8, ±2.9, 
±0.3, respectively. Compound 9 and 12 therefore displayed a moderate Aβ-42 lowering 
activity, but the effect was rapidly lost upon dilution of the compound. 
Further characterizations of compound 9 and 12 are advised to assess the potential of these 
compounds as Aβ-42 lowering agents. Such studies should investigate in which way these 
compounds interact with β- or γ-secretases, and if they belong to the group of secretase 
inhibitors or modulators. If they act as secretase inhibitors it would be important to know, if 
substrate selectivity is provided by one of these compounds.  
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Figure 4-29: MTS cell survival assay  
Effects of compound 9, 12 and Aftin-5 on N2a-APP695 cell viability  
Compounds (in blue) were tested at 10 μM. As control, Aftin-5 (in red) was tested at 100 μM. 
 
Figure 4-30: Inducing of Aβ-42 production 
Amyloid β-42 inducing activity of compound 9 and 12, compared to 100 μM of the reference compound 
Aftin 5. Compounds (in blue) were tested at 10 μM. Results are expressed as fold change ± s.d. The fold 
change was calculated by dividing the amount of Aβ peptides produced by treated cells by the of Aβ 
peptides produced by untreated cells. All experiments were performed in triplicate. 
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Figure 4-31:  Initial screening; Influence of samples on Aβ-42 production 
Reduction of Aβ-42 production, induced by a treatment with 100 μM of Aftin-5, in the presence of compound 9 
and 12 at 10 μM. Results are expressed as fold change ± s.d. The fold change was calculated by dividing the 
amount of Aβ peptides produced by treated cells by the of Aβ peptides produced by untreated cells. All 
experiments were performed in triplicate. 
 
 
Figure 4-32: Reduction of Aβ-42 production: Dose response 
Reduction of Aβ-42 production, induced by treatment with 100 μM of Aftin-5. Compound 9 (blue line) and 12 
(violet line) were tested and activity was confirmed in dose-response. Control with 100 μM Aftin-5 (red bar), an 
activator of Aβ-42 production and 10 μM DAPT (green bar), an inhibitor of Aβ-42 production. Results are 
expressed as fold change ± s.d. The fold change was calculated by dividing the amount of Aβ peptides produced 
by treated cells by the of Aβ peptides produced by untreated cells. All experiments were performed in triplicate. 
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4.3.5    Discussion of isolated sterols and xanthocillin X derivatives and their biological 
activities 
 
Biological activity 
Recently, the natural product derived triterpenoid glycoside 24-O-acetylhydroshengmanol 3-
O-β-D-xylopyranoside-Δ16,17-enol ether (IC50 of 0.1 µM towards Aβ42) and its further 
developed derivatives like SPI-1865 (IC50 of 0.1 µM towards Aβ42)  have been identified as 
GSMs.
134,135
 This triterpene-based γ-secretase modulators gained a lot of interest, because 
they possess an unusual profile, when compared to other GSMs, in that they raise Aβ37 and 
Aβ39 and lower Aβ37 and Aβ42 levels. In contrast to that, common GSMs usually solely 
reduce Aβ42 and increase Aβ37 and Aβ38 production.135  
Subtle differences between GSMs, regarding the modulation of AβP-subspecies 
production, are considered to be maybe therapeutically important and could display different 
biological activity profiles.
125
 Aside from Alzheimer disease, Aβ-42 lowering agents are also 
considered as therapeutics for further indications, e.g. various cancers or macular 
degeneration.
125
 The potential of Aβ-42 lowering agents is immense and for the diverse 
indications, different anti Aβ agents with distinct properties could be beneficial.  
Therefore, the improved characterization of existing, and the identification of further Aβ-
42 lowering agents can be very valuable for future drug development. The development of 
triterpenoid GSMs illustrates the potential of natural products as lead structures and our 
results confirm that screening of natural compounds, like 9 and 12, is a valuable strategy to 
find new active compounds, which could be used for further investigation of the 
pathophysiology of Aβ42 related diseases and drug development.134 
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4.4    Isolation of thiodiketopiperazines and evaluation for activities toward 
nuclear receptors 
4.4.1   Introduction to the role of nuclear type II receptors 
 
Nuclear receptors (NRs) are a family of ligand-regulated transcription factors.
136
 Their ligands 
can cross plasma membranes, and their subsequent interaction with NRs then alters the 
transcription of a spectrum of genes. The latter control a wide range of biological processes, 
like reproduction or metabolism.
136,137
  
Nuclear receptors share a common basic structure and are composed of 6 domains. The 
well conserved E domain contributes to ligand binding and is also called ligand binding 
domain (LBD). There are four types of nuclear receptors, i.e. type I-IV. Among these, type II 
receptors reside bound in the nucleus and generally form heterodimers with the retinoid X 
receptor (RXR). Without ligand interaction they induce repressive functions via bound co-
repressor complexes. Whereas binding of ligands to the LBD replaces co-repressors by co-
activator complexes and induce individual receptor functions. Because they bind to small 
molecules, NRs represent promising therapeutic targets for a range of disorders, for which 
selective agonists and antagonist can be engineered. 
138,137
  
Peroxisome proliferator-activated receptors (PPAR) or Liver X receptors (LXR) are 
prominent, well investigated representatives of type II NRs. There are three known PPAR 
subtypes (PPARα, PPARβ/δ and PPARγ). A multitude of divers endogenous PPAR ligands, 
derived from fatty acid and lipid metabolism, have been identified.
139
 
PPARα plays an important role in the hepatic lipid metabolism.140 PPARα agonists like 
fibrates are already used as hypolipidemic agents. However, the use of PPARα agonist is 
challenged by safety concerns regarding potential side effects like renal dysfunction or 
rhabdomyolysis and unsatisfactory clinical outcome and health benefits. It is uncertain if 
these effects are derived from specific toxicity of the individual investigated compound or a 
general adverse effect of PPARα activation.140,141 More potent and selective PPARα agonist 
are therefore investigated for the treatment of hyperlipidaemia in the hope to achieve more 
robust benefits with less unwanted side effects.
140–142
 
PPARsβ/δ are almost ubiquitously expressed, but show particular high levels inter alia in 
adipocytes, skeletal muscles and heart.
143
 PPARβ/δ activation has demonstrated anti-
inflammatory effects which are connected to increased insulin sensitivity of adipose tissues. 
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Anti-obese effects are correlated to PPARβ/δ activity as well. Therefore a potential use of 
PPARβ/δ agonists for the treatment of metabolic syndrome is supposed.143 Furthermore 
PPARβ/δ plays an important role in muscle fatty acid metabolism and muscle development. 
PPARβ/δ agonists are therefore suggested as potential therapeutical treatment in muscle 
degenerative diseases and heart failures, which are often associated with reduced myocardial 
fatty acid oxidation.
143
 However controversial results of pro-tumorigenic effects in different 
cancer cell lines induced by PPARβ/δ activation, raise safety concerns which have to be 
clarified.
143
 
PPARγ plays an important role for the insulin sensitivity in numerous tissues.136 These 
effects are already therapeutically addressed by thiazolidones, like pioglitazone in the 
treatment of type II diabetes, where insulin sensitivity is usually reduced. Due to side effects 
of the known PPARγ agonists, like increased risk for heart failures and bone fractures, their 
therapeutically use is restricted and safer PPARγ agonists are desired.136 Therefore selective 
PPARγ modulators (SPPARγMS) like SR1664 are supposed to have improved side effect 
profiles and are considered to have the chance to revival the role of PPARγ ligands in the 
therapeutical treatment of type 2 Diabetes.
136,138
 
Liver X receptors LXRα and LXRβ  are inter alia important regulators of cholesterol, lipid 
and glucose metabolism.
144,145
 LXRα is highly expressed in liver, adipose tissue and 
macrophages, whereas LXRβ is expressed more widespread in distinct tissues.144 Endogenous 
ligands are oxidized cholesterol derivatives (oxysterols), like e 22(R)-hydroxycholesterol.
136
 
Targeting LXR has demonstrated to possess therapeutic potential in the treatment of 
atherosclerosis, diabetes, cancer, cardiovascular disease, autoimmune disorders, and 
Alzheimer disease
136,146–151
 However, synthetic unselective LXR ligands have shown to have 
problematic side effects, like hypertriglyceridemia induced by activation of SREBP1 
expression, which limit their application.
136
 To avoid these problems, further development of 
LXR agonist, which display selectivity for the LXRα or LXRβ subtype or act as LXR 
modulators is desired.  
We evaluated a group of nontoxic gliotoxin derivatives and one nonadride for agonistic 
effects toward several type II nuclear receptors (PPAR subtype α, β/δ and γ and LXR subtype 
α and β). 
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4.4.2    Isolation of compounds 14–17 from Dichotomomyces cejpii 
 
Bioassay- and chemical (LC-MS and 
1
H NMR)-guided fractionation of the crude extracts, 
obtained from the marine derived fungus Dichotomomyces cejpii on cultivation medium 1 
yielded four thiodiketopiperazines (14–16) and the nonadride heveadride (17). The 
investigated fungal strain was cultivated on cultivation medium 1 as described before (3.2.2–
3.2.3) Fungal biomass and media were homogenized using an Ultra-Turrax apparatus and 
extracted with 5 L EtOAc to yield 4.1 g of crude extract. This material was fractionated by 
NP vacuum liquid chromatography (VLC) using a stepwise gradient solvent system of 
increasing polarity starting with 100% CH2CL2 to 100% EtOAc and to 100% MeOH which 
yielded 10 fractions. Fraction 2 was separated via NP VLC, using stepwise elution with 
CH2Cl2-petroleum ether (50-50) to 100% CH2Cl2, and 100% MeOH which yielded 15 
fractions. VLC fraction 1 contained compounds 14–17 and was distributed between hexane 
(100%) and MeOH-H2O (60-40) using a solvent/solvent extraction three times. The 
methanolic phase was further separated using a RP18 VLC column and eluted stepwise with 
H2O-MeOH (80-20) to 100% MeOH, 100% CH2CL2 which yielded 8 fractions. Subfraction 
1.3 was further separated with a second NP VLC column, eluted stepwise with petrolether-
acetone (95-5), to 100% acetone, and acetone-MeOH (50-50) which yielded 8 fractions. 
Subfraction 1.3.3 contained compound 14–17. 
Compound 14 (6-acetylmonodethiogliotoxin) was isolated from subfraction 1.3.3 via NP-
HPLC system D (Eurosphere II, 250mm x 4.6 mm) with petroleum ether-acetone (85-15), 1.0 
mL/min as a yellowish white powder, tR: 22 min  (19.5 mg). 
Compound 15 was found in VLC fraction 4 and subfraction 1.3.3. Subfraction 1.3.3 was 
separated as described above and compound 15 (6-acetylbisdethiobis(methylthio)gliotoxin) 
was obtained as yellowish white powder, tR: 30.2 min (98.9 mg). Minor amounts were 
isolated from VLC fraction 4 via RP8-HPLC system D (Eurosphere II, 250mm x 8mm) with 
H2O-MeOH (50-50), 1.5 ml/min,  tR: 15.5 min (4.5 mg). 
Compound 16 was obtained from subfraction 1.3.3, as well, which was in a first round 
separated as described above. From this separation, subfraction 1.3.3.3 (tR:18.2 min) 
resultated, and was further purified using NP-HPLC system D (Eurosphere II, 250mm x 4.6 
mm) with petroleum ether-acetone (90-10), 1.0 mL/min and compound 16 (5a,6-
anhydrobisdethiobis(methylthio)gliotoxin) was isolated as yellowish white powder, tR: 33.5 
min (4.6 mg). 
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Compound 17 was found in subfractions 1.3.1, 1.3.2 and 1.3.3. Subfraction 1.3.1 was 
separated with NP-HPLC system D (Eurosphere Si, 250mm x 8mm) using petrolether-acetone 
(90-10), flow 1.0. The resulting subfraction 1.3.1.3, tR: 8.0 min was further purified via RP18-
HPLC system B with (Nucleodur 250 x 4.6mm) H2O-CH3CN (43-57), flow: 1.7 ml/min, tR: 
8.0 min to obtain heveadride (17) (30.0 mg). Subfraction 1.3.2 was purified via NP-HPLC 
system D (Eurosphere Si, 250mm x 8mm) with petrolether-acetone (90-10), flow 1.0, tR: 8.0 
min and heveadride (17) was isolated as white powder (35.0 mg). Subfraction 1.3.3 was 
separated via NP-HPLC system D (Eurosphere II, 250mm x 4.6 mm) with petroleum ether-
acetone (85-15), 1.0 mL/min and heveadride (17) was isolated as white powder, tR: 6.0 min 
(12.9 mg). 
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Figure 4-33:  Isolation scheme for compounds 14–17. For reasons of clarity only the most important fractions 
are listed. 
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4.4.3    Structure elucidation of isolated thiodiketopiperazines and heveadride 
 
Compound 14 was obtained from the marine sponge-derived fungus D. cejpii and its structure 
was elucidated via intensive analysis of spectroscopic data. A UV maximum at 262 nm 
evidenced the presence of a conjugated π π* system. A broad IR absorption at 3425 cm-1 
pointed toward a hydroxyl group, while a strong IR absorption at 1722 cm
-1
, arising from 
C=O
 
stretching frequencies, indicated an ester moiety. The molecular formula of compound 
14 was deduced from the results of an accurate mass measurement (HRESIMS, m/z = 
359.0672 (M+Na)
+
 as C15H16N2O5S, implying ten degrees of unsaturation. The 
13
C NMR and 
DEPT135 spectra denoted the presence of 15 resonances for two methyl groups, two sp
3
 
methylene groups, three sp
2 
methine, two sp
3
 methine, and six quaternary carbons in the 
molecule (Table 4-15). 
The first substructure was deciphered as a cyclohexadiene by interpreting 
1
H-
1
H COSY 
correlations from H-5a through to H-9, and HMBC cross peaks between the resonances for H-
9 and C-9a, C-5a, C-6, C-7 and C-8. The two conjugated carbon-carbon double bounds within 
this substructure could be assigned as ∆7,8 and ∆9,9a due to the 13C NMR chemical shifts of the 
respective carbon atoms (127.1/125.7, 119.5/137.4 ppm). The methine group CH-6 resonated 
at δH 5.87 and δC 74.9, indicating a substitution with oxygen at this site. Due to the 
13
C NMR 
chemical shift 172.1 ppm, C-12 was assigned to be part of a carbonyl group. HMBC 
correlations arising from the resonance of CH3-13 to C-12, as well as to CH-6 established that 
an acetyl group was linked via the oxygen atom at CH-6. 
An extension of this first substructure was possible taking HMBC cross peaks between the 
resonances for the methylene group CH2-10 to C-9a on one side, and to C-10a and C-1 on the 
other side into account. The 
13
C NMR chemical shifts of C-10a (δC 82.5) and of the protons 
and carbon atoms of the methine group CH-5a (δH 4.60, δC 61.6), indicated a substitution with 
a heteroatom at these sites, whereas C-1 was a carbonyl (δC 174.2). CH3-11 resonating at 3.02 
and 27.8 ppm, respectively had to be linked to nitrogen. HMBC cross peaks between the 
resonances for this methyl group to the carbonyl carbon atoms C-1 thus revealed an amide 
bond. A second amide was obvious when considering the 
13
C NMR chemical shift (δC 170.5) 
for C-4. 
1
H NMR chemical shifts of δH 4.30 and 4.17 for the geminal methylene protons 3a’ 
and 3a’’ indicated the presence of a –CH2OH moiety. Regarding HMBC cross peaks between 
the resonances for these methylene group protons CH2-3a to carbon C-3 and C-4, and of CH3-
11 to C-1 and C-3, the second substructure from C-1 through to C-4 (including C-11) could 
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be deduced, which was linked via N-5 to the first substructure. Compound 14 thus is a 
diketopiperazine with a dihydro-indoline moiety.  
The molecular formula indicated the presence of one single sulphur atom within the 
molecule, and also two double bond equivalents were still to be accounted for. The sulphur 
atom was assigned to form a sulphur bridge between carbon C-10a and C-3, due to the 
13
C 
NMR chemical shift of the respective carbons (C-3: 80.4 ppm, C-10a: 82.5 ppm). This is 
comparable to the disulfide bridge in the related compound gliotoxin (C-10a and C-3: δC 77.3 
and 77.5, respectively).
152–154
 Overall, this structural arrangement of 14 is consistent with the 
established structures of gliotoxin-type metabolites and with recent biosynthetic evidence for 
this class of compounds.
155,156
 
The relative configuration was deduced on the basis of a NOESY experiment and the 
magnitude of significant 
1
H-
1
H coupling constants. The coupling constant of JH-5a/H-6 = 13.2 
Hz indicated that both protons are orientated 180 ° to each other, i.e. H-6 is axial and α-
orientated whereas the axial H-5 is β-orientated.  NOESY correlations between H-3a’’, H-5a 
and H-10’ indicated that these protons are located on the same side, of the molecule, whereas 
NOESY correlations between H-3a’, H-6 and H-10’’ proved the opposite orientation for these 
substituents. This again confirmed that proton H-5a and H-6 are trans orientated to each other. 
The configuration at the quaternary carbon C-10a could not be determined. We assume it to 
be as that of the co-occurring 6-acetylbisdethiobis(methylthio)gliotoxin (2) with the same 
basic structural arrangement.
23,24 
Furthermore the fungus D. cejpii is a known producer of 
gliotoxin for which the absolute configuration had been determined and confirmed by 
biosynthetic evidence, the latter demonstrating the necessity of this configuration.
153,154,156,157
 
The fungal metabolite 14 is thus a naturally occurring gliotoxin derivative with the untypical 
feature of a single sulphur atom bridge. We suggest the trivial name 6-
acetylmondodethiogliotoxin for 14. 
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Figure 4-34:  NMR key correlations of compound 14 
 
Aside from 14, a further gliotoxin derivative, an acetylated dithiodiketopiperazine with two 
methylthio substituents, i.e. 6-acetylbisdethiobis(methylthio)gliotoxin (15) was isolated for 
the first time as a natural product. The structure of 15 was elucidated on the basis of detailed 
1
H and 
13
C NMR data (Table 4-16) and comparison with literature values of the semi-
synthetically obtained compound.
158
 
1
H NMR values of 15 match very well with literature 
data. There were slight differences, however between the here observed 
13
C NMR resonances 
for carbon C-3 and literature values (+3.6 ppm). These differences may be explained by the 
fact that reported literature 
13
C NMR data had been determined only indirectly via HMBC 
correlations. Furthermore, it is known that NMR data of gliotoxin and its derivatives are 
strongly influenced by temperature and solvent.
154
 Mass spectral data are according to the 
here shown structure and literature data. 
 
    
 
Figure 4-35:  NMR key correlations of compound 15 
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5a,6-anhydrobisdethiobis(methylthio)gliotoxin (16) an aromatic gliotoxin derivative similar to 
compound 15 could also be isolated for the first time as a natural product during this study. 
The structure of 16 was elucidated on the basis of detailed 
1
H and 
13
C NMR data (Table 4-17) 
and comparison with literature values for the formerly semi-synthetically produced 
compound.
159,160
 
Figure 4-36:  Structure of isolated thiodiketopiperazines (14–16) 
 
Table 4-15: NMR Spectroscopic Data (300 MHz, methanol-d4) for 6-acetylmonodethiogliotoxin (14) 
Position δC , mult δH (J in Hz) 
1H -1H COSY 1H-13C HMBC 1H -1H NOESY 
1 174.2, C - - - - 
2 N - - - - 
3 80.4 , C - - - - 
3a 58.0, CH2 3a’:  4.30, d (13.2) 
3a’’: 4.17, d (13.2) 
 
3a’’ 
3a’ 
3,4 
3,4 
3a’’,5a 
3a’,6 
4 170.5, C - - - - 
5 N - - - - 
5a 61.6, CH 4.60, d (13.2) 6,7,8,9,10’,10’’ 6,9a 3a‘,7,8,9,10‘,13 
6 74.9, CH 5.87, d (13.2) 5a 7,8,9 5a,7, 8,9,9a, 10 3a‘‘,7,8,9,10‘‘,13 
7 127.1, CH 5.57, dd (5.9, 13.2) 5a,6,8,9 5a,6,8,9 5a,6,8,9  
8 125.7, CH 6.05, m 5a,6,7 5a,6,7,9,9a,  5a,6,7,11 
9 119.5, CH 6.03, m 5a,6,7,10’,10’’ 5a,6,7,8,9a,10 5a,6,7,11 
9a 137.4, C - - - - 
10 29.5, CH2  10’: 3.52, d (18.3) 
10’’:2.98 br d 
5a, 9,10’’ 
5a,9,10’ 
5a,1,9,9a,10a 
5a,1,9,9a,10a 
5a,10’’ 
6,10’ 
10a 82.5, C - - - - 
11 27.8, CH3 3.02, s - 1,3 8,9 
12 171.3, C - - - - 
13 21.2, CH3 2.16, s - 3,6 5a,13 
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Table 4-16: NMR Spectroscopic Data (300 MHz, methanol-d4) for 6-acetylbisdethiobis(methylthio)gliotoxin (15) 
 
Position δC , mult δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC 
1
H -
1
H NOESY 
1 168.6, C  - - - - 
2 N - - - - 
3 75.4, C -    
3a 64.6, CH2 3a’ : 4.17, d (11.3) 
3a’’ : 3.76, d (11.3) 
3a’’ 
3a’ 
3,4 
3,4 
3a’’,12,13 
3a’,10’,12 
4 166.1, C - - - - 
5 N - - - - 
5a 67.1, CH 5.21, d (13.9) 6,7,10’,10’’ 9a 7,8,9,10‘‘ 
6 76.6, CH 6.28, d (13.9) 5a,7,8 5a,7, 9,10,14,15 7,8,9,10’,11,13,15 
7 128.4, CH 5.58, m 6,7,9,10’’ 6,9 5a,6,7,9,10’,15  
8 126.7, CH 6.07, m 5a,6,8,10’’ 9 5a,6,8,11,13 
9 120.6, CH 6.04, m 5a,6,7,8,10’,10’’ 5a,6,7,8,9a,10’ 5a,6, 10’,11,13 
9a 135.9, C - - - - 
10 40.9, CH2  10’:  3.13, d (15.4) 
10’’: 2.91, d 
5a,10’’ 
5a,7,9,10’ 
5a,  9a, 10a, 10’’ 
5a,  9, 9a, 10a, 10’ 
6, 7, 8, 9, 10’’, 11 
5a, 10’ 
10a 74.4, C - - - - 
11 15.0, CH3 2.33, s - 10a 6,7,9,10’,13 
12 29.2, CH3 3.09, s - 1,3,3a 3a‘,3a‘‘,13 
13 12.9, CH3 2.24, s - 3 6,7, 9,10‘,11,12  
14 172.6, C - - - - 
15 21.4, CH3 2.13, s - 6,14 6,8 
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Table 4-17: NMR Spectroscopic Data (300 MHz, acetone-d6) for 5a,6-anhydrobisdethiobis(methylthio)gliotoxin (16) 
 
Position δC , mult δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC 
1
H -
1
H NOESY 
1 166.3, C - - - - 
2 N - - - - 
3 73.2, C -    
3a 64.8, CH2 3a’  : 4.42, dd (4.0, 12.1) 
3a’’ : 3.95, dd (4.0, 12.1) 
3a’’ 
3a’ 
- 
3,4 
3a’’,13 
3a’,12 
4 162.9, C - - - - 
5 N - - - - 
5a 142.4, C - - - -‘ 
6 118.3, CH 8.02, d (7.3) 7 5a,8  7 
7 128.3, CH 7.30, dd (7.3, 7.7) 6,8,9 5a,9a,8,9 8, 9  
8 126.3, CH 7.19, dd (7.3, 7.7) 6,7,9 5a,6,7,9,9a 7,9 
9 126.4, CH 7.39, d (7.3) 8,10 5a,10 8,10 
9a 130.3, C - - - - 
10 40.0, CH2  3.55, d (5.5) 9 1,5a,9,9a,10a, 9,11 
10a 71.6, C - - - - 
11 14.4, CH3 2.22, s - 10a 10,13 
12 28.9, CH3 3.15, s - 1,3,3a 3a‘,13 
13 13.5, CH3 2.32, s - 3 11,12,  
 
 
 
 
 
 
 
 
 
 
 
Additionally heveadride (17), a nonadride, formerly obtained from strains of 
Helminthosporium heveae 161, could be re-isolated by us. The structure of 17 was elucidated 
on the basis of detailed 
1
H and 
13C NMR and [α]D
25
 data comparison with literature 
values.
161,162
 (Table 4-18) 
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Figure 4-37:  Structure of isolated heveadride (17) 
 
 
Table 4-18: NMR Spectroscopic Data (300 MHz, acetone-d6) for hevadride (17) 
 
Position δC , mult δH (J in Hz) 
1
H -
1
H COSY 
1
H-
13
C HMBC 
1 40.6, CH 2.94, m (4.4, 9.2, 18.7) 2,5’a,5’b 3a,3’,4’,5’a,5’b 
2 48.9, CH 2.07, m 1,3a,3b,1’,4’,5’a,5’b 1,3a,3b,5’a,5’b 
3  27.7, CH2 3a: 2.74, dd (2.9, 13.2) 
3b: 2.26 t (13.2) 
2,3b 
2,3a 
1,2,6b 
1,2,6b 
4  145.3, C - - - 
5  145.5, C - - - 
6  21.4, CH2 6a: 2.97, m 
6b: 2.49, m  
2,6a,6b,7b 
2,6a,6b,7a  
3,6a,6b 
3,6a,6b 
7  22.1, CH2 7a. 3.03, dd (4.4, 12.8)  
7b:.2.55, m  
3a,3b,6b,7a,7b 
3a,3b,6a,7a,7b 
6b,7a,7b  
6a,7a,7b 
8 146.0, C - - - 
9 148.0, C - - - 
10 166.8, C - - - 
11  166.6, C - - - 
12  166.7, C - - - 
13 166.2, C - - - 
1’ 13.25, CH3 1.03, d (6.2) 2,3,2’ 2,2’a,2’b 
2’ 23.97, CH2 2’a: 2.02, m  
2’b: 1.05, m 
1’,2’b 
1,3,3’,   
1,1’,3a,3b 
1,1’,3a,3b 
3’  14.4, CH3 0.80, t (7.3) 4‘,5’a,5’b 4‘,5’a,5’b 
4’ 21.9, CH2 1.15, m 3‘,5’a,5’b 1,3‘,5’a,5’b,  
5’ 32.6, CH2 5’a: 2.09 m 
5’b: 1.58 m (5.5, 10.6) 
1,2,4’ 1,3b,3‘,4‘ 
   
 Results  
96 
 
    6-Acetylmonodethiogliotoxin (14): yellowish white amorphous compound (19.5 mg; 2.0 
mg/L); [α]D
25 
-4.9 (c 0.34, MeOH); UV (MeOH ), λmax (log ε) 203 (3.62), 262 (3.28)  nm; IR 
(ATR) νmax 3425, 2922, 1722, 1368, 1234, 1047, 877, 719,668, 628 cm
-1
; 
1
H and 
13
C NMR 
data (see Table 4-15); ESI-MS m/z 337 [M+H]
+
, 354 [M+NH4]
+
; HRESI-MS m/z 359.0672 
[M+Na]
+
 (calcd. for C15H16N2O5SNa,  m/z 359.0678). 
 
  6-Acetylbisdethiobis(methylthio)gliotoxin (15): yellowish white amorphous compound 
(94.4 mg; 9.4 mg/L); [α]D
25
 - 62.9 (c 0.28, MeOH); UV (MeOH ), λmax (log ε) 203 (3.95), 
269 nm (3.42) nm; IR (ATR) νmax 3425, 2922, 1734, 1648, 1418, 1386, 1237, 1189, 1142, 
1051, 979, 878, 668, 600, 534 cm-1; 1H and 13C NMR data (see Table 4-16); ESI-MS m/z 
416 [M+NH4]
+
, 421 [M+Na]
+
,  819 [2*M+Na]
+
; HRESI-MS m/z 421.0801 [M+Na]
+
 (calcd. 
for  C17H22N2O5S2Na,  421.0868). 
 
5a,6-Anhydrobisdethiobis(methylthio)gliotoxin (16): yellowish white amorphous 
compound (4.6 mg; 0.5 mg/L). [α]D
25 
-65.1 (c 0.36, MeOH); 
1
H and 
13
C NMR data (see Table 
4-17); ESI-MS m/z 361 [M+Na]
+
, 700 [2*M+Na]
+
; HRESI-MS m/z 361.0662 [M+Na]
+
 
(calcd. for  C15H18N2O3S2Na,  361.0651). 
 
Heveadride (17): white crystalline compound (77.9 mg; 7.8 mg/L). [α]D
25 
+ 20.9 (c 2.22, 
MeOH) [lit value [α]D
25 
+ 63 (c 1.19, CH2Cl2
161
]; 
1
H and 
13
C NMR data (see Table 4-18); 
ESI-MS m/z  333 [M+H]
+
, 331 [M-H]
-
.  
 
4.4.4    Biological activities of isolated thiodiketopiperazines and hevadride 
 
We evaluated the gliotoxin derivatives 6-acetylmonodethiogliotoxin (14) and 6-
acetylbisdethiobis(methylthio)gliotoxin (15) as well as the nonadride derivative heveadride 
(17) for activity toward several nuclear receptors. None of the examined compounds 
displayed relevant cytotoxic effects at a concentration of 100 μM in K562 cells. (Figure 4-38) 
The compounds were tested for their agonistic activity towards several nuclear receptors, 
including PPAR subtype α, β/δ and γ as well as towards LXR subtype α and β. None of these 
compounds displayed agonistic activity toward PPAR subtype α, β and γ or LXRβ at or up to 
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a concentration of 125 µM or 80 µM respectively in comparison to known agonists (Table 4-
19 and appendix).  
In contrast, compound 14 demonstrated selective agonist activity toward LXRα. 40 µM of 
compound 14 were capable to activate the reporter system of LXRα. (Table 4-19 and Figure 
4-39) This activity has to be judged as moderate, but is selective without relevant cytotoxic 
effects. 
 
 
 
Figure 4-38: Effect of fungal products on K562 cell viability (see 3.6.7.3) 
   
 
 Results  
98 
 
Figure 4-39: Evaluation of Compounds 14, 15 and 17 for LXRα agonist activity 
 
Table 4-19: Summary of compounds 14, 15 and 17 for nuclear receptor agonist activity 
 
 Activity and concentration (µM) 
Compound 
PPARα PPARβ/δ LXRα LXRβ 
6-acetylmonodethiogliotoxin (14) n.d. n.d 40 n.d 
6-acetylbisdethiobis(methylthio) 
gliotoxin (15) 
n.d. n.d. n.d n.d 
heveadride (17) n.d. n.d. n.d
 
n.d 
 
 
4.4.5    Discussion of isolated epithiodiketopiperazine  
 
Structural features 
It is interesting to note, that monosulphides of gliotoxin derivatives have been obtained semi-
synthetically from disulfid gliotoxin derivatives by reaction with tervalent phosphorus 
compounds, e.g. triphenylphosphine.
163
 But up to our knowledge there is only the one 
example of emestrin-G, isolated from the fungus Armillaria tabescens, where such a bridged 
monosulphid was obtained directly by isolation as a natural product.
164
However 6-
acetylmonodethiogliotoxin (14) has been isolated directly, without chemically treatment and 
reveals a new biosynthetic source for monosulphid gliotoxin derivatives.             
14 
 
15 
 
17 
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Biological activity 
Compound 14 demonstrated selective agonist activities toward LXRα and 40 µM of this 
compound were capable to activate the reporter system of LXRα.  
A transannular sulphur bridge as present in compound 14 seems to be essential for this 
activity, as the related compound 15 without this feature did not display any activity. The 
finding of 6-acetylmonodethiogliotoxin with a monosulphide bridge is of importance, as this 
compound may serve as lead for the development of more potent and selective ligands for this 
therapeutically interesting nuclear receptor. 
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4.5    Overview of further bioactivity tests performed with isolated 
compounds   
 
4.5.1    Antibiotic activities of pure compounds 
 
11 out of 16 isolated secondary metabolites were evaluated for their antimicrobial activities in 
agar diffusion assays; the observed activities are summarized in Table 4-20 and 4-21. Two 
compounds were isolated with prominent activity against the Gram-negative bacterium 
Eschericha coli. Xanthocillin X monomethylether (13) exhibited explicit antibiotic activities 
against gram negative bacteria. The antibiotic activitiy of asporyzin C (6) was not determined 
in our institute, but was described in the literature by Qiao et al., 2010 where 30 µg/disk of 
asporyzin C displayed an inhibition diameter of 8.3 mm against E. coli.
102
 Both compounds 
may explain the antibiotic activities of the crude extracts against E. coli. The two known 
isocyanide bearing compounds xanthocilin X mono- and dimethylether (12 and 13) 
demonstrated clear antibiotic activities against gram positive bacteria in form of Bacillus 
megaterium and the examined test fungi strains (Table 4-20). However the antibiotic activity 
of xanthocillin X monomethylether is according to literature data based on general unselective 
protein biosynthesis inhibition, that is accompanied by cytostatic or even cytotoxic effects 
which limit its therapeutical use as an antibiotical agent.
129,165
 All examined 
indoloditerpenenes (1–5), including the newly isolated compounds 1–3, display moderate 
activities against gram positive bacteria, like Bacillus megaterium and Staphylococcus spp.  
The nonadride heveadride displays neglible antifungal activities against Eurotium rubrum 
whereat  minor antifungal effects had been described before by Hosoe et al., 2004.
160
 
According to literature other strains of Dichotomomyces cejpii have the ability to produce 
gliotoxin, a potent mycotoxin which displays antibacterial, antifungal but also cytotoxic 
effects.
152,155,166
 This fungal strain did not produce detectable amounts of gliotoxin. The 
isolated gliotoxin derivatives 14 and 15 did not show any antibiotic activity. Probably, 
because they lack the characteristic disulfide bridge of gliotoxin, which is considered as the 
toxicophore of gliotoxin.
155
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Table 4-20: Agar diffusion assay of isolated compounds in WG König (3.6.1) 
 
Escherichia Bacillus Microbotryum Eurotium Mycotypha
Compound coli megaterium violaceum rubrum microspora
1
2
3 0 3.5 (T) 0 0 0
4 0 2.5 (T) 0 2.5 (GI) 0
5 0 5.0 (T) 0 2.5 (GI) 0
6
7
9 0 0 0 0 0
10
11
12 7.0 (T) 7.0 (T) 6.0 (T) 3.5 (T) 12 (T)
13 0 2.0 (T) 3.5 (GI) 2.5 (GI) 2.5 (T)
14 0 0 0 0 0
15 0 0 0 0 0
16
17 0 0 0 2.5 (GI) 0
HF 10  0 0 0 0 0 /
HF 11 0 0 0 0 0 0
HF 11 0 0 0 0 0 0
HF 11 0 0 0 0 0 0
HF 12 0 0 0 0 0 0
HF 12 0 0 0 0 0 0
HF 12 0 0 0 0 0 0
HF 13 0 0 0 0 0 0
HF 13 0 0 0 0 0 0
HF 13 0 0 0 0 0 0
HF 14 0 0 0 0 0 0
HF 14 0 0 0 0 0 0
HF 14 0 0 0 0 0 0
HF 15 0 0 0 0 0 0
HF 15 0 0 0 0 0 0
HF 15 0 0 0 0 0 0
HF 16  0 0 0 0 0 0
HF 16  0 0 0 0 0 0
HF 16  0 0 0 0 0 0
HF 17 0 0 0 0 0 0
HF 17 0 0 0 0 0 0
HF 17 0 0 0 0 0 0
HF 18 0 0 0 0 0 0
HF 18 0 0 0 0 0 0
HF 18 0 0 0 0 0 0
HF 19 0 3 (GI) 0 0 0 0
HF 19 0 3 (GI) 0 0 0 0
HF 19 0 4 (GI) 0 0 0 0
HF 20 0 0 0 3 (GI) 0 0
HF 20 0 0 0 0 0 0
HF 20 0 3 (T) 0 3 (GI) 0 0
HF 21 0 3 (GI) 0 0 0 0
HF 21 0 3 (GI) 0 0 0 0
HF 21 0 2 (GI) 0 0 0 0
HF 22 0 0 0 0 0 0
HF 22 0 0 0 0 0 0
HF 22 0 2.5 (T) 0 0 0 0
agar diffusion assay of isolated compounds in AG König (3.6.1)
growth inhibition (GI) and total inhibition (T) zones against test organisms [mm] 
sample concentration: 1 mg/mL (at 50 μg/disk level)
1
 
 
 
Table 4-21: Agar diffusion assay of isolated compounds in AG Sahl (3.6.2) 
 
b a a
1 2 13
0 7.0 (GI) 4.0 (GI)
4.0 (GI) 7.0 (GI) 5.0 (GI)
0 0 2.0 (T)
0 / /
0 4 (GI) 0
0 9 (T) 3 (GI)
/ 0 /
4 (GI) 0 0
0 0 4 (GI)
0 0 4 (GI)
0 0 0
0 5.0 (GI) 0
Klebsiella pneumoniae subsp. Ozeanae 0 0 0
0 9.0 (T) 3 (T)
/ / 5 (GI)
/ 0 /
3.0 (GI) 9.0 (GI) 3 (T)
/ 9.0 (GI) /
0 4.0 (GI) 0
CZ 0 0 0 0
MYA 0 3 (T) 0 3 (GI)
BMS 0 3 (GI) 0 0
CZ 0 3 (GI) 0 0
MYA 0 2 (GI) 0 0
BMS 0 0 0 0
Citrobacter freundii 
Arthrobacter crystallopoietes
Candida albicans
Pseudomonas aeruginosa
Candida glabrata
Micrococcus luteus
Bacillus cereus
Staphylococcus epidermidis (MRSE)
Enterococcus faecium 
Bacillus subtilis 
Bacillus megaterium
Corynebacterium xerosis
Mycobacterium smegmatis
Echerichia coli 
test organism
Listeria welchimeri 
agar diffusion assay of isolated compounds in AG Sahl  (3.6.2)
sample concentration: 1 mg/mL (at 3 μg
a 
and 5 µg
b
)
growth inhibition (GI) and total inhibition (T) zones against test organisms [mm] 
Staphylococcus aureus (MSSA)
Staphylococcus aureus (MRSA)
Staphylococcus simulans 
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4.5.2    Further activity tests with isolated pure compounds 
Table 4-22:  Performed bioactivity tests of isolated pure compounds 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
3.6.3-3.6.5
CB1
CB2
GPR18
GPR55
3.6.8–3.6.10
Aβ-42 inhibition
Aβ-42 induction
3.6.11
CDK1/ cyclin B
CDK2/cyclin A
CDK5/ p25
CDK9/ cyclin T
CK1
CLK1
DYRK1A
GSK-3
3.6.12
PPAR α
PPAR β/δ
PPAR γ
LXR α
LXR β
3.6.13
Cathepsin L
Cathepsin B
Cathepsin K
Chymotrypsin
Trypsin 
Cholesterol  esterase 
3.6.14
FFA1
FFA2
FFA3
3.6.15
Sulfotransferase
3.6.16
HIV
3.6.17.1–3.6.17.2
P. falciparum
T. brucei
T. brucei
L. donovani
3.6.17.3
L. donovani
Performed bioactivity tests 
Bioassay
Compounds
 
Overview of performed bioactivity tests (for details about assay and sample preaparation see chapter 3.6.3–
3.6.17) red: activity in performed assay; yellow: minor activity in performed assay; blue: no activity in 
performed assay; grey: not tested. For details about active substances see chapter 4.2.2–4.4.4.5 
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4.5.3    Antiparasitic activites of isolated pure compounds 
 
Table 4-23:  Antiparasitic activity tests of isolated pure compounds 
 
 
Leishmania spp are parasites which are responsible for the disease leishmaniasis. They are 
transmitted through sandflies and their primary hosts are vertebrates. During their life cycle 
stage in mammalian hosts, Leishmania spp. are housed within phagolysosomes of 
macrophages.
167
 
Compound heveadride (17) displays prominent antiparastic effects against axenic 
Leishmania donovani in assay 3.6.14.2, but no antiparasitic activity was detected against 
Leishmania donovani in L. donovani Macrophage assay (3.6.14.3). The obtained results 
indicate that heaveadrid possesses desirable selective toxic effects against isolated Leishmania 
donovani. Unfortunately heveadride is unable to effect Leishmania donovani within 
macrophages which limits its therapeutical use.
167
 Therefore, heveadride derivatives with the 
ability to reach and effect Leishmania spec. within macrophages could be an interesting 
approach for antiparasitic drug development against Leishmania parasites. 
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5    General discussion  
5.1    Classification and structural evaluation of isolated compounds 
 
The main goal of this study was the in-depth chemical examination of a marine derived fungal 
strain of Dichotomomyces cejpii and the secondary metabolites produced by this 
microorganism. Therefore, the isolation, identification and biological evaluation of preferably 
such new natural products was intended, which might be used as potential drug leads.  
Fifteen complex natural products were obtained, of which seven possess new structures, 
and two had been obtained semisynthethically before. Altogether, these compounds revealed 
the astonishing biosynthetic potential of the investigated fungal strain and its remarkable 
utilization of multiple biosynthetic pathways. In the following these biosynthetic pathways 
will be briefly described.  
    The six isolated indoloditerpene alkaloids (1–6) represent hybrid molecules, produced by a 
combination of two biosynthetic pathways. The indoloditerpene biosynthesis was investigated 
by Tagami et al., 2013 for paxilline by Penicillium paxilli.
168
 According to their results a 
biosynthesis for the indoloditerpenes in Dichotomomyces cejpii can be assumed as shown in 
Figure 5.3. Thus, the indoloditerpene core structure consists of a cyclic diterpene skeleton 
derived from geranylgeranyldiphosphat (GGPP) and an indole nucleus. The isoprene units 
may be derived via the mevalonate or the methylerythritol phosphate (MEP) pathway, which 
uses mevalonic acid or rather deoxyxylulose phosphate as precursors. The indole substructure 
is derived from indole-3-glycerolphosphate (IGP), which has its origin in the shikimate 
pathway. The shikimate pathyway starts with a coupling of phosphoenolpyruvat (PEP) and D-
erythrose-4-phosphate. Via shikimic and chorismic acid, anthranilic acid is formed. The 
phosphoribosylation and decarboxylation of anthranilic acid leads to indole-3-
glycerolphosphate, which is a precursor of the aminoacid L-tryptophan.
169,170
 (figure 5-1) 
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Figure 5-1: Putative indoloditerpene biosynthesis in Dichotomomyces cejpii 
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 Three uncommon steroids (9–11) can be seen as examples of modified triterpenoids. 
Triterpenoids generally consist of six C5 isoprene units. For triterpenoid synthesis in fungi 
two molecules of C15 farnesyl PP are head to head joined to yield the intermediate squalene. 
Oxidation and multiple cyclization steps lead to lanosterol which already shows the 
tetracyclic core structure of the steroids. Further structural modifications lead to the different 
types of steroids, whose nomenclature is based on a series of parent hydrocarbons. 
 Due to their basic chemical structure the isolated sterols (9–11) can be assigned to the 
‘ergostane’ or rather ‘campestane’ type of steroids, depending on the absolute configuration at 
C-24.
169
 Analogous conclusions to this general steroid formation led to the proposed 
biosynthesis as given in figure 5-2. 
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Figure 5-2: Putative sterol biosynthesis in Dichotomomyces cejpii. 
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The two isocyanide containing xanthocillin derivatives, xanthocillin X dimethylether (12) and 
xanthocillin monomethylether (13), are derived from the shikimate pathway as well.
171
 
However, their biosynthesis does not follow the route via trypthophan and its precursors but it 
is supposed to proceed via prephenic acid and the aromatic amino acid L-tyrosine. Several 
feeding experiments with labelled precursors in strains of Dichotomomyces cejpii and 
Aspergillus spec. indicated that a dimerization of L-tyrosine derivatives leds to xanthocillin X 
formation.
172,173
 The formation of the prominent isocyanide group, however is not clarified 
yet. The nitrogen originates apparently from L-tyrosine, but the origin of the isocyanide 
carbon remains uncertain.
171,174
 
 
 
 
Figure 5-4: Putative xanthocillin X derivative biosynthesis in Dichotomomyces cejpii  
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Implying the same biosynthesis as for the parent substance gliotoxin in Aspergillus fumigatus, 
a non-ribosomal peptide synthase (NRPS) is responsible for the construction of the three here 
isolated sulphur containing gliotoxin derivatives (14–16). Their diketopiperazine basic 
structure is formed by L-phenylalanine and L-serine via a cyclo-L-phenylalanyl-L-seryl 
intermediate. 
156,175–178
 A complex reaction cascade, utilizing a glutathione-S-transferase, 
establishes the functional thiol group, which can be further processed to a transannular sulfid 
bridge. (see figure 5-4 for details)  
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Figure 5-4: Putative biosynthesis of gliotoxin and its derivatives in Dichotomomyces cejpii  
GSH: glutathione 
GSH-:glutathione anion 
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Finally heveadride (17) represents a nonadride which are chemically characterized by the 
presence of a nine-membered alicyclic ring and two five-ring anhydride functions. These are 
supposed to originate from the acetate pathway, i.e. to be a polyketide. The biosynthesis of 
glauconic acid, the infamous rubratoxin and related nonadrides have been investigated using 
feeding experiments.
179–182
 Taking the results of these investigations into account leads to the 
suggestion that heveadride is the head-to-head dimerization product of two identical 
unsaturated anhydrides. These moieties are in turn produced by the condensation of 
oxaloacetyl-CoA and an unspecified C6 polyketide, which could be an unsaturated hexanoyl-
CoA or a ß-ketothioester. The oxaloacetyl moiety appears to be particularly derived from 
succinat via the citric acid cycle, whereat also other sources, e.g. via aspartate transamination, 
may contribute as well. The production of the C6 polyketide instead can be achieved by either 
a fatty acid or a polyketide synthesis pathway utilizing acetyl-CoA and malonyl-CoA as 
precursors. (see figure 5-5) 
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Figure 5-5: Putative nonadride biosynthesis in Dichotomomyces cejpii  
 
5.2    Biological evaluation of isolated compounds 
 
It is of major interest to investigate the obtained molecules for their biological activities. Their 
potential to interact with biological targets can be regarded as high due to their origin as 
natural products. Depending on structural features and the available quantities of the 
respective compounds, they were subjected to diverse, pharmacologically highly relevant 
bioassays. By collaboration with many working groups a wide array of activities could be 
examined. These included activities toward several receptors, like cannabinoid (CB), fatty 
acid and diverse nuclear receptors. Antibiotic effects against several bacteria, fungi and 
parasites were examined as well.  Furthermore, inhibitory effects toward several enzymes like 
e.g. cerebrosid-sulfotransferase were investigated. The majority of the examined compounds 
indeed displayed any bioactivity in the examined assays (see table 4-23). Among these there 
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are three compounds that display selective activity towards one specific receptor subtype. A 
selective CB2 or rather GPR18 receptor blocking activity was found for the indoloditerpenes 1 
and 2, respectively. While, a selective LXRα agonistic effect was observed for the 
epimonothiodiketopiperazine 14 (see chapter 4.2-4.5 for details). Furthermore compound 1 
and 14 were tested for effects toward mammalian cells and none of these compounds 
displayed relevant cytotoxicity.  Thus, these compounds form a good starting point for further 
investigations and compound development. 
The antibiotic activities of the fungal extracts were assigned to several clearly defined 
compounds. These include the known xanthocillin X mono- and dimethylether (12 and 13) 
and the indoloditerpenes JBIR-03 (4) and asporyzin C (6), 
101,102,183
 but also the structurally 
new indoloditerpenes 1–3. With the exception of the potent compound 13 all of these 
compounds displayed moderate antibiotic activites (Table 4-21–4-22). In an ecological sense 
this may indicate effective chemical defense of D. cejpii against competitors and predators.  
 
 
5.3    New approaches for natural product research 
 
New approaches to facilitate sample separation and compound isolation for natural 
product research, in consideration of the applied methodology in this study 
 
Within the scope of this study, a classical approach for natural product research was used, 
which was in case of antibiotic activity, supported by bioactivity-guided fractionation.This 
time and resources consuming compound isolation process, starting from complex crude 
extracts, is often considered as an inherent and major disadvantage of natural product drug 
research.
184
 Moreover, classical bioassay-guided fractionation allows physicochemical 
profiling only after accomplished compound isolation. This means that selection of lead- and 
drug-like compounds can usually be applied for the first time after the long isolation process 
has been accomplished. This might lead in unfavorable cases to bioactive, but for example not 
bioavailable compounds, which severely restricts their therapeutical usability.
184
  
Nowadays many pharmaceutical companies base their screening libraries on the so called 
Lipinski ‘Rule of five’ to preselect compounds due to their drug like properties.184 The 
generally accepted Lipinski ‘Rule of five’ (Ro5) describes four simple physicochemical key 
properties for bioavailable, orally administrable drugs, i.e. molecular weight (MW) < 500, H-
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bond donors (HBD) < 5, H-bond acceptors < 10 and calculated log P (clogP) < 5.
185
 Among 
these log P, an indicator for drug lipophilicity and solubility, is considered to be the most 
important parameter.
184,186
 There are approaches to improve natural product research in that 
respect and thus to facilitate their use in HTS screening approaches. 
184
  In so called lead-like 
enhanced (LLE) extracts.
184
 the relationship between log P and retention time on C18 
chromatography columns is used to enrich compounds with desirable physicochemical 
properties. An optimized solid phase extraction (SPE) protocol can be used as a primary filter 
on log P. Log P as a primary filter can optionally be supplemented by further filters like the 
consequent use of MS techniques in order to establish molecular weight (MW) as a second 
filter. Further fractionations can be used to establish HTS friendly LLE fractions of reduced 
complexity, but retained chemical diversity space. Compared to classical NP drug discovery, 
this procedure could allow the acceleration of the process to afford natural product leads with 
lead like properties. 
On the other hand there are voices which criticize the limitations of the Ro5 and emphasize 
that especially the first four rules do not apply for natural products and molecules recognized 
by an active transport mechanism.
3,187,188
 Furthermore history has shown that many natural 
products with insufficient properties, which restricted their therapeutical use, have been great 
starting points for drug optimization on the way to therapeutically usable drugs. A range of 
examples for this are given in the introduction (1.1). Therefore one should perhaps also take 
into consideration that, following this LLE approach too strictly, we might lose powerful lead 
structures with insufficient physicochemical key properties, which however could have been 
further modified to obtain active and bioavailable drugs. Within the scope of this study, which 
dealed with the in-depth analysis of one single fungal strain, the application of the LLE 
approach, would have been an option to accelerate the separation process. However this 
option was rejected in favor of a more exhaustive analysis of the secondary metabolites 
produced by D. cejpii on the examined media.  
Certainly the LLE approach has its potential however, especially for researchers working 
with very large sample amounts, which do not allow a complete exhaustive separation of all 
samples and require a stronger preselection. In addition, the progressive improvement of 
analytical methodologies provides new opportunities for natural drug research. Of particular 
interest in this area are analytical techniques which facilitate bioactive hit assessment in semi-
purified fractions, containing only minute concentrations of each individual compound. 
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A combination of techniques that may also include LLE extract fractionation and improved 
analytical methodologies, therefore, have the potential to enhance and accelerate natural 
product research  and make it more competitive to chemical synthesized single compound 
HTS.
7,184,189
 
 
Future strategies to reveal and explore the full potential of fungal secondary metabolite 
production 
 
As illustrated during this study and by viewing fungi-derived drugs, these microorganisms are 
capable to produce an amazing range of pharmaceutically interesting secondary metabolites.
7,8
 
Obviously, many of these compounds are already known today, but many more can be 
expected. Thus the question arises how we can induce the production and facilitate the 
identification of these secondary metabolites? 
The increased availability of genome sequences for ever more fungal species and the 
improved recognition of fungal biosynthetic gene clusters provide detailed insight into fungal 
secondary metabolite production. The latter revealing that under routine laboratory conditions 
the harbored biosynthetic genes are apparently only in part transcribed into fungal 
products.
9,190
 
In their natural environment fungi are generally growing in close neighborhood to other 
microorganisms, competing for living space and nutrients. These interactions are supposed to 
induce secondary metabolite production to asserten the specific fungus in its ecological niche 
(see 1.2). 
9,190
 Under laboratory conditions, growing free of annoying competitors and with an 
abundance of nutrients, secondary metabolite production may be regarded by the producer 
strain as a waste of its resources, and can be downregulated or even arrested. Co-cultivation 
studies with other fungi or bacteria have demonstrated the great potential of a well considered 
co-cultivation approach in order to obtain new unpredicted metabolites.
9,190
 As an example 
the cocultivation of a marine-derived mangrove fungal strain led e.g. to the production of the 
new antibacterial compound aspergicin.
191
 Future research activities regarding our fungal 
strain of D. cejpii could potentially pursue this option, as well. As described in chapter 4.2.2 
first cultivation experiments with minimal agar media in comparison to nutrient rich agar 
media, revealed an increased antibiotic activity for some of the hydrophilic fractions. In the 
scope of this study, further investigations of this phenomenon have not been possible, but 
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these results indicate an enhanced secondary metabolite production triggered due to external 
influences. 
Induction of fungal secondary metabolite production may also be achieved on the genomic 
level. The identification of gene clusters typically involved in secondary metabolite 
production by genome sequencing provides the opportunity to influence their transcription. 
Different strategies have been pursued, like the utilization of a) cluster-specific activation on 
the one hand, b) global regulators on the other hand as well as c) histone modifications.
192
  
 Concerning approach a), Zn(II)2Cys6 proteins which are a group of transcription factors 
generally activating gene clusters may be addressed to produce the encoded metabolites. This 
group of transcription factors share a common protein sequence motif, the ‘Zn(II)2Cys6 
binuclear cluster’ DNA binding motif , which can be used for recognition. Recognition and 
targeted induction of cluster-embeded Zn(II)2Cys6 genes can be used to activate the 
according gene cluster.
192
 This method was already utilized to activate otherwise silent gene 
clusters, which led to the production of new metabolites, like asperfuranone which displays 
anti-proliferative effects in human cancer cell lines. 
192–195
 
 Approach b) is similar but uses global regulators of secondary metabolism like LeA and 
its homologs. Introduction and overexpression of LeA genes have been applied to awaken 
silent secondary metabolite clusters and to enhance general productivity of secondary 
metabolites.
192,196
  
Finally, strategy c) involves histone modifications like acetylation or methylation, which 
have been associated with effects on global gene expression due to epigenetic effects. Genetic 
deletion of histone methylation complexes, which normally induce gene silencing or the 
application of histone deacetylase inhibitors, have for example demonstrated to be capable to 
induce the production of secondary metabolites and can be valuable tools to induce the 
expression of silent gene clusters.
192,197,198
 
Taken all together, natural products will keep on playing a major role in drug discovery in 
the future. Natural products derived from fungal sources, like investigated in this study, will 
thereby continue to provide new lead compounds. Innovative techniques and approaches will 
facilitate the identification of chemically novel structures from known and new sources. The 
recognition and manipulation of silent or cryptic biosynthesis genes furthermore will increase 
the wide spectrum of available chemical diverse secondary metabolites, thus providing a 
resource for future discoveries. 
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6    Summary 
 
Natural products display an astonishing diversity of bioactive structures. These compounds 
play a prominent role in the drug development process for a wide array of therapeutic 
indications. This eminent position may be explained due to the circumstance that natural 
products, as well as their biological targets (e.g. receptors/proteins), are produced by the 
interaction with biosynthetic enzymes. Due to this ‘biosynthetic imprint’ or shared ‘protein 
fold topology’ (PFT) they exhibit ‘natural product binding motifs’, which facilitate 
interactions with their biological targets.  
Among natural products, fungal metabolites have turned out to be very valuable as lead 
structures, i.e. many antibiotics and immunomodulatory agents are derived from fungal 
metabolites. The secondary metabolite production in fungi is strongly affected by 
environmental influences and the isolation of fungal strains from uncommon, less investigated 
habitats is considered as promising approach for the discovery of novel bioactive compounds. 
Therefore, investigation of marine-derived fungi was targeted in the current study.  
The main goal of this investigation was the isolation, identification and biological evaluation 
of secondary metabolites from the marine-derived fungus Dichotomomyces cejpii with 
emphasis on compounds exhibiting activities toward cannabinoid and type II nuclear 
receptors. Aβ-42 lowering activity potentially useful to treat Alzheimer dementia was also 
assayed. Of further interest were secondary metabolites with antibiotic activities. 
  
For initial bioassays four different agar-based media were chosen for small scale cultivation, 
following the idea of the so-called OSMAC (One Strain Many Compounds) approach. On the 
basis of the chemical and biological results obtained with these extracts, two  cultivation 
methods which differed greatly in their nitrogen and carbohydrate supply sources were 
selected for large scale cultivation.  
 
Detailed chemical investigation of the resulting two extracts provided in total fifteen complex 
natural products. Seven of these have new structures (1–3, 9–11 and 14) and two had only 
been obtained semi-synthethically before (15–16). 
The new emindole SB beta-mannoside (1) and 27-O-methylasporyzin C (2) belong to the 
class of indoloditerpenes. They were obtained together with another new indoloditerpene, 
referred to as emindole SB-formate (3) and three further structurally related metabolites (4–6). 
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All investigated indoloditerpenes display activities toward cannabinoid and related receptors, 
whereat compound 1 shows selective antagonistic activity toward cannabinoid receptor 
subtype 2 (CB2: Ki 10.6 µM), while compound 2 has selective antagonistic activity toward the 
cannabinoid related receptor GPR18 (IC50 13.4 µM). Due to the potent physiological 
responses, such as, e.g. immunomodulatory effects, both receptors are targets for drug 
development. The new natural indole derivatives 1 and 2 may thus serve as lead structures for 
the development of potent and selective CB2 or GPR18 receptor-blocking drugs, respectively. 
 
 
 
Further, we identified three new sterols with an untypical pattern of carbon-carbon 
double bounds (9–11) and reisolated the isocyanid xanthocillin X dimethylether (12). The 
new sterol 16-O-desmethylasporyergosterol-ß-D-mannoside (9) and xanthocillin X 
dimethylether (12) display moderate Aβ-42 lowering activity. Given that Aβ-42 lowering 
agents are, inter alia, considered as therapeutics for Alzheimer disease, these results suggest 
further investigations. 
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Additionally, three non-cytotoxic gliotoxin derivatives were isolated (14–16). The new 6- 
acetylmonodethiogliotoxin (14) is characterized by a naturally occurring very rare 
transannulated monosulfide bridge. This characteristic moiety seems to be essential for the 
observed selective agonistic activity toward nuclear liver X receptor α (LXRα). Targeting 
LXR has demonstrated to possess therapeutic potential in the treatment of atherosclerosis, 
diabetes, cancer, cardiovascular diseases, autoimmune disorders, and Alzheimer disease, 
whereat LXR α/β subtype selective ligands are desired. Therefore compound 14 may serve as 
lead for the development of more potent and selective ligands which interact with this 
therapeutically interesting receptor. 
 
In conclusion the marine-derived strain of Dichotomomyces cejpii has been identified as 
powerful producer of highly diverse and bioactive secondary metabolites. 
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8    Appendix 
8.1    Metabolites isolated during this study 
 
Compound 
no. 
trivial name 
1 emindole SB beta-mannoside 
2 27-O-methylasporyzin 
3 emindole SB beta-formate 
4 JBIR-03 
5 emindole SB 
6 asporyzin C 
7 emindole SB-N-propylcarbamate (semisynthetic derived from emindole SB) 
8 amauramin (isolated by Mahmoud Fahmi Elsebai) 
9 16-O-desmethylasporyergosterol-ß-D-mannoside 
10 16-O-desmethylasporyergosteron-ß-D-mannoside 
11 16-O-desmethylasporyergosterol 
12 xanthocillin X dimethylether 
13 xanthocillin X monomethylether 
14 6-acetylmonodethiogliotoxin 
15 6-acetylbisdethiobis(methylthio)gliotoxin 
16 5a,6-anhydrobisdethiobis(methylthio)gliotoxin 
17 heveadride 
 
8.2    Spectroscopic data of isolated compounds 
 
1
H NMR spectrum (300 MHz in acetone-d6) of compound emindole SB beta-mannoside (1). 
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13
C NMR spectrum (75.5 MHz in acetone-d6) of compound emindole SB beta-mannoside (1).  
 
 
 
Dept 135 NMR (75.5 MHz in acetone-d6) of compound emindole SB beta-mannoside (1). 
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IR spectrum of compound emindole SB beta-mannoside (1). 
 
 
1
H-
13
C HMBC 2D-NMR spectrum of compound 1 in acetone-d6. 
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1
H NMR spectrum (300 MHz in acetone-d6) of compound 27-O-methylasporyzin C (2). 
 
 
 
13
C  NMR spectrum (75.5 MHz in acetone-d6) of compound 27-O-methylasporyzin C (2). 
 
 
 
Dept135 NMR spectrum of (75.5 MHz in acetone-d6) of compound 27-O-methylasporyzin C 
(2).
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IR spectrum of compound 27-O-methylasporyzin C (2). 
 
 
 
1
H NMR spectrum (300 MHz in acetone-d6) of compound emindole SB beta-formate (3). 
 
 
 
13
C NMR spectrum (300 MHz in acetone-d6) of compound emindole SB beta-formate (3). 
 
 
 
 Appendix 
136 
 
13
C  DEPT NMR spectrum (75.5 in acetone-d6) of compound emindole SB beta-formate (3). 
 
 
 
IR spectrum of compound emindole SB-formate (3). 
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1
H NMR spectrum (300 MHz in methanol-d4) of compound JBIR-03 (4). 
 
 
 
13
C NMR spectrum (75.5 MHz in methanol-d4) of compound JBIR-03 (4). 
 
 
 
Dept 135 NMR spectrum (75.5 MHz in methanol-d4) of compound JBIR-03 (4). 
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1
H NMR spectrum ( 300 MHz in acetone-d6) of compound emindole SB (5). 
 
 
13
C NMR spectrum (75.5 MHz in acetone-d6) of compound emindole SB (5). 
 
 
 
 
Dept 135 NMR spectrum (75.5 MHz in acetone-d6) of compound emindole SB (5). 
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1
H NMR spectrum (500 MHz in methanol-d4) of compound asporyzin C (6). 
 
 
 
1
H NMR spectrum (300 MHz in methanol-d4) of compound emindole SB-N-propylcarbamate 
(7).
 
 
13
C NMR spectrum (300 MHz in methanol-d4) of compound emindole SB-N-
propylcarbamate (7). 
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Dept 135 NMR spectrum (300 MHz in methanol-d4) of compound emindole SB-N-
propylcarbamate (7). 
 
 
1
H NMR spectrum (300 MHz in methanol-d4) of compound 16-O-
desmethylasporyergosterol-ß-D-mannoside (9). 
 
 
 
 
13
C NMR spectrum (75.5 MHz in methanol-d4) of compound 16-O-
desmethylasporyergosterol-ß-D-mannoside (9). 
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Dept 135 NMR spectrum (75.5 MHz in methanol-d4) of compound 16-O-
desmethylasporyergosterol-ß-D-mannoside (9) 
 
220 200 180 160 140 120 100 80 60 40 20 0 ppm  
 
IR spectrum of compound 16-O-desmethylasporyergosterol-ß-D-mannoside (9). 
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1
H-
13
C HMBC 2D-NMR spectrum of compound 9 in methanol-d4. 
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1
H NMR spectrum (500 MHz in methanol-d4) of compound of 16-O-
desmethylasporyergosteron-ß-D-mannoside (10). 
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13
C NMR spectrum (75.5 MHz in methanol-d4) of compound desmethylasporyergosteron-ß-
D-mannoside (10). 
 
 
Dept 135 NMR spectrum (75.5 MHzin methanol d4) of compound 
desmethylasporyergosteron-ß-D-mannoside (10). 
 
 
 
IR spectrum of compound desmethylasporyergosteron-ß-D-mannoside (10). 
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1
H-
13
C HMBC 2D-NMR spectrum of compound 10 in methanol-d4. 
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1
H NMR spectrum (300 MHz in acetone-d6) of compound 16-O-desmethylasporyergosterol 
(11)  
 
 
13
C NMR spectrum (75.5 MHz in acetone-d6) of compound 16-O-desmethylasporyergosterol 
(11).  
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135 NMR spectrum (75.5 MHz in acetone-d6) of compound 16-O-desmethylasporyergosterol 
(11).  
 
 
IR spectrum of compound 16-O-desmethylasporyergosterol (11). 
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1
H NMR spectrum (300 MHz in chloroform-d1) of compound xanthocillin X dimethylether 
(12).  
 
 
13
C NMR spectrum (75.5 MHz in chloroform-d1) of compound xanthocillin X dimethylether 
(12).  
 
 
 
Dept 135 NMR spectrum (75.5 MHz in chloroform-d1) of compound xanthocillin X 
dimethylether (12).  
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1
H NMR spectrum (500 MHz in chloroform-d1) of compound xanthocillin X 
monomethylether (13). 
 
 
 
13
C NMR spectrum (75.5 MHz in chloroform-d1) of compound xanthocillin X 
monomethylether (13).  
 
 
 
 
1
H NMR spectrum (300 MHz in acetone-d6) of compound 6-acetylmonodethiogliotoxin (14).  
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13
C NMR spectrum (300 MHz in acetone-d6) of compound 6-acetylmonodethiogliotoxin (14).  
 
 
 
Dept 135 NMR spectrum (300 MHz in acetone-d6) of compound 6-acetylmonodethiogliotoxin 
(14).  
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IR spectrum of compound 6-acetylmonodethiogliotoxin (14).  
 
 
 
1
H NMR spectrum (300 MHz in acetone-d6) of compound 6-acetylbisdethiobis 
(methylthio)gliotoxin (15). 
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13
C NMR spectrum  (300 MHz in acetone-d6) of compound 6-acetylbisdethiobis 
(methylthio)gliotoxin (15). 
 
 
Dept 135 NMR (75.5 MHz in acetone-d6) of compound 6-
acetylbisdethiobis(methylthio)gliotoxin (15). 
 
 
1
H NMR spectrum (300 MHz acetone-d6) of compound 5a,6-
anhydrobisdethiobis(methylthio)gliotoxin (16). 
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13
C NMR spectrum (300 MHz acetone-d6) of compound 5a,6-
anhydrobisdethiobis(methylthio)gliotoxin (16). 
 
 
 
Dept 135 NMR spectrum (300 MHz acetone-d6) of compound 5a,6-
anhydrobisdethiobis(methylthio)gliotoxin (16). 
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1
H NMR spectrum (300 MHz in acetone-d6) of compound heveadride (17)  
 
 
 
13
C NMR spectrum (75.5 MHz in acetone-d6) of compound heveadride (17) 
 
 
 
Dept 135 NMR spectrum (75.5 MHz in acetone-d6) of compound heveadride (17) 
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8.3    Activities of isolated thiodiketopiperazines and nonadride toward 
nuclear receptors 
 
Evaluation of Compounds 14, 15 and 17 for PPARβ/δ agonist activity 
AC 14 15 17 DMSO 
µM average activity average activity average activity average 
125 400 -40 287.093 -1 289.427 -1 297.760 
41.67 41.760 -21 228.480 5 212.640 2 194.500 
13.89 112.693 -10 255.507 10 195.453 1 191.820 
4.63 162.840 -3 234.067 7 217.253 4 177.500 
1.54 183.387 0 216.160 4 191.467 1 177.820 
0.514 212.133 4 241.200 8 199.000 2 186.840 
0.171 257.573 10 257.573 10 203.973 3 177.160 
0.057 268.320 11 268.320 11 204.360 3 197.640 
Values relative to luciferase activity obtained by activating the reporter gene system with the known 
agonist  GW 501516 
Data value represent means ±SEM of three independent experiments 
 
 
 
 
Evaluation of Compound 14, 15 and 17 for PPARγ agonist activity 
AC 14 15 17 DMSO 
µM average activity average activity average activity average activity 
125 1.373 -72 194.440 63 126.813 16 104.500 111 
41.67 25.920 -30 125.467 40 94.760 19 68.300 38 
13.89 63.040 5 98.587 30 73.293 12 61.060 23 
4.63 85.960 21 112.320 39 70.000 10 62.980 27 
1.54 84.013 20 108.213 36 78.200 15 61.700 24 
0.514 95.000 27 109.720 37 61.413 4 47.940 -3 
0.171 102.613 33 101.027 31 80.187 17 52.100 5 
0.057 88.640 23 112.227 39 72.387 11 50.980 3 
Values relative to luciferase activity obtained by activating the reporter gene system with the known agonist 
rosiglitazone (BRL) 
Data value represent means ±SEM of three independent experiments 
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Table 4-25: Evaluation of Compounds 14, 15 and 17 for LXRα agonist activity 
AC 14 15 17  DMSO 
µM average activity average activity 
 
activity average activity 
 80 63,280 161 29,560 68 4,900 13 45,827 126 
40 55,340 140 26,480 61 23,680 65 34,973 96 
20 46,000 117 23,260 53 31,640 87 36,507 100 
10 40,860 104 26,720 61 31,920 88 33,933 93 
5 42,420 108 36,700 84 36,100 99 34,227 94 
3 42,840 109 35,620 81 34,000 93 35,307 97 
1.25 38,660 98 44,920 103 36,020 99 30,000 82 
0.63 39,400 100 43,760 100 36,380 100 36,480 100 
Values relative to luciferase activity obtained by activating the reporter gene system with the known 
agonist T0901317, 
Data value represent means ±SEM of three independent experiments 
 
 
Table 4-26: Evaluation of Compounds 1, 2 and 4 for LXRβ agonist activity 
AC 1 2 4 DMSO 
µM average activity 
 
activity 
 
activity average activity 
80 23.460 98 5.880 24 1.160 6 23.747 84 
40 19.940 83 6.040 25 8.100 39 22.000 78 
20 19.920 83 9.760 41 14.080 68 21.653 77 
10 21.720 91 9.460 39 17.480 85 22.840 81 
5 20.000 83 14.960 62 18.960 92 22.600 80 
3 22.760 95 13.940 58 23.000 112 22.960 81 
1 21.760 91 21.480 89 20.180 98 27.413 97 
1 23.980 100 24.040 100 20.560 100 28.280 100 
Values relative to luciferase activity obtained by activating the reporter gene system with the known agonist T0901317 
Data value represent means ±SEM of three independent experiments 
 
